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ABSTRACT 
 
 
 
 
 
Aim of the research: to develop a prototype of homogeneous high-throughput screening 
(HTS) for identification of novel integrin antagonists for the treatment of ocular allergy and 
to better understand the mechanisms of action of integrin-mediated levocabastine anti-
allergic action. 
Results: This thesis provides evidence that adopting scintillation proximity assay (SPA) 
levocabastine (IC50=406 µM), but not the first-generation antihistamine chlorpheniramine, 
displaces [125I]fibronectin (FN) binding to human α4β1 integrin. This result is supported by 
flow cytometry analysis, where levocabastine antagonizes the binding of a primary antibody 
to integrin α4 expressed in Jurkat E6.1 cells. Levocabastine, but not chlorpheniramine, binds to 
α4β1 integrin and prevents eosinophil adhesion to VCAM-1, FN or human umbilical vein 
endothelial cells (HUVEC) cultured in vitro. Similarly, levocabastine affects αLβ2/ICAM-1-
mediated adhesion of Jurkat E6.1 cells. Analyzing the supernatant of TNF-α-treated (24h) 
eosinophilic cells (EoL-1), we report that levocabastine reduces the TNF-α-induced release 
of the cytokines IL-12p40, IL-8 and VEGF. Finally, in a model of allergic conjunctivitis, 
levocastine eye drops (0.05%) reduced the clinical aspects of the early and late phase 
reactions and the conjunctival expression of α4β1 integrin by reducing infiltrated 
eosinophils. 
Conclusions: SPA is a highly efficient, amenable to automation and robust binding assay to 
screen novel integrin antagonists in a HTS setting. We propose that blockade of integrin-
mediated cell adhesion might be a target of the anti-allergic action of levocabastine and may 
play a role in preventing eosinophil adhesion and infiltration in allergic conjunctivitis. 
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CHAPTER 1 
INFLAMMATION 
 
 
 
 
1.1 Historical background 
Inflammation was first described by the Egyptians (3000 BC), but a more extensive 
and accurate picture was available after Celsus, a Roman writer of the first century AD. He 
identified the four cardinal signs of inflammation: dolor, rubor, tumor, and calor (pain, 
redness, swellness, and heat). This symptoms are more common in the acute form of 
inflammation, than in the chronic one. Centuries later Virchow added a fifth sign: functio 
laesa (loss of function) (Tracy, 2006; Heidland et al., 2006). Further details of the 
inflammatory process where added in the course of the centuries thanks to the development 
of the technology used. For example, Cohneheim first used the microscope to observe 
inflamed blood vessels (Plytycz et al., 2003) and the subsequent edema caused by increased 
vascular permeability and the characteristic leukocyte emigration. 
During the twentieth century many other discoveries were carried out, starting from 
Paul Ehlrich and Ilya Metchnikov – who shared the Nobel prize in Physiology or Medicine 
in 1908 for the humoral theory of immunity and phagocytosis, respectively (Germain, 2004) 
– to the nowadays break throughs by the means of molecular biology. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 
Aulus Cornelius Celsus (ca 25 BC – ca 50 AD) on the far left (from the internet); Iliya Metchnikov (1845 
– 1915) in the middle and Paul Ehrlich (1854 – 1915) on the right (from Schmalstieg et al., 2008) 
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1.2 Essential meaning of inflammation 
Inflammation is a complex reaction to injurious agents such as microbes and 
damaged, usually necrotic, cells that consists of vascular responses, migration and activation of 
leukocytes, and systemic reactions: the unique feature of the inflammatory process is the reaction 
of blood vessels, leading to the accumulation of fluid and leukocytes in extravascular tissues. 
Inflammation serves to destroy, dilute, or wall off the injurious agent, and sets into motion 
a series of events that try to heal and reconstitute the damaged tissue. The injured tissue is 
replaced through regeneration of native parenchymal cells, by filling of the defect with 
fibrous tissue (scarring) or, most commonly, by a combination of these two processes. 
Inflammation, in fact, is fundamentally a protective response, the ultimate goal of which is 
to rid the organism of both the initial cause of cell injury (e.g. microbes or toxins) and the 
consequences of such injury (e.g. necrotic cells and tissues). However, inflammation and 
repair may be potentially harmful. Inflammation reactions, for example, underlie common 
chronic diseases such as rheumatoid arthritis, atherosclerosis, and lung fibrosis, as well as 
life threatening hypersensitivity reactions to insect bites, drugs, and toxins. 
The inflammatory response consists of two main components: a vascular reaction and 
a cellular reaction. Many tissues and fluids are involved in these reactions, including the 
fluid and proteins of plasma, circulating cells, blood vessels, and cellular and extracellular constituents of 
connective tissue. The circulating cells include neutrophils, monocytes, eosinophils, 
lymphocytes, basophils, and platelets. The connective tissue cells are the mast cells 
which intimately surround blood vessels; the connective tissue fibroblasts; resident 
macrophages; and lymphocytes. The extracellular matrix consists of the structural 
fibrous proteins (collagen and elastin), adhesive glycoproteins (fibronectin, laminin, 
nonfibrillar collagen, tenascin, and others), and proteoglycans. The basement membrane 
is a specilized component of the extracellular matrix consisting of adhesive glycoproteins 
and proteoglycans. 
Inflammation can be acute or chronic. The first is rapid in onset (seconds or 
minutes) and is of relative short duration, lasting for minutes, several hours, or a few days; 
its main characteristics are the exudation of fluid and plasma proteins (edema) and the 
emigration of leukocytes, predominantly neutrophils. Chronic inflammation is of longer 
duration and is associated histologically with the presence of leukocytes and 
macrophages, the proliferation of blood vessels, fibrosis, and tissue necrosis. The 
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vascular and celluar responses of both acute and chronic inflammation are mediated by 
chemical factors that are derived from plasma proteins or cells and are produced in 
response to or activated by the inflammatory stimulus. 
Inflammation is a defensive mechanism of the body that occurs after a noxious stimulus of 
various nature (a toxin, a xenobiotic, a microorganism, a chemical-physical insult). The 
length of the process depends on many factors and on this basis we can distinguish acute 
and chronic inflammation. It is also important to underline that the inflammatory process 
itself includes the healing process, which intervenes concomitantly. However, some forms 
of inflammation can be dangerous for the organism which cannot resolve them with its 
own means, causing harmful conditions. It is therefore of no surprise the abundance of 
anti-inflammatory drugs available in pharmacies, which are one of the most sold class of 
medicines. 
 
 
1.3 Acute inflammation 
In recent years, inflammation has emerged as a new and major process underlying 
many prevalent diseases. These include Alzheimer disease, cardiovascular disease (Hansson 
et al., 2006), and cancer (Erlinger et al., 2004) which now join the well-known inflammatory 
disorders such as arthritis and periodontal disease (Nathan et al., 2002; Serhan et al., 2007). 
Acute inflammation is a rapid response to an injurious agent that serves to deliver 
mediators of host defense (leukocytes and plasma proteins) to the site of injury. It has three 
major components: alterations in vascular caliber and that lead to an increase in blood flow, structural 
changes in the microvasculature that permit plasma proteins and leukocytes to leave the circulation, and 
emigration of the leukocytes from the microcirculation, their accumulation in the focus of injury, and their 
activation to eliminate the offending agent. 
Acute inflammation is triggered by a variety of stimuli such as infections, trauma, 
physical and chemical agents, tissue necrosis, foreign bodies, immune reactions (also called 
hypersensitivity reactions). During this process blood vessels undergo a series of changes 
that are designed to maximize the movement of plasma proteins and circulating cells out of 
the circulation and into the site of injury or infection. Changes in vascular flow and 
caliber begin early after injury and develop at varying rates depending on the severity of the 
injury: (1) VASODILATION: is one of the earliest manifestations of acute inflammation. It 
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produces an increase in blood flow which is the cause of the heat and the redness. Vasodilation 
is induced by the action of several mediators, notably histamine and nitric oxide, on 
vascular smooth muscle; (2) INCREASED PERMEABILITY OF THE 
MICROVASCULATURE: with the outpouring of protein-rich fluid into the extravascular 
tissues; (3) STASIS: the loss of fluids results in concentration of red cells in small vessels 
and increased viscosity of the blood, reflected by the presence of dilated small vessels 
packed with red cells and slower blood flow. With mild stimuli, stasis may not become 
apparent until 15 to 30 minutes have elapsed, whereas with severe injury, stasis may occur 
in a few minutes; (4) ACCUMULATION OF LEUKOCYTES: leukocytes, principally 
neutrophils, accumulate along the vascular endothelium. Leukocytes then stick to the 
endothelium, and soon afterward they migrate through the vascular wall into the interstitial 
tissue. 
The loss of protein from the plasma reduces the intravascular osmotic pressure and 
increases the osmotic pressure of the interstitial fluid that, together with the increased 
hydrostatic pressure owing to increased blood through the dilated vessels, leads to a marked 
outflow of fluid and its accumulation in the interstitial tissue causing edema. Other suggested 
mechanisms are: 
§ Formation of endothelial gaps in venules: this is the most common mechanism of 
vascular leakage and is elicited by histamine, bradykinin, leukotrienes, the 
neuropeptide substance P, and many other classes of chemical mediators. 
It occurs rapidly after exposure to the mediator and is usually reversible and 
short lived (15 to 30 minutes); it is thus known as the immediate transient 
response. Classically, this type of leakage affects venules 20 to 60 µm in 
diameter, leaving capillaries and arterioles unaffected. Parenthetically, many 
of the later leukocyte events in inflammation, such as adhesion and 
emigration, also occur predominantly in the venules in most organs. Binding 
of mediators, such as histamine, to their receptors on endothelial cells 
activates intracellular signalling pathways that lead to phosphorylation of 
contractile and cytoskeletal proteins, such as myosin. These proteins 
contract, leading to contraction of the endothelial cells and separation of 
intercellular junctions. Thus, the gaps in the venular endothelium are largely 
intercellular or close to the intercellular junctions. Cytokines such as 
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interleukin-1 (IL-1), tumor necrosis factor (TNF), and interferon-γ (IFN-γ) 
also increase vascular permeability by inducing a structural reorganization of 
the cytoskeleton, such that the endothelial cells retract from one another. 
§ Direct endothelial injury, resulting in endothelial necrosis and detachment: this effect is 
usually encountered in necrotizing injuries and is due to direct damage to 
the endothelium by the injurious stimulus as, for example, severe burns or lytic 
bacterial infections. Neutrophils that adhere to the endothelium may also 
injure the endothelial cells. In most cases, leakage starts immediately after 
injury and is sustained at a high level for several hours until the damaged 
vessels are thrombosed or repaired. The reaction is known as the immediate 
sustained response. All levels of the circulation are affected, including 
venules, capillaries, and arterioles. 
§ Delayed prolonged leakage: in this case the increase of permeability begins after 
a delay of 2 to 12 hours, lasts for several hours or even days, and involves 
venules as well as capillaries. It may result from the direct effect of the 
injurious agent, leading to delayed endothelial cell damage (perhaps by 
apoptosis), or the effect of cytokines causing endothelial retraction. 
§ Leukocyte-mediated endothelial injury: leukocyte adhere to endothelium and 
become activated releasing toxic oxygen species and proteolytic enzymes, 
which then cause endothelial injury or detachment, resulting in increased 
permeability. 
§ Increased transcytosis: certain factors, for example vascular endothelial growth 
factor (VEGF), appear to cause vascular leakage by increasing the number 
and the size of the channels between the cells. 
§ Leakage from new blood vessels: during repair, endothelial cells proliferate and 
form new blood vessels in the process called angiogenesis; new vessels 
sprouts remain leaky until the endothelial cells mature and form intercellular 
junctions. 
Although all these mechanisms are separable, all may play a role in response to one 
stimulus. The vascular leakage induced by all these mechanisms accounts for the life-
threatening loss of fluid in severely burned patients. 
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1.4 Cellular events in acute inflammation 
A critical function of inflammation is to deliver leukocytes to the site of injury and 
to activate the leukocytes to perform their normal functions in host defense. Leukocytes 
ingest offending agents, kill bacteria and other microbes, and get rid or necrotic tissue and 
foreign substances. A price that is paid for the defensive potency of leukocytes is that they 
may induce tissue damage and prolong inflammation, since the leukocyte products that 
destroy microbes and necrotic tissues can also injure normal host tissues. 
The process of extravasation can be divided in the following steps: 
1. In the lumen: margination, rolling, and adhesion. Vascular endothelium 
normally does not bind circulating cells or impede their passage. In 
inflammation, the endothelium needs to be activated to permit it to bind 
leukocytes, as a prelude to their exit from the blood vessels. 
2. Transmigration across the endothelium. 
3. Migration in interstitial tissues toward a chemotactic stimulus. 
In normal flowing blood in venules, erythrocytes are confined to a central axial 
column, displacing the leukocytes toward the wall of the vessel. Because blood flow slows 
early in inflammation (stasis), hemodynamic conditions change, and more white cells 
assume a peripheral position along the endothelial surface, a phenomenon called 
margination. Subsequently, individual and then rows of leukocytes tumble slowly along the 
endothelium and adhere transiently (a process called rolling), finally coming to rest at some 
point where they adhere firmly. After firm adhesion, leukocytes insert pseudopods into the 
junctions between the endothelial cell, squeeze through interendothelial junctions, and 
assume a position between the endothelial cell and the basement membrane and escape into 
the extravascular space. Neurophils, monocytes, lymphocytes, eosinophils, and basophils all use the 
same pathway to migrate from the blood into tissues. 
Leukocyte adhesion and transmigration are regulated largely by the binding of 
complementary adhesion molecules on the leukocyte and endothelial surfaces, and chemical 
mediators (chemoattractants and certain cytokines) affect these processes by modulating the 
surface expression or avidity of such adhesion molecules. The adhesion receptors involved belong to 
four molecular families: the selectins, the immunoglobulin superfamily, the integrins, 
and mucyn-like glycoproteins (see table 1.1 and table 1.2). 
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Table 1.1 
Endothelial/Leukocyte Adhesion Molecules 
SELECTINS 
E-selectin (CD62E, ELAM) confined to the 
endothelium; P-selectin (CD62P, GMP140, 
PADGEM), present in endothelium and platelets; L-
selectin (CD62L, LAM-1), expressed on most 
leukocytes. Selectins bind through their lectin domain to 
sialylated forms of oligosaccharides (e.g. sialylated Lewis X), 
which are themselves covalently bound to various mucin-like 
glycoproteins (GlyCAM-1, PSGL-1, ESL-1, and CD34) 
IMMUNOGLOBULIN 
FAMILY 
ICAM-1 (intercellular adhesion molecule 1) and 
VCAM-1 (vascular cell adhesion molecule 1). Both 
these molecules serve as ligands for integrins found on leukocytes 
INTEGRINS 
Transmembrane heterodimeric glycoproteins made up of α and β 
chains that are expressed on many cell types and bind to ligands 
on endothelial cells, other leukocytes, and the extracellular 
matrix. LFA-1 (leukocyte function-associated 1; αLβ2) 
and Mac-1 (macrophage antigen 1, αMβ2, 
CD11a/CD18) are β2 integrins and bind to ICAM-1, 
while β1 integrins (such as VLA-4, very late antigen 4) 
bind to VCAM-1 
MUCIN-LIKE 
GLYCOPROTEINS 
Heparan sulphate, is an example. Serve as ligands for 
the leukocyte adhesion molecule called CD44. This proteins are 
found in the extracellular matrix and on cell surfaces 
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The recruitment of leukocytes to sites of injury and infection is a multistep process 
involving attachment of circulating leukocytes to endothelial cells and their migration 
through the endothelium. The first events are the induction of adhesion molecules on 
endothelial cells by a number of mechanisms. Mediators such as histamine, thrombin, and 
platelet activating factor (PAF) stimulate the redistribution of P-selectin from its normal 
intracellular stores in granules (Wibel-Palade bodies) to the cell surface (Rondaij et al., 2006). 
 
 Table 1.2  
Endothelial Molecule Leukocyte Receptor Major Role 
P-selectin 
Sialyl-Lewis X 
PSGL-1 
Rolling (neutrophils, 
monocytes, lymphocyes) 
E-selectin Sialyl-Lewis X 
Rolling, adhesion to 
activated endothelium 
(neutrophils, 
monocytes, T cells) 
ICAM-1 
CD11/CD18 
(integrins) 
(LFA-1, Mac-1) 
Adhesion, arrest, 
transmigration (all 
leukocytes) 
VCAM-1 
α4β1 (VLA-4) 
(integrins) 
α4β7 (LPAM-1) 
Adhesion (eosinophils, 
monocytes, 
lymphocytes) 
GlyCAM-1 L-selectin 
Lymphocyte homing to 
high endothelial venules 
CD31 (PECAM) CD31 
Leukocyte migration 
through endothelium 
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Agonist-induced release of these endothelial cell specific storage granules provides 
the endothelium with the ability to rapidly respond to changes in its micro-environment. 
Originally being defined as an intracellular storage pool for von Willebrand factor, it has 
recently been shown that an increasing number of other components, including P-selctin, 
interleukin-8 (IL-8), eotaxin-3, endothelin-1, and angiopoietin-2, is present within this 
subcellular organelle, implicating a role for Weibel-Palade bodies exocytosis in 
inflammation, hemostasis, regulation of vascular tone and angiogenesis. In fact, resident 
tissue macrophages, mast cells, and endothelial cells respond to injurious agents by 
secreting the cytokines TNF, IL-1, and chemokines (chemoattractant cytokines). TNF 
and IL-1 act on the endothelial cells of post-capillary venules adjacent to the infection and 
induce the expression of several adhesion molecules. Endothelial cells lining the 
vasculature, provide a tightly regulate barrier that regulate a number of physiological 
processes including extravasation of leukocytes to the underlying tissues, neovascularisation 
in response to a vascular injury, vascular tone and hemostasis (Aird, 2006). Endothelial cells 
phenotypes are differentially regulated in space and time. Endothelial cells work as an input-
output adaptive device that contains an elaborate non-linear array of dynamic signalling 
pathways that couple extracellular signals to cellular responses or phenotype changes. As 
input is coupled to output, variations in the extracellular environment across space and time leads to 
phenotypic heterogeneity (see Appendix I). Interestingly, Ary Goldberger et al. (2002) has argued 
that health is associated with organized (fractal chaotic-like) complexity, and disease with 
loss of variability and so the endothelium: a quiescent endothelium is associated with 
pathological conditions. Therefore, an inflammatory stimulus induces phenotipical changes 
in the endothelium that, within one or two hours, the begin to express E-selectin. The 
concept of endothelial cell activation first arose from in vitro studies demonstrating the 
ability of well defined stimuli (e.g. lectin phytohemagglutinin, endotoxin, tumor necrosis 
factor α (TNF-α), interleukin-1 (IL-1) and others) to induce the expression of so-called 
activation antigens on their surface (Ia-like antigen, ELAM-1, later designed E-selectin). 
Leukocytes express at the tips of their microvilli carbohydrate ligands for the selectins. 
These are low-affinity interactions with a fast-off rate, and they are easily disrupted by the 
flowing blood. As a result, the bound leukocytes detach and bind again, and thus begin to 
roll along the endothelial surface. TNF and IL-1 also induce endothelial expression of 
ligand for integrins, mainly VCAM-1 (the ligand for the VLA-4 integrin) and ICAM-1 (the 
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ligand for the LFA-1 and Mac-1 integrins). Leukocytes normally express these integrins in a 
low-affinity state. Meanwhile, chemokines that were produced at the site of injury enter the 
blood vessel, bind to endothelial at the site of injury enter the blood vessel, bind to 
endothelial cell heparan sulphate glycosamminoglycans, and are displayed at high 
concentrations on the endothelial surface. These chemokines act on the rolling leukocytes 
and activate the leukocytes. One of the consequences of activation is the conversion of a 
VLA-4 and LFA-1 integrins on the leukocytes to high-affinity state (a process described 
more in detail in the following chapters of the manuscript). The combination of induced 
expression of integrin ligands on the endothelium and activation of integrins on the 
leukocytes results in firm integrin-mediated binding of the leukocytes to the 
endothelium at the site of infection. The leukocytes stop rolling, their cytoskeleton is 
reorganized, and they spread out on the endothelial surface (Fig. 1.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.2 
Mechanism of leukocyte rolling, adhesion and diapedesis. The initial interactions between the activated 
leukocyte and endothelium are weak: attachment and detachment alternate causing leukocyte rolling. On 
the contrary, the integrin-mediated binding is firm, so that the activated leukoccytes are steadily localized 
at the level of the inflammatory process and can move through the endothelium to the extracellular 
space, in a process called diapedesis. (from Vicente-Manzanares et al., 2004) 
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 Chemokines act on the adherent leukocytes and stimulate the cells to migrate 
through interendothelial spaces toward the chemical concentration gradient, that is toward 
the site of injury or infection. Once the leukocytes enter the extravascular connective tissue, 
they are able to adhere to the extracellular matrix by virtue of β1 integrins and CD44 
binding to matrix proteins. The most telling proof of the importance of adhesion molecules 
is the existence of genetic deficiencies in the leukocyte adhesion proteins, which result in 
impaired leukocyte adhesion and recurrent bacterial infections, as in the leukocyte adhesion 
deficiency type 1 (LAD1), the leukocyte adhesion deficiency type 2 (LAD2), and the leukocyte adhesion 
deficiency type 3 (see Box 1.1). 
 
 
  
The type of emigrating leukocytes varies with the age of the inflammatory 
response and with the type of stimulus. In most form of acute inflammation neutrophils 
predominate in the inflammatory infiltrate during the first 6 to 24 hours, then are replaced 
by monocytes in 24 to 48 hours. There are several reasons that justify this event: 
Box 1.1 
Leukocyte adhesion deficiency type 1 
(LAD1) is a rare, inherited 
immunodeciency that affects 1 in 1 million 
people yearly and usually presents with 
recurrent, indolent bacterial infections of 
the skin, mouth and respiratory tract and 
impaired pus formation and wound healing. 
Features of this disease result from 
mutation of the CD18 gene, which is 
encoded on chromosome 21q22.3. This 
gene codes for the common subunit of the 
leukocyte integrins LFA-1, Mac-1, and 
p150,95. Failure to produce a functional 
subunit results in the defective expression 
of all three leukocyte integrins, and the 
leukocytes of LAD have subnormal 
adhesion properties. 
Leukocyte adhesion deficiency type 2 
(LAD2) is caused by the absence of sialyl-
Lewis X, the fucose-containing ligand for 
E-selectin, owing to a defect in fucosyl 
transferase, the enzyme that attach fucose 
moieties to protein backbones. 
While in LAD1 and 2 the defect in the 
adhesion cascade is restricted to leukocytes, 
all four cases of leukocyte adhesion 
deficiency type 3 (LAD3) described to 
date also had defects in platelet aggregation. 
These patients suffered from recurrent 
bacterial infections and a severe bleeding 
tendency. All cases were reported to have 
activation defects in all major integrin 
subfamily members expressed in circulating 
leukocytes and platelets (Etzioni et al., 
2004). In three of the cases, consanguinity 
was reported suggesting an autosomal 
recessive type of inheritance. While in 
LAD1 and LAD2 only a specific molecule 
was involved in adhesion, CD18 and 
CD15a respectively, in LAD3 β1, β2 and β3 
integrins are affected and thus both 
leukocytes and platelets are defective in 
their ability to adhere and hence a tendency 
for bleeding accompanied the severe 
recurrent infections (Alon et al., 2003). 
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neutrophils are more numerous in the blood, they respond more rapidly to chemokines, and 
they may attach more firmly to the adhesion molecules that are rapidly induced on 
endothelial cells, such as P- and E-selectins. In addition, after entering the tissues, 
neutrophils are short-lived; they undergo apoptosis and disappear after 24 to 48 hours, 
whereas monocytes survive longer. There are exceptions to this pattern of cellular 
exudation. In certain infections neutrophils predominate over 2 to 4 days; in viral infections, 
lymphocytes may be the first cells to arrive; in some hypersensitivity reactions, eosinophilic 
granulocytes may be the main cell type. 
 Microbes, products of necrotic cells, antigen-antibody complexes, and cytokines, 
including chemotactic factors, induce a number of responses in leukocytes that are part of 
the defensive functions of the leukocytes (neutrophils and monocytes/macrophages) and 
are referred to under the title of leukocyte activation. Activation results from several 
signaling pathways that are triggered in leukocytes, resulting in increases in cytosolic Ca2+ 
and activation of enzymes such as protein kinase C (PKC) and phospholipase A2 (PLA2). 
The intracellular elaboration of the stimuli results in: 
▶ Production of arachidonic acid metabolites 
▶ Secretion of cytokines 
▶ Modulation of leukocyte adhesion molecules 
▶ Toll-like receptors (TLRs) and GPCRs expression 
▶ Expression of receptors for opsonins 
 
 
1.5 Termination of the acute inflammatory response 
 The inherent capacity of the acute inflammatory response to cause tissue injury need 
to be tightly controlled to minimize the damage. In part, inflammation declines simply 
because the mediators of inflammation have short half-lives, are degraded after their release, 
and are produce in quick bursts, only as long as the stimulus persists. In addition, as 
inflammation develops, the process also triggers a variety of stop signals that serve to 
actively terminate the reaction (figure 1.2). These active mechanisms include a switch in the 
production of pro-inflammatory leukotrienes to anti-inflammatory lipoxins from 
arachidonic acid; the liberation of anti-inflammatory cytokines, transforming growth factor- 
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Figure 1.2 
Time course of inflammation from the beginning to the resolution. (Serhan et al., 2007) 
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β (TGF-β), from macrophages and other cells; and neural impulses (cholinergic discharge) that 
inhibit the production of TNF in macrophages. They also reduce vascular permeability, 
promote nonphlogistic recruitment of monocytes, and stimulate clearance of apoptotic 
neutrophils via macrophages (Serhan, 2007). Recently, new families of local-acting 
mediators were discovered that are biosynthesized from the essential fatty acids 
eicosapetaenoic (EPA) acid and docosahexaenoic acid (DHA) (Ariel et al., 2007). These 
new chemical mediators are endogenously generated in inflammatory exudates collected 
during the resolution phase, and were termed resolvins and protectins because specific 
members of these families control the magnitude and duration of inflammation in animals. 
Elucidating the mode of action of omega-3 PUFAs (polyunsaturated fatty acids, or simply 
fish oils), novel enzymatic oxygenated products generated in vivo were identified in murine 
systems and in humans by pathways initiated from the precursors EPA and DHA. These 
new families of compounds are biosynthesized and contribute functionally to the resolution 
of inflammatory exudates and neuroprotection (Serhan et al., 2000; Serhan et al., 2002; 
Hong et al., 2003; Marcheselli et al., 2003; Mukherjee et al., 2004; Lukiw et al., 2005). 
Resolvins are endogenous local mediators possessing stereospecific and potent anti-
inflammatory, in addition to immunoregulatory, actions (Serhan et al., 2002). They reduce 
neutrophil trafficking, cytokine and oxyne reactive species release, and lowering the 
magnitude of the inflammatory response. The terms protectin D1 (PD1) and 
neuroprotectin D1 (NPD1) – when generated in neural tissue – were introduced given the 
general anti-inflammatory and protective actions of this unique 10R,17S-dihydroxy-
docosatriene in neural systems, stroke, animal models of Alzheimer’s disease, and peritonitis 
(Serhan et al., 2006). These new families of anti-inflammatory and pro-resolving mediators 
contrast with the earlier omega-3 PUFA-derived oxygenated products that possess similar 
structures to previously known arachidonic acid originated eicosanoids, but were less potent 
pro-inflammatory mediators or devoid of bioactions (Lee et al., 1984). Members of the 
resolving and protectin families specifically evoke potent stereoselective bioactions evident 
in the nanomolar and picomolar ranges in vitro and in vivo. Because the precursors to both 
resolvins and protectins are the essential omega-3 PUFAs, their relation to dietary 
supplementation by omega-3 PUFAs also raises new and interesting questions, given the 
widely appreciated notion that omega-3 supplementation reduces inflammatory diseases and 
brings about an anti-inflammatory status. Lipoxins, specifically LXA4 and LXB4, as well as 
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their aspirin triggered forms, stop further polymorphonuclear cells entry into the exudates 
as well as counter-regulate the main signs of inflammation. As new polymorphonuclear cells 
(PMN) enter the exudates, older and apoptotic immune cells must be removed from the site 
in a timely fashion for the inflammation to resolve (figure 1.3). Once PMN enter an 
exudate, they interact with other cells (such as other leukocytes, platelets, endothelial cells, 
and fibroblasts) in their immediate vicinity and can perform transcellular biosynthesis to 
produce lipoxin and eventually new mediators: when platelets adhere to PMNs the platelet-
PMN aggregates become a major intravascular source of lipoxin that in turn halts further 
PMN diapedesis and recruitment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 
Resolution of inflammation. (from Serhan, 2007) 
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These events clearly demonstrate the ability of PMNs to switch their phenotype changing 
the profile of lipid mediators produced depending upon their local environment (Levy et al., 
2001; Serhan et al., 2000). Therefore, during the course of inflammation and complete 
resolution, mediator switching also occurs between families of lipid mediators, namely from 
eicosanoids to resolvins as well as protectins (Serhan et al., 2002; Bannenberg et al., 2005). 
 
 
1.6 Chemical mediators of inflammation 
 The chemical mediators of inflammation orchestrate the inflammatory process 
working in a coordinated manner. They can originate either from plasma or from cells. 
Plasma-derived mediators (e.g. complement proteins, kinins) are present in plasma in 
precursor forms that must be activated, usually by a series of proteolytic cleavages, to 
acquire their biologic properties. Cell-derived mediators are normally sequestered in 
intracellular granules that need to be secreted (e.g. histamine in mast cell granules) or are 
synhesized de novo (e.g. prostaglandins, cytokines) in response to a stimulus. The major 
cellular source are platelets, neutrophils, monocytes/macrophages, and mast cells, but 
mesenchymal cells (endothelium, smooth muscle, fibroblasts) and most epithelia can also be 
induced to elaborate some of the mediators. The production of active mediators is triggered 
by microbial products or by host proteins, such as the proteins of the complement, kinin, 
and coagulation systems, that are themselves activated by microbes and damaged tissues. 
Most mediators perform their biologic activity by initially binding to specific receptors on 
target cells. Some, however, have direct enzymatic activity (e.g. lysosomal proteases) or 
mediate oxidative damage (e.g. reactive oxygen and nitrogen intermediates). Furthermore, 
one mediator can stimulate the release of other mediators by target cells themselves. These 
secondary mediators may be identical or similar to the initial mediators but may also have 
opposing activities. They provide mechanisms for amplifying or, in certain instances, 
counteracting the initial mediator action. Once activated and released from the cell, most 
mediators are short-lived. They quickly decay or are inactivated by enzymes, or they are 
otherwise scavenged or inhibited. There is thus a system of checks and balances in the 
regulation of mediator actions. 
 Among the most important mediators are the vasoactive amines histamine and 
serotonin. They are especially important because they are present in preformed stores in 
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cells and are therefore among the first mediators to be released during inflammation. 
Histamine is widely distributed in tissues, the richest source being the mast cells that are 
normally present in the connective tissue adjacent to blood vessels. It is also found in blood 
basophils and platelets. Proformed histamine is present in mast cell granules and is released 
by mast cell degranulation in response to a variety of stimuli: physical injury, such as trauma, 
cold or heat; immune reactions involving binding of antibodies to mast cells; fragments of 
complement called anaphylatoxins (C3a and C5a); histamine-releasing proteins derived from 
leukocytes; neuropeptides; and cytokines. Histamine causes dilation of the arterioles and 
increases the permeability of venules (it, however, constrict large arteries). It is considered 
to be the principal mediator of the immediate transient phase of increased vascular 
permeability, causing venular gaps. It acts on the microcirculation mainly via binding to H1 
receptors on endothelial cells. Serotonin (5-hydroxytryptamine) is a preformed vasoactive 
mediator with actions similar to those of histamine. It is present in platelets and 
enterochromaffin cells, and in mast cells in rodents but not humans. Release of serotonin 
and histamine from platelets is stimulated when platelets aggregate after contact with 
collagen, thrombin, adenosine diphosphate (ADP), and antigen-antibody complexes. 
Platelet aggregation and release are also stimulated by platelet activating factors (PAF) 
derived from mast cells during IgE-mediated reactions. In this way, the platelet release 
reaction results in increased permeability during immunologic reactions. 
 Plasma proteins mediate a variety of phenomena in the inflammatory reponse 
through an interrelated system of complement, kinin and clotting systems. 
 When cells are activated by diverse stimuli, their membrane lipids are rapidly 
remodelled to generate biologically active lipid mediators that serve as intracellular or 
extracellular signals to affect a variety of biologic processes, including inflammation and 
hemostasis. These lipid mediators are thought of as autacoids, or short-range hormones that 
are formed rapidly, exert their effect locally, and then either decay spontaneously or are 
destroyed enzymatically. 
 Cytokines are proteins produced by many cell types (principally activated 
lymphocytes and macrophages, but also endothelium, epithelium, and connective tissue 
cells) that modulate the functions of other cell types. Long known to be involved in cellular 
immune responses, these products have additional effects that play important roles in both 
acute and chronic inflammation. Tumor necrosis factor (TNF) and interleukin-1 (IL-1) are 
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two of the major cytokines that mediate inflammation. They are produced mainly by 
activated macrophages, but they can be released from many other cell types as well. Their 
most important actions in inflammation are their effects on endothelium, leukocytes, and 
fibroblasts, and induction of systemic acute-phase reactions. In endothelium, they induce a 
spectrum of changes, mostly regulated at the level of gene transcription, referred to as 
endothelial activation (Mantovani et al., 1997). In particular, they induce the synthesis of 
endothelial adhesion molecules (see Appendix 1) and chemical mediators, including other 
cytokines, chemokines, growth factors, eicosanoids, and nitric oxide (NO); production of 
enzymes associated with matrix remodelling; and increases in the surface of 
thrombogenicity of the endothelium. TNF also induces priming of neutrophils, leading to 
augmented responses of these cells to other mediators. IL-1 and TNF induce the systemic 
acute-phase responses associated with infection or injury. Features of these systemic 
responses include fever, loss of appetite, slow-wave sleep, the release of neutrophils into the 
circulation, the release of corticotrophin and corticosteroids and, particularly with regard to 
TNF, the hemodynamic effects of septic shock: hypotension, decreased vascular resistance, 
increased heart rate, and decreased blood pH. TNF also regulates body mass by promoting 
lipid and protein mobilization and by suppressing appetite. Sustained production of TNF 
contributed to cachexia, a pathologic state characterized by weight loss and anorexia that 
accompanies some infections and neoplastic diseases. 
 Chemokines are a family of small proteins that act primarily as chemoattractants for 
specific types of leukocytes. About 40 different chemokines and 20 different receptors for 
chemokines have been identified. They are classified in four major groups, according to the 
arrangement of the conserved cysteine residues in the mature protein (see table 1.3). 
Chemokines mediate their activities by binding to seven transmembrane G protein-coupled 
receptors. These receptors usually exhibit overlapping ligand specificities, and leukocytes 
generally express more than one receptor type. Chemokines stimulate leukocyte recruitment 
in inflammation and control the normal migration of cells through various tissues. Some 
chemokines are produced transiently in response to inflammatory stimuli and promote the 
recruitment of leukocytes to the sites of inflammation. Other chemokines are produced 
constitutively in tissues and function in organogenesis to organize different cell types in 
different anatomic regions of the tissues. In both situations, chemokines may be displayed 
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at high concentrations attached to proteoglycans on the surface of endothelial cells and in 
the extracellular matrix. 
 
Table 1.3 
CLASS NAME ACTIONS 
C-X-C IL-8 
Secreted by activated macrophages, 
endothelial cells, and other cell types and 
causes activation and chemotaxis of 
neutrophils, with limited activity on 
monocytes and eosinophils 
C-C 
MCP-1; eotaxin; 
MIP-1α; 
RANTES 
Generally attract monocytes, eosinophils, 
basophils, and lymphocytes but not 
neurophils. Eotaxin selectively recruits 
eosinophils 
C Lymphotactin Relatively specific for lymphocytes 
C-X3-C Fractalkine 
Exist in two forms: the cell surface bound 
protein can be induced on endothelial cells 
by inflammatory cytokines and promotes 
strong adhesion of monocytes and T cells; 
and a soluble form derived by proteolysis  
of the membrane-bound protein that has a 
potent chemoattractant activity for the 
same cells 
 
 Nitric oxide (NO), a pleiotropic mediator of inflammation, was discovered as a 
factor released from endothelial cells that caused vasodilation by relaxing vascular smooth 
muscle and was therefore called endothelium-derived relaxing factor. NO is a soluble gas 
that is produced not only by endothelial cells, but also by macrophages and some neurons 
in the brain. NO acts in a paracrine way on target cells through induction of cyclic 
guanosine monophosphate (GMP), which, in turn, initiates a series of intracellular events 
leading to a response, such as the relaxation of vascular smooth muscle cells. Since the in 
vivo half-life of NO is only seconds, the gas acts only on cells in close proximity to where it 
is produced. NO plays an important role in the vascular and cellular components of 
inflammatory responses. NO is a potent vasodilator by virtue of its actions on vascular 
 26 
smooth muscle. In addition, NO reduces platelet aggregation and adhesion, inhibits several 
features of mast cell-induced inflammation, and serves as an endogenous regulator of 
leukocyte recruitment. Blocking NO production under normal conditions promotes 
leukocyte rolling and adhesion in postcapillary venules, and delivery of exogenous NO 
reduces leukocyte recruitment. Thus, production of NO is an endogenous compensatory 
mechanism that reduces inflammatory responses. NO and its derivatives are microbicidal, 
and thus NO is also a mediator of host defence against infection. 
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CHAPTER 2 
ALLERGY 
 
 
 
2.1 Introduction to allergy 
 Allergic disorders, which affect approximately 30% of the population in developed 
countries, are genetically determined and/or environmentally affected multifactorial, 
refractory diseases. These disorders are associated with chronic inflammation characterized 
by influx of a large number of eosinophils and accumulation of mast cells in the lesions and 
increased IgE production (Parronchi et al., 2000; Valenta et al., 2004). Leukemic patients 
who did not have any allergic symptoms, developed allergic diseases after therapeutic 
transplantation of bone marrow stem cells from donors who had allergic disorders, 
suggesting that bone marrow-derived immune cells contribute to the development of 
allergic disorders. 
 The allergic inflammatory response is characterized by IgE synthesis, IgE-
dependent mast cell activation and connective tissue infiltration by T lymphocytes and 
eosinophils. The immediate-phase response is mediated by a range of inflammatory 
mediators such as histamine, leukotrienes, and prostaglandins, resulting in vasodilation, 
oedema, mucus secretion, itching. Individuals who experience a late-phase response have 
further symptoms 4-24 hours after the initial challenge with allergen. Biopsies indicate that 
the late-phase allergic response involves T lymphocyte activation, production of Th2-type 
cytokines and tissue eosinophilia. The pattern of the inflammatory responses to allergen is 
mediated by a number of different cells and a complex sequence of release of different 
inflammatory mediators. The cardinal features of allergic inflammation, which distinguish 
it from other types of inflammation, include IgE synthesis, IgE-dependent mast cell 
activation, and tissue infiltration of T lymphocytes and eosinophils. Allergen interaction 
with IgE on the surface of mast cells results in the production of a range of inflammatory 
mediators that may be granule-derived (e.g. histamine and tryptase) or newly formed 
membrane-derived mediators such as leukotrienes B4, C4, D4, and E4 and prostaglandins. 
Further mediators are bradykinin and platelet activating factor (PAF). There is good 
evidence that these agents mediate the immediate allergic response. Their biological actions 
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include vasodilation and increased vascular permeability (givin rise to oedema), stimulation 
of mucous secretion, and stimulation of afferent nerves promoting itching. Late-phase 
responses are characterized by the presence in the tissue of T lymphocytes and eosinophils. 
The mechanism of local tissue eosinophilia is not well understood, but it is hypothesized 
that the regulation of eosinophil movement and IgE production is under the T lymphocytes 
and mediated by Th2 cytokines. When biopsy tissue is taken from allergic individuals 24 
hours after an allergen challenge ouside the pollen season, a marked increased in the 
number of CD4+ T lymphocyte is seen (Varney et al., 1992). To identify the mediators 
released by these cells, in situ hybridization techniques – using RNA for selected cytokines – 
were carried out to monitor the increased gene expression. These experiments 
demonstrated an increased expression of IL-3, IL-4, IL-5, and GM-CSF at mRNA level 
after local allergen provocation (Durham et al., 1992). This interleukin profile is consistent 
with activation and proliferation of Th2 lymphocytes. By contrast, the Th1-type cytokines 
IL-2 and IFN-γ are not increased. Approximately 70-80% of IL-4 and IL-5-producing cells 
were T cells (Ying et al., 1992). IL-4, along with IL-13, is the key mediator in promoting B 
lymphocyte isotype switching in favour of IgE production. During the late-phase response, 
it was demonstrated that not only was there an increase in IL-4, but also significant 
elevation of Cε and Iε RNA expressing cells, suggesting that increased IgE synthesis may be 
occurring locally, although further studies to detect IgE protein production by B cells 
and/or plasma cells are required. Exaggerated IgE production is part of the phenomenon 
underlying the development of atopy. Just why allergic responses are different in each 
individual – for example some people develop asthma, some rhinitis, and others eczema – is 
not fully understood. It may be that the local T-cell response and B-cell IgE production 
predict target organ response, while the underlying predisposition to IgE 
hyperresponsiveness is determined by intrauterine, developmental or pollution factors. 
Another important effect of IL-4 is to promote increased expression of adhesion 
molecules (including VCAM-1) on vascular endothelium, which may selectively recruit 
eosinophils. Increased IL-5 production is also an important observation, since IL-5 is an 
eosinophil-specific cytokine (Takatsu et al., 2008) that is not only responsible for the 
terminal differentiation of eosinophils and their release from the bone marrow, but also 
during allergic reactions it promotes adhesion of the eosinophils to vascular endothelium 
and prolongation of their survival at the site of the inflammation, possibly by inhibition of 
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apoptosis. All these actions will have the effect of increasing the number of eosinophils in 
the tissue. Thus, it would appear that the late phase response is associated with T 
lymphocyte and eosinophil recruitment and activation and expression of Th2-type 
cytokines. Cytokine production occurs predominantly in T cells, with a smaller but 
significant amount being found in mast cells and eosinophils (Bradding et al., 1994). 
 Mast cells have long been recognized for their role in the genesis of allergic 
inflammation; and more recently for their participation in innate and acquired immune 
responses. These cells were first described by Paul Ehrlich in 1879, who called them mast 
cells from the German word mastzellen meaning well fed, as he observed the granular nature 
of these cells. He was also the first to demonstrate the metachromatic nature of the mast 
cells using special stains. Typically, mast cells stain metachromatically because of the 
interaction of the aniline dyes with acid heparin contained in their cell granules. Mast cells 
reside within tissues and including the skin and mucosal membranes, which interface with 
the external environment; as well as being found within vascularised tissues next to nerves, 
blood vessels and glandular structures. Mast cells have the capability of reacting both within 
minutes and over hours to specific stimuli, with local and systemic effects. Mast cells arise 
from pluripotential stem cells, mature in tissues, and have the ability to generate 
inflammation following exposure to a variety of receptor-mediated signals initiated by both 
innate and acquired immune response mechanisms. Mast cells are easily indentified by the 
presence of prominent granules within their cytoplasm. These mast cells are heterogeneous 
in morphology and staining characteristics (Fig. 2.1). Tissue mast cells can be activated in 
wound healing, fibrosis, cardiovascular disease and auto-immunity in addition to allergic 
inflammation. Upon activation of mast cells via cross-linking of the high affinity IgE 
receptor (FcεRI) or non-IgE-mediated activation through complement receptors or Toll-
like receptor (TLR) activation, mast cells can release a variable spectrum of pro-
inflammatory mediators. These include pre-formed mediators such as histamine, serotonin 
and proteases; newly synthesized mediators including leukotrienes and prostaglandins; and 
cytokines and chemokines (see table 2.1). In addition to IgE-mediated activation, human 
mast cells exposed to IFN-γ can be activated following IgG-mediated aggregation of FcγRI 
to release similar mediators (Tkaczyk et al., 2002). Addition IgE-independent mast cell 
triggers have been described. These include SCF, complement factors (C3a and C5a), 
neuropeptides (substance P), adenosine, TLR and scavenger receptors (Brown et al., 2007).  
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Figure 2.1 
Images of mast cells: (a) murine mast cells stained with Wright-Geimsa; (b) human CD34+-derived mast 
cells stained with toluidine blue; (c) murine skin mast cells stained with toluidine blue; (d) tryptase stained 
mast cells aggregated in the bone marrow of a mastocytosis patient; (e) HuMC stained with phalloidin for 
F-actin following treatment with 5-HT; (f) phagocytosed fluorescent Escherichia coli particles in BMMC 
(Brown et al., 2007) 
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 Table 2.1  
Class Mediators Physiologica Effects 
Preformed 
Mediators 
Histamine, serotonin, 
heparin, neutral proteases 
(tryptase and chymase, 
carboxypeptidase, cathepsin 
G), major basic protein, acid 
hydorlases, peroxidase, 
phospholipase 
Vasodilation/vasoconstriction; 
angiogenesis; mitogenesis; 
pain; protein 
processing/degradation; 
lipid/proteoglycan hydrolysis; 
arachidonic acid generation; 
tissue damage; inflammation 
Lipid 
Mediators 
LTB4, LTC4, PGE2, PGD2, 
PAF 
Leukocyte chemotaxis; 
vasoconstriction; 
bronchoconstriction; platelet 
activation; vasodilation 
Cytokines 
TNF-α, TGF-β, IFN-α, 
IFN-β, IFN-γ, IL-1α, IL-
1β, IL-3, IL-4, IL-5, IL-6, 
IL-8, IL-9, IL-10, IL-11, IL-
12, IL-13, IL-15, IL-16, IL-
18, IL-25, SCF, MIF 
Inflammation; leukocyte 
migration/proliferation  
Chemokines 
CXCL8, CCL2, CCL3, 
CCL5, CCL7, CCL13, 
CCL11, CCL19 
Chemoattraction and tissue 
infiltration of leukocytes 
Growth 
Factors 
CSF, GM-CSF, bFGF, 
VEGF, NGF, LIF 
Growth of various cell types; 
vasodilation; 
neovascularisation; 
angiogenesis 
 
The level and pattern of mediator release is influenced by cytokines, growth factors and 
microenvironmental conditions.For example, IL-4 enhances FcεRI-mediated reactions from 
human mast cells (Bischoff et al., 1999). In addition to enhancing activation of mast cells, 
several modulatory cytokines produced by regulatory T cells such as IL-10 and TGF-β can 
decrease FcεRI-mediated reactions (Gebhardt et al., 2005). Mast cell activation and 
mediator release can independently, as well as in concert with other immune cells, induce 
much of the pathology observed in allergic inflammatory conditions. Mast cell mediators 
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such as histamine, leukotrienes, and prostaglandins contribute to eosinophil recruitment, 
increase vascular permeability, and smooth muscle contraction. Proteases can activate 
fibroblasts thereby promoting collagen deposition and fibrosis (Levi-Schaffer et al., 2003). 
Mast cell-derived cytokines have numerous effects on other cells of the immune system as 
well as endothelial cells. These mediators can cause B cells to class switch to synthesize IgE, 
induce basophil histamine release, recruit neutrophils and eosinophils, and promote the 
development of T cells into a T helper 2 (Th2) phenotype (Gauchat et al., 1993). Mast cell 
products may both induce an immediate reaction and contribute to a late-phase reaction. 
The immediate phase reaction occurs within minutes of FcεRI cross-linking and its 
consequences are referred to as an immediate hypersensitivity reaction. Pre-formed granule-
associated and newly generated mediators released during this phase include histamine, 
proteases and lipid-derived mediators. Late phase reactions peak 6-12 h following antigen 
challenge and are associated with cytokine and chemokine production and release in part 
form eosinophils, neutrophils and basophils that have entered the inflammatory site 
following the immediate reaction (Fig. 2.2). Therefore, mast cells have long been recognized 
for their role in immediate hypersensitivity reactions, by virtue of the presence of high 
affinity receptors for IgE (FcεRI) on their surface. More recently, mast cells have been 
postulated to be involved in a variety of chronic inflammatory disorders as numerous 
mediators released by activated mast cells are characterized. The humoral and cellular 
inflammatory responses occurring during immediate hypersensitivity reactions are initiated 
by numerous mediators of mast cells and possibly basophils.  
 
2.2 Mast cells and their mediators 
As shown in Table 2.1 some mediators are stored preformed in the secretory 
granules of mast cells and are released rapidly upon mast cell activation by a process of 
regulated secretion or degranulation. Other mediators are synthesized de novo upon mast 
cell activation and are released without a prolonged intracellular storaged phase after 
variable time intervals. In humans, the principal preformed mediators of mast cells include 
histamine, proteoglycans, neutral proteases, and possibly, basic fibroblast growth factor. 
Newly generated mediators include the arachidonic acid metabolites prostaglandin D2, and 
leukotriene (LT) C4, and TH2-like cytokines such as interleukins (ILs) 4, 5, 6, and 13, and 
tumor necrosis factor α (TNF-α): 
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 Preformed granule associated mediators 
BIOGENIC AMINES: Histamine is stored in secretory granules of mast 
cells, is bound to carboxyl and sulphate groups on protein and 
proteoglycans, and is the sole biogenic amine in human mast cells and 
basophils. Human mast cells contain 1 to 5 pg of histamine per cell 
(Schwartz et al., 1987), which is equivalent to a concentration of 0,1 M inside 
the secretory granules. In constrast, plasma concentration of histamine 
averages 2nM. Intermediate concentrations in various biologic fluids, such as 
nasal lavage fluid reflect local rates of production and diffusion or 
metabolism. After mast cell degranulation, released histamine is metabolized 
within minutes. Elevated levels of histamine in plasma or urine are found 
following anaphylactic reactions and indicate mast cell or basophil 
involvement. Histamine exerts potent biologic effects through its interaction 
with cell specific receptors designated H1, H2 and H3 receptors (Arrang et 
al., 1987; Black et al., 1972; Polk et al., 1988). Stimulation of H1 receptors 
results in vasodilation and increased capillary permeability, contraction of 
bronchial and grastrointestinal smooth muscle, and increased mucous 
secretion at mucosal sites. H2 receptor agonists stimulate gastric acid 
secretion and exerts numerous effects on cells of the immune system, 
including augmentation of suppression by T lymphocytes, inhibition of 
mediator secretion by cytotoxic lymphocytes and granulocytes, and 
suppression of eosinophil chemotaxis (Clark et al., 1975). Additional effects 
include activation of endothelial cells to release prostacyclin, a potent 
inhibitor of platelet aggregation. Stimulation of H3 receptors affects 
neurotransmitter release and histamine production in the central and 
peripheral nervous system (Arrang et al., 1988). H3 receptors are postulated 
to mediate interactions between mast cells and peripheral nerves, and they 
may be involved in histamine-mediated neurogenic hyperexcitability. 
PROTEOGLYCANS: the presence of highly sulphated proteoglycans in 
secretory granules of mast cells confers the metachromatic staining 
properties of these cells when stained with basic dyes, such as toluidine blue 
or alcian blue (Fig. 2.2).  
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In human mast cells, heparin and chondroitin sulphate E are the major 
intracellular proteoglycans (Stevens et al., 1988; Thompson et al., 1988). 
Heparin is found in all mature mast cells, but not in other cell types. The 
biologic functions of endogenous mast cell proteoglycans await further 
clarification. These proteoglycans bind to histamine, neutral proteases, and 
acid hydrolases at the acidic pH found inside the mast cell secretory 
granules, and may play an important role in intracellular packaging. Heparin 
facilitates processing of chymase and tryptase forms to their active forms. 
The stabilizing effect of heparin and (to a lesser degree) chondroitin sulphate 
E on tryptase activity may be critical for mast cell physiology. Heparin and 
chondroitin sulphate E express anticoagulant, anticomplement, and 
antikallikrein activities. Heparin facilitates fibroblast growth factor activity in 
cutaneous mast cells and modulates the cell adhesion properties of matrix 
proteins, such as vitronectin, fibronectin and laminin. 
NEUTRAL PROTEASES: cleave peptide bonds near neutral pH and are 
the dominant protein components of secretory granules in rodent and 
human mast cells from one another. Tryptase is a serine class protease with 
tryptic-like activity. It is stored in secretory granules bound to heparin, which 
 
Figure 2.2 
Well differentiated canine mast cells. (From the internet) 
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is essential for tryptase  to retain its enzymatic activity, and it is not inhibited 
by biologic inhibitors of serine proteases present in plasma and urine. 
Tryptase is present in all mast cells at concentrations that vary from 10 pg 
per mast cell derived from the lung to 35 pg per mast cell derived from the 
skin. Negligible amounts have been have been detected in human basophils 
(0,04 pg/cell), but not in other cell types (Xia et al., 1995). Tryptase is 
released together with histamine during degranulation and serves as a 
specific marker of human mast cells. Potential biological activities of tryptase 
include inactivation of fibrinogen, with subsequent anticoagulant effect, 
which explains the lack of fibrin deposition in reaction involving urticaria 
and angioedema, and consequently, their rapid resolution. Tryptase 
augments histamine constriction effects on airway smooth muscles and 
degrades vasoactive intestinal peptide (an intrinsic neuropeptide with 
bronchodilating properties), effects that may result in increased 
bronchospasm. Chymase is a serine protease with chymotryptic-like activity 
that was purified from human skin. Like tryptase, chymase is bound to 
heparin, but remains stable after dissociation from heparin. Chymase activity 
is inhibited by the classical biologic inhibitors of serine proteases. Potential 
biological activity of chymase include activation of angiotensin I and 
procollagenase and inactivation of bradykinin. Chymase digests the lamina 
lucida of the basement membrane at the dermal-epidermal junction of 
human skin and degrades substance P, vasoactive intestinal peptide, and 
probably other neuropeptides. Dog chymase stimulates mucous production 
from glandular cells in vitro (Sommerhoff et al., 1989), suggesting a similar 
role in allergic disorder at various organ sites, such as mucous hypersecretion 
in asthma and allergic rhinitis and mucous hypersecretion in allergic ocular 
disorders. Chatepsin G is a serine neutral protease with chymotryptic activity 
that colocalizes with chymase in human mast cells. It also found in 
neutrophils and monocytes and therefore cannot be used as a specific 
marker of mast cells. 
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 Newly generated mediators 
LIPID MEDIATORS: unstimulated mast cells incorporate exogenous 
arachidonic acid into membrane and cytoplasmic lipid. Upon activation of 
mast cells, arachidonate released by hydrolysis of these lipids is metabolized 
along the cycloxygenase pathway, givin rise to PGs and thromboxane, or 
(along the lipoxygenase pathway) LTs. The production of arachidonic acid 
metabolites begins within minutes of cell activation and lasts to about 30 
minutes. Relative production of these lipid mediators cannot be used to 
distinguish various types of mast cells. The biologic activity of arachidonic 
acid metabolites has been underscored by the favourable clinical effects of 5-
lipoxygenase inhibitors in atopic and aspirin-induced asthma, where mast 
cell activation occurs. 
CYTOKINES: upon activation human mast cells produce an array of 
cytokines, including up-regulation of the IL-4 gene cluster on human 
chromosome 5 (IL-4, IL-5, IL-6, IL-9, IL-13, and granulocyte macrophage-
colony stimulating factor), and of TNF-α on human chromosome 6 (Walsh 
et al., 1991; Bradding et al., 1993;  Burd et al., 1995). Mast cells preferentially 
produce IL-13 over IL-4 as opposed to basophils, which produce more IL-4. 
Cytokine production occurs minutes to hours following mast cell activation. 
Cytokines derived from activated mast cells serve to activate endothelial 
cells to recruit eosinophils and other inflammatory cell types at the site of 
immediate hypersensitivity reactions, thus giving rise to the late phase of 
allergic response and sustained inflammation. These cytokines also may be 
involved in modulating the local distribution of the Th1 and Th2 types of T 
lymphocytes, thereby expanding the biologic role of mast cells far beyond 
type I hypersensitivity reactions only. 
 Another cell type that is involved in the development of the allergic inflammatory 
response is the Th lymphocyte. Since the discovery of two distinct types of Th cells (IFN-γ-
producing Th1 cells and IL-4-producing Th2 cells) in mice by Coffman and collegues 
(1986), mutual regulation between Th1 and Th2 cells (Th1/Th2 balance) has been 
considered to be important for homeostatic maintenance of the immune system in the 
whole body. The dysregulation of the Th1/Th2 balance leads to excessive Th1 or Th2 cell 
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activation, resulting in the development of autoimmune diseases associated with 
accumulation of Th1 cells or induction of allergic diseases due to accumulation of Th2 cells, 
respectively (Bach, 2002). Thus, the concept of a Th1/Th2 balance provided the basis for 
understanding the molecular mechanisms of immune responses and/or disease 
development and has been widely accepted as a “paradigm” of the immune system for the 
past two decades. The factors responsible for the Th cell polarization into a predominant 
Th1 or Th2 profile have been extensively investigated. Current evidence suggest that Th1 
and Th2 cells develop from the same Th-cell precursor under the influence of mechanisms 
associated with antigen presentation. Both environmental and genetic factors influence the 
Th1 or Th2 differentiation by determining the “leader cytokine” in the microenvironment 
of the responding Th cell. IL-4 is the most powerful stimulus for Th2 differentiation, 
whereas IL-12 and IFNs favour Th1 development. A role has been demonstrated for the 
site of antigen presentation, the physical form of the immunogen, the type of adjuvant, and 
the dose of antigen. Potent adjuvants and microbial products induce Th1-dominated 
responses because they stimulate IL-12 production. On the contrary, both the primary 
source of IL-4 and the mechanisms responsible for its early production involved in the 
differentiation of naïve Th cells into Th2 effectors are still unclear. Th1- and Th2-
dominated responses not only provide different strategies of protection against pathogens, 
but also play a role in some physiologic and pathophysiologic conditions. Evidence is 
accumulating in animal models to suggest that Th1 responses are involved in the genesis of 
organ-specific autoimmune diseases, such as experimental uveo-retinitis, experimental 
encephalomyelitis, or insulin-dependent diabetes mellitus. Th2 responses are apparently 
insufficient per se to protect against the majority of infectious agents but can provide some 
protection against parasites and by limiting potentially harmful Th1-mediated responses. On 
the other hand, changes in autoimmune diseases that could not be explained by the 
Th1/Th2 paradigm were also observed in several settings: unexpectedly, IFN-γ/IFN-γ-R-
deficiency or neutralization resulted in exacerbation, rather than attenuation, of 
development of autoimmune diseases such as murine encephalomyelitis (Ferber et al., 
1996), arthritis (Vermeire et al., 1997), uveitis (Jones et al., 1997), and nephritis (Ring et al., 
1999), which have classically been considered to be Th1-mediated diseases. Therefore, the 
paradigm has been recently integrated with the Th17 cells (Oboki et al., 2008) (Fig. 2.3). 
Allergic asthma is considered to be a Th2-dominant chronic inflammatory disease  of the 
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lungs. Th2 are characterized by secretion of IL-4, IL-5, IL-9 and IL-13. The transcription 
factor GATA-binding protein 3 (GATA3) is crucial for the differentiation of uncommitted 
T cells into Th2 cells and regulates the secretion of Th2 cytokines (Ho et al., 2007). There is 
an increase in GATA3+ T cells in the airways of stable asthmatic subjects. Nuclear factor of 
activated T cells (NFAT) is a T-cell specific transcription factor and enhances the 
transcriptional activation of the Il4 promoter by GATA3. Finally, IL-33, a member of the 
IL-1 family of cytokines, promotes differentiation of Th2 cells by translocating to the 
nucleus and regulating transcription through an effect on chromatin structure (Carriere et 
al., 2007), but it also acts as a selective chemoattractant of Th2 cells (Komai-Koma et al., 
2007). Increased Th2-cytokine and IgE levels and accumulation/activation of Th2 cells, 
eosinophils and mast cells are observed in asthmatic lungs (Wills-Karp, 1999; Cohn et al., 
2004). 
 IL-4 plays a critical role in the differentiation of Th2 cells from uncommitted Th0 
cells and may be important in initial sensitization to allergens. It is also important for 
isotype switching of B cells from producers IgG to producers of IgE. IL-13 mimics IL-4 in 
inducing IgE secretion and causing structural changes in the airways, but does not play a 
role in promoting Th2 cell differentiation. IL-13 has attracted particular attention as a 
therapeutic target for the treatment of asthma, as it not only induces airway 
hyperresponsiveness in animal models of asthma, but also produces several of the structural 
changes seen in chronic asthma (Wills-Karp et al., 2004). 
 The transcription factor T-bet is crucial for Th1 cell differentiation and secretion of 
the Th1-type cytokine IFN-γ. Consistent with the prominent role of Th2 cells in asthma, T-
bet expression is reduced in T cells from the airways of asthmatic patients compared with 
airway T cells from non-asthamtic patients (Finotto et al., 2002). After phosphorylation, T-
bet associates with and inhibits the functions of GATA3 by preventing it form binding to 
its DNA target sequences. In turn, GATA3 inhibits Th1-type cytokines by inhibiting 
STAT4, the main transcription factor activated by T-bet-inducing IL-12. Th1 cells are the 
prominent CD4+ T cells, and Tc1 cells the predominant CD8+ T cells expressed in chronic 
obstructive pulmonary disease lungs. IFN-γ is the predominant cytokine produced by Th1 
and Tc1 cells and may play an important role in inflammation by inducing the release of 
chemokines. In contrast, it is usally found at reduced levels in individual with asthma, 
 43 
although levels of IFN-γ are increased in patients with more severe disease and acute 
exacerbations. 
 Th17 cells are a subset of CD4+ T cells that play an important role in inflammatory 
diseases and are regulated by the transcription factor retinoic acid orphan receptor-γt 
(RORγt). IL-6, IL-1β, TGF-β, and IL-23 are all involved in the differentiation of human 
Th17 cells. Th17 cells also produce IL-21 which is important for the differentiation of these 
cells and thus acts as a positive autoregulatory factor. It also inhibits expression of the 
forkhead transcription factor forkhead box P3 (FOXP3) and thereby the development of 
Treg. IL-22 is also released by Th17 cells and stimulates the production of IL-10 and acute-
phase proteins. IL-25 (IL-17E) another member of the IL-17 superfamily, is produced by 
Th2 cells, mast cells, and epithelial cells. IL-25 induces the expression of IL-4, IL-5, and IL-
13, resulting in inflammation mediated by eosinophils, increased IgE production and 
allergic hyperresponsiveness in mice. A blocking antibody specific for IL-25 inhibits the 
development of allergic hyperresponsiveness in response to allergens in mice and is in 
clinical development for asthma (Ballantyne et al., 2007). 
 Several cytokines implicated in allergic inflammation either promote the 
differentiation and survival of inflammatory cells or result in proliferation and/or activation 
of structural cells, contributing to tissue remodelling. Examples are GM-CSF and SCF. 
Another class of compounds that have growth factor-like characteristics are the 
neurotrophins. Neurotrophins are cytokines that play an important role in the function, 
proliferation and survival of autonomic nerves. In sensory nerves, neurotrophins increase 
responsiveness and expression of takychinins. Nerve growth factor (NGF) may be 
produced by mast cells, lymphocytes, macrophages and eosinophils as well as structural 
cells, such as epithelial cells, fibroblasts, and smooth muscle cells. Although neurotrophins 
have predominant effects on neuronal cells, they can also act as growth factors for 
inflammatory cells, such as mast cells, as well as increasing chemotaxis and survival of 
eosinophils (Freund-Michel et al., 2008; Nassenstein et al., 2006). 
 Chemokines play a fundamental role in the recruitment of inflammatory cells from 
the circulation to the site of antigen exposure. There has been particular interest in the role 
of cemokines in the allergic inflammation as they signal through GPCRs, for which small 
molecule antagonists can be relatively easily developed. Chemokines are best discussed in 
the light of the receptors to which they bind, and these are divided into receptors for CC 
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chemokines (CCRs), receptors for CXC chemokines (CXCRs), and the receptor for the 
lone CX3C chemokine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IL-17 can potentiate bronchial fibroblast, epithelial cell and smooth muscle cell activation 
enhancing IL-6, IL-8, IL-11 and CXCL1/Groα production by bronchial fibroblast, β-
defensin-2, ICAM-1, IL-8, CXCL1, CCL20, G-CSF, MUC5B and MUC5AC 
expression/production by human bronchial epithelial cells, and IL-6 and IL-8 production 
by human airway smooth muscle cells. Nevertheless, these IL-17-mediated inflammatory 
mediators do not seem to contribute to the development of Th2-mediated eosinophil-
dominant allergic asthma, since IL-8 and CXCL1/Groα are potent chemoattractant factors 
 
Figure 2.2 
The revised scheme of Th cell differentiation in humans and mice. In the mouse, naïve T cells differentiate 
into Th1 cells in the presence of IL-12 or IL-27, Th2 cells in the presence of IL-4, TSLP or IL-25, Th17 
cells in the presence of IL-23 after TGF- β1 plus IL-6- or IL-21-mediated cell differentiation, Tr1 cells in 
the presence of IL-27 after TGF- β1 plus IL-6- or IL-21-mediated cell differentiation, and Th3/iTreg cells 
in the presence of TGF-β1 and IL-2. In man, naïve T cells differentiate into Th1 cells in the presence of IL-
2, Th2 cells in the presence of IL-4 and Th17 cells in the presence of IL-1β plus IL-6 or IL-1β plus IL-23. 
The mechanisms of human Tr1 and Th3/iTreg cell differentiation remain unclear. 
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for neutrophils, and IL-6 and G-CSF are important for granulopoiesis, especially neutrophil 
development. In addition, IL-17 inhalation led to induction of neutrophilia rather than 
eosinophilia in the airways of rodents (Laan et al., 1999; Hoshino et al., 1999). However, 
these observations may provide us with new insight into the pathogenesis of “non-Th2-
type” asthma. The heterogeneity in the symptoms of asthma has been classified as atopic 
and non-atopic and eosinophilic and non-eosinophilic. Amin et al. (2000) demonstrated 
that atopic asthmatics showed Th2-type airway inflammation characterized by increased IL-
4+ and IL-5+ cells and eosinophils in bronchial biopsies and increased serum IgE levels, 
whereas non-atopic asthmatics exhibited non-Th2-type airway inflammation characterized 
by increased IL-8+ cells and neutrophils in bronchial biopsies, and no elevation of serum 
IgE. On the other hand, increased mast cell accumulation was observed in both atopic and 
non-atopic patients irrespective of the IgE level. 
Allergic and parasitic worm immunity is characterized by infiltration of tissue with 
IL-4- and IL-13-expressing cells, including Th2 cells, eosinophils and basophils. Tissue 
macrophages assume a distinct phenotype, designated alternatively activated macrophages. 
The major mast cell product PGD2 is released during the allergic response and stimulates 
the chemotaxis of eosinophils, basophils, and Th2-type T lymphocytes (Schleimer et al., 
1985; Lewis et al., 1982). The chemoattractant receptor homologous molecule of Th2 cells 
(CRTH2) has been shown to mediate the chemotactic effect of PGD2. PGH2 is the 
common precursor of all PGs and is produced by several cells that express cyclooxygenases. 
Like other prostanoids, PGD2 rises from the phospholipase A2/arachidonic 
acid/cyclooxygenase pathways. PGD2 is finally isomerized by from the primary 
cyclooxygenase product, PGH2, by two specific cytosolic enzymes: lipocalin-type PGD 
synthase (PGDS) and hematopoietic PGDS. The latter is express in immune cells such as 
mast cells, antigen-presenting cells, microglia, and Th2-type lymphocytes (Kanaoka et al., 
2003; Mohri et al., 2003). In contrast, lipocalin-type PGDS is most abundant in the CNS 
but can also be found in osteoblasts, male genital organs, the heart, and vascular 
endothelium (Urade et al., 2000; Grill et al., 2008; Schuligoi et al., 2005; Gallant et al., 2005). 
Upon damage of these tissues, lipocalin-type PGDS become up-regulated and is also been 
secreted into the cerebrospinal liquor, seminal fluid, and blood plasma, respectively. In 
agreement with the expression patterns and localization of PDGS, PGD2 has been 
implicated in allergic disease, sleep, nociception, male fertility, and vascular function. 
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Importantly, Sculigoi et al. (2009) demonstrated that PGH2 potently induces the chemotaxis 
of human eosinophils, elicits a shape change, and stimulates intracellular Ca2+ flux and that 
these effects appear to be mediated by the CRTH2 receptor. Also endothelial cells are able 
to release PGH2 in response to mechanical stimuli, acetylcholine, endothelin-1, and IL-1β. 
These studies suggest that activation of endothelial cells results in enhanced metabolization 
of arachidonic acid to PGH2, which cannot be metabolized any further by prostacylin 
synthase or other PG synthases as a result of the limited capacity and, thus, PGH2 is 
released untransformed from cells (Folco et al., 2006). The released PGH2 can promote 
platelets aggregation and vasoconstriction acting on thromboxane receptor TP (Corey et al., 
1975; Saito et al., 2003). Furthermore, PGH2 can activate two prostanoid receptors CRTH2 
and DP that regulate inflammatory cells that are involved in the allergic response and that 
point to a novel role of PGH2 in leukocyte-endothelial cell interaction in allergic disease. 
PGH2 acts on the CRTH2 receptor of eosinophils causing their shape change and acting 
rearrangement, almost as potently as eotaxin – which binds the CCR3 receptor and is the 
most potent eosinophil chemoattractant known – and similarly to basophils. Consistent 
with its effect to cause eosinophil shape change, PGH2 also induced the elevation of 
intracellular free Ca2+ in eosinophils to similar levels as PGD2 and eotaxin. Therefore, the 
primary role of PGD2 and CRTH2 in eosinophil function is the regulation of eosinophil 
trafficking, as activation of CRTH2 results in eosinophil mobilization from bone marrow, 
direct stimulation of chemotaxis, and priming eosinophil for migration toward other 
chemoattractants (Hirai et al., 2001; Heinemann et al., 2003; Schratl et al., 2006; Royer et al., 
2007). Accumulation of eosinophils at sites of allergic reactions is a hallmark of tissue injury 
and lung dysfunction. Asthmatic patients that receive treatment based on eosinophil count 
in sputum have significantly fewer severe asthma exacerbations than patients treated 
according to standard management therapy (Green et al., 2002). Moreover, genetically 
modified mice lacking eosinophils are protected against allergen-induced lung injury and 
asthma. It is now clear that the mast cell-derived and T cell-derived cytokines, such as IL-5 
and GM-CSF, are pivotal in eosinophil maturation and chemotaxis (Rothenberg, 1998; 
Lampinen et al., 1999; Oliveira et al., 1997). Mast cell-derived chemokines and inflammatory 
cytokines, such as TNF-α and IL-2, also can regulate eosinophil chemotaxis, activation, and 
function. This mast cell-eosinophil axis needs further study, as it could lead to insights into 
the pathogenesis of chronic allergic inflammation and may lead to new therapeutic targets. 
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Mast cells and eosinophils colocalize in diseases such as allergic responses and 
parasitic diseases. Eosinophil participation in allergic responses is in turn mediated by the 
release of a plethora of mediators when activated. Studies from several laboratories suggest 
that ligand-receptor interactions, such as stem cell factor (SCF)-c-kit and cytokine-cytokine 
receptor interaction, as well as tryptase protein-activated receptor 2 (PAR2) binding, may 
mediated mutual activation and signalling in mast cell-eosinophil interactions. Among the 
mast cell products that affect eosinophils are cytokines, including IL-1, IL-3, Il-4, IL-5, IL-
13, TNF-α, and GM-CSF, and chemokines, including IL-8, eotaxin, regulated upon 
activation normal T cell expressed and secreted (RANTES), and monocyte chemotactic 
protein 1 (MCP-1). In human allergies, mast cells may serve as amplifiers of IgE-mediated 
inflammatory responses and eosinophil influx. Kung et al. (1995) using mast-cell deficient 
mice demonstrated that these mice develop less eosinophila than their normal counterpart. 
In another study by Das et al. (1998) mast cells were required for the induction of 
eosinophilia in response to eotaxin injection in air pouches of sensitized mice. Thus, in all 
likelihood, based on their prolific cytokine/chemokine synthetic capacity, human mast cells 
play a pivotal role in allergic inflammation and in eosinophil mediated diseases. 
 
2.3 Cytokine expression in allergic inflammation 
Allergic inflammatory responses are driven by cells of the immune system that rely 
on cytokines to regulate the activity of other immune and structural cells. Cytokines are 
extracellular signalling proteins produced by different cell types that act on target cells to 
modulate diverse cellular functions. Some cytokines recruit specific cell types to the site of 
inflammation; others can act on immune cells to increase activation and survival, whereas 
some, like INF-γ, suppress cellular activity. The role of cytokines to mount an adequate 
immune response is further supported by the ability of lymphokines to induce 
immunoglobulin isotype switch in B cells and to modulate T cell differentiation. Therefore, 
identifying the pattern of cytokine expression observed during the development of allergic 
inflammation provides a valuable insight to the underlying immunological mechanisms. 
Allergen challenge studies have demonstrated that chemotactic cytokines and lymphokines 
are significantly increased as a result of allergen challenge. Chemokines, such as eotaxin and 
MIP-1α, are released by immune and structural cells of the injured tissue and are 
responsible for the late recruitment of eosinophils, neutrophils and basophils to the site of 
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inflammation. This recruitment is an essential step in the development of the late-phase 
allergic response and, therefore, it represents a candidate immunological mechanism to be 
targeted by new therapeutic approaches. 
Here follows a list of some important cytokines involved in allergic disease: 
o SCF (Stem Cell Factor): SCF bind to its receptor c-kit which is present, in 
particular, on mast cells and eosinophils. Hence, SCF is also called c-kit-ligand 
and, because it is encoded by the steel locus, it has also been referred to as the 
steel factor. SCF induces growth of mast cells and also regulates their activation, 
degranulation, and chemotaxis. Many factors, including mast cell cytokines and 
chymase, regulate expression of SCF by human eosinophils. Thus, the addition 
of cytokines or chymase to eosinophils induces SCF secretion. Several studies 
support the hypothesis that paracrine and autocrine SCF-based loops can 
regulate bidirectional mast cell-fibroblast-eosinophil interactions, leading to 
chronic inflammation. SCF is produced by epithelial cells, smooth muscle cells, 
endothelial cells, fibroblasts, mast cells, and eosinophils. It is a critical growth 
factor for mast cells and promotes their generation from CD34+ progenitors. 
SCF induces mast cell survival, adhesion, chemotaxis, degranulation, which 
releases histamine and tryptase, and synthesis of pro-inflammatory cytokines 
and chemokines. SCF is upregulated by inflammatory stimuli and shows 
increased expression in epithelial cells of the inflamed tissue. A bloking antibody 
specific for SCF inhibits the inflammation mediated by eosinophils after allergen 
exposure (Berlin et al., 2004). 
o IL-1β and TNF-α: important cytokines expressed by human mast cells. They 
induce the expression of chemokines from adventitial cells, such as fibroblasts, 
which in turn serve to chemoattract eosinophils. IL-1β increases eosinophil 
survival through paracrine production of TNF-α, IL-5, and GM-CSF from mast 
cells in an autocrine manner. TNF-α is stored in mast cells granules and has 
important effects on eosinophil function inducing the release of GM-CSF that 
increase their survival and the NF-κB translocation to the nucleus. TNF-α 
activates eosinophils and stimulate them to release eosinophil peroxidise (EPO). 
It can act direcly on the smooth muscle increasing the sensitivity to spasmogens 
and may thus play a role in asthma, or can play a role in the amplification of the 
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allergic inflammation throught the activation of NF-κB. IL-1β expression is 
increased is increased in allergic individuals and activates many inflammatory 
genes that are expressed in allergy. IL-1 receptor antagonist (IL-1ra) 
administration reduces the allergic response in mice, but human recombinant 
IL-1ra is not effective. 
o IL-2: important eosinophil chemoattractant. Although its dominant source is 
the T cells, mast cells and eosinophils are able to express this cytokine. IL-2 can 
enhance eosinophil cationic protein production in platelet activating factor-
stimulated eosinophils. IL-2 is an important eosinophilic activator and induces 
the release of eosinophil peroxidase and IL-6 from these cells. IL-2 can regulate 
eosinophil chemotaxis, and eosinophilia is a recognized feature of the adverse 
effect of infusion of recombinant IL-2. 
o IL-3, IL-5, and GM-CSF: these cytokines together regulate growth, 
differentiation and survival of eosinophils, while their absence is cause of 
apoptosis and death of these cells. This survival is necessary for eosinophils to 
sufficiently exert their effects. IL-3, IL-5 and GM-CSF delay the apoptosis of 
eosinophils for a minimum of 12-14 days, whereas in their absence, the life-span 
of these cells does not exceed 48 hours. They also cause eosinophils to express 
large numebers of receptors for cytokines, immunoglobulins, and complement. 
IL-5 induces eosinophil differentiation in the bone marrow and also stimulate 
eosinophil precursors to synthesize granule proteins. IL-5, like GM-CSF, is also 
essential for eosinophil activation and may play a role following tissue 
infiltration by the eosinophil. IL-3 is a hematopoietic cytokine that activates 
eosinophils and allows them to present superantigens and peptides to T cells. It 
also downregulates the chemokine receptor CCR3 from the surface of the 
human eosinophil. IL-3 works in tandem with IL-5 to induce differentiation of 
eosinophil progenitor cells. GM-CSF induces hypodense, activated eosinophils 
and prolongs eosinophil survival secondary to its production and release by 
activated mast cells through TNF-α. GM-CSF can also induce the release of 
EPO from eosinophils. Thus, induction of autocrine and paracrine GM-CSF 
production is one of the ways mast cell increase eosinophil survival. The major 
sources of IL-5 are Th2 cells, Tc2 cells, mast cells, eosinophils, and γδT cells. 
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IL-5 acts as a co-activator of B cell proliferation in combination with anti-
CD38. Eosinophil development is supported by GM-CSF, IL-3 and IL-5. 
Among these cytokines IL-5 signaling is especially important to develop 
eosinophilia. In fact, IL-5 plays a key role in inflammation mediated by 
eosinophils, since it is critically involved in the differentiation of eosinophils 
from bone marrow precursor cells and also prolongs eosinophil survival. 
Systemic and local administration of IL-5 to allergic patients results in an 
increase of in circulating eosinophils and CD34+ eosinophil precursors (Stirling 
et al., 2001). GM-CSF plays a role in the differentiation and survival of 
eosinophils, neutrophils, and macrophages. It is secreted predominantly by 
macrophages, epithelial cells and T cells in response to inflammatory stimuli.  
o IL-4 and IL-13: key cytokines responsible for the late phase reaction observed 
in allergic inflammation. Both IL-4 and IL-13 are products of human mast cells. 
IL-4 regulates IgE synthesis and also allows for eosinophil recruitment. IL-4 
also regulates eosinophil apoptosis, thus contributing to the resolution of 
inflammation. IL-13 can prolong eosinophil survival by inducing autocrine 
production of IL-3, IL-5, and GM-CSF. IL-4 and IL-13 can also affect 
eosinophils by also enhancing the activating effect of TNF-α. This effect is also 
seen with IL-5, suggesting an in vitro synergism among all four of these 
cytokines. IL-4 and IL-13, however, play a pivotal role in transmigration of 
eosinophils across the endothelium of vasculature by activation of adhesion 
pathways specific to eosinophils as well as promoting IL-5 and eotaxin 
production by inflammatory cells. IL-4 induces vascular cell adhesion molecule 
1 (VCAM-1) on endothelial cells, allowing eosinophil recruitment into tissue 
involving VCAM-1- very late antigen 4 (VLA-4) interactions. Eosinophils tether, 
roll, and accumulate when exposed to endothelial cells activated by IL-4 and 
expressing VCAM-1. Inhibition of VCAM-1 or VLA-4 integrin leads to the 
inhibition of eosinohil tethering. When IL-4 is injected into the tissue, leukocyte 
recruitment occurs, and the majority of these infiltrating cells are eosinophils. 
IL-4, in conjunction with IL-1 and TNF-α, also induces eotaxin from 
endothelial cells which, in turn, modulates eosinophil recruitment. IL-13 induces 
inflammation through stimulating the expression of multiple chemokines, 
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including CCL11 (also known as eotaxin) from structural cells in the airways, 
including epithelial cells. IL-13 is produced by several cell types in addition to 
Th2 cells, (Th1 cells, Tc2 cells, and invariant NKT cells). After antigen challenge 
there is a transient increase in IL-4, whereas the release of IL-13 is sustained and 
correlates with the increase in the number of eosinophils (Kroegel et al., 1996). 
o IL-6: often works in concert with other cytokines and provides a link between 
innate and acquired immunity. IL-6 is found in increased amounts in induced 
sputum of asthmatic patients after mast cell activation. It may play a role in the 
expansion of Th2 and Th17 cells and therefore have a proinflammatory effect in 
asthma. IL-6 release C-reactive protein from the liver and can be involved in 
some systemic features of allergies such as muscle weakness and endothelial 
dysfunction. 
o IL-9: its overexpression in mice induces inflammation mediated by eosinophils, 
mucous hyperplasia, mastocytosis, airway hyperresponsiveness, and increased 
expression of other Th2 cytokines and IgE (Zhou et al., 2001). Many of the 
effects of IL-9 in mice (eosinophilic inflammation and mucous hypersecretion) 
are mediated via the release of IL-13, whereas its effect on mast cell expansion 
and B cells seem to be direct. IL-9 plays an important role in differentiation and 
proliferation of mast cells and interacts synergistically with SCF. 
o Type I and type III IFNs: Type 1 INFs (IFN-α and INF-β) and type III 
INFs (IFN-λ) play an important role in innate immunity against viral infections, 
but IFN-β and IFN-λ show reduced expression in epithelial cells of asthmatic 
patients and are associated with increased rhinovirus replication, which may 
predispose these patients to viral exacerbation of asthma. Low dose IFN-α 
seems to give marked benefit in patients with severe corticosteroid-resistant 
asthma but the mechanism is unknown. 
o IL-12 and related cytokines: IL-12 plays an important role in differentiating 
and activating Th1 cells and is produced by activated macrophages, dendrocyte, 
and airway epithelial cells. IL-12 induces T cells to release IFN-γ, which 
regulates the expression of IL-12Rβ2 and so maintains the differentiation of 
Th1 cells, whereas IL-4 suppresses IL-12Rβ2 expression and thus antagonizes 
Th1 cell differentiation.  
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o IL-18: Originally described as IFN-γ-releasing factor, IL-18 has a mechanism of 
action different from that of IL-12 and may enhance Th1 responses 
independently of IL-12. IL-18 and IL-12 appear to have synergistic effects on 
the induction of IFN-γ release and the inhibition of IL-4-dependent IgE 
production and allergic hyperresponsiveness. 
o IL-27: is a member of the IL-12 family that promotes Th1 cell differentiation 
through a STAT1-dependent mechanism independently of IL-12. It is produced 
by activated antigen-presenting cells and enhances Th1 function by 
downregulating GATA3 expression and upregulating T-bet expression, thereby 
favouring the production of Th1-type cytokines, which then act to further 
inhibit GATA3 expression. 
o IL-17: IL-17A and the closely related IL-17F are linked to neutrophil-mediated 
inflammation by induction of the release of the of the neutrophil 
chemoattractant CXCL1 and CXCL8 from epithelial cells and smooth muscle 
cells and thereby may play a role in the neutrophilic inflammation. IL-17 also 
increases the expression of mucin-encoding genes (MUC5AC and MUC5B) in 
human epithelial cells. However, the functional role of IL-17 in asthma is 
unclear, as it seems to be involved in allergic sensitization of animal models but 
to inhibit eosinophilic inflammation in sensitized animals (Schmidt-Weber, 
2007). 
o IL-25: part of the IL-17 superfamily (aka IL-17E) and produced by Th2 cells, 
mast cells, and epithelial cells. Induces the expression of IL-4, IL-5, and IL-13 
leading to an inflammatory condition characterized by the presence of 
eosinophils, increased IgE production and allergic hyperresponsiveness. It also 
enhances Th2 cytokine secretion from human Th2 cells. 
o TSLP: Thymic stromal lymphopoietin is a cytokine belonging to the IL-7 family 
that shows a marked increase in expression in the epithelium and mast cells of 
allergic patients. It is released by epithelial cells, and its synergistic interaction 
with IL-1β and TNF-α results in the release of Th2 cytokines from mast cells 
independently of T cells. TSLP also play a key role in programming tissue 
dendritic cells to release the chemoattractants CCL17 and CCL22 and thus is 
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important in recruiting Th2 cells to the inflamed tissue. TSLP may also directly 
stimulate Th2 cytokine release from CD4+ T cells. 
o TGF-β: family of pleiotropic cytokines that play several roles in allergy. TGF-β 
is a multifunctional growth factor that induces the proliferation of fibroblasts 
and smooth muscle cells, deposition of ECM, and epithelial repair. It also has 
immunoregulatory effects that are largely mediated by through Tregs through 
the induction of FOXP3, resulting in suppression of Th1 and Th2 T cells. There 
is increased expression of TGF-β1, particularly in eosinophils and this has been 
associated with subepithelial fibrosis. Increased expression of TGF-β2 has also 
been reported in patients with severe asthma. Many of the fibrotic effects of 
TGF-β are mediated via increased secretion of connective tissue growth factor 
(CTGF). 
o EGF: EGF activated EGFR tyrosine kinases that are also activated by TGF-α 
and may play a critical role in regulating mucous secretion in individuals with 
asthma. 
o VEGF: plays an important role in regulating the growth of new vessels and 
vascular leakage in asthmatic airways. Increased expression of VEGF and 
VEGF receptors is correlated with increased vascularity in inflamed tissues. 
Blockage of the VEGF receptors induces apoptosis of endothelial cells and 
development of emphysema. 
 
2.4 Chemokine expression in allergic inflammation 
 Chemokines are cellular products that mediate the recruitment of eosinophils, 
among other inflammatory cells. Chemokines constitute a family of chemotactic cytokines 
that regulate leukocyte chemotaxis. Most chemokines exert their effect through binding to 
specific receptors, such as the chemokine receptor CCR3. In fact, CC chemokines are 
chemotactic cytokines that can induce mediator secretion and chemotaxis of leukocytes 
(Taub, 1997). Leukocyte recruitment from the circulation into inflammatory tissues requires 
a series of soluble and cell-bound signals between the responding leukocyte and vascular 
endothelial barrier. Chemotactic factors are believed to be responsible for this selective 
adhesion and transmigration. A superfamily of small, solube, structurally-related molecules 
called “chemokines” have been identified and shown to selectively promote the rapid 
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adhesion and chemotaxis of a variety of leukocyte subtypes both in vitro and in vivo. 
Chemokines are produced by almost every cell type in the body in response to a number of 
inflammatory signals, in particular those which activate leukocyte-endothelial cell 
interactions. Through a coordinated series of signals generated within the tissue lesion, the 
local vascular endothelial barrier becomes primed and quite sticky, quickly altering the 
circulating leukocytes that can intervene in the inflammatory process. Responding 
leukocytes become rolling along this primed endothelium slowing their transit through the 
circulation. Upon interaction with a pro-adhesive molecule, leukocyte adhere tightly to and 
spread out along  this endothelial cell layer. These primary adhesion events are prerequisite  
for the successful trafficking of circulating leukocytes into extravascular tissues. 
Chemotaxis is the process by which leukocytes are directed to site of inflammation under 
the influence of a concentration gradient of the soluble chemotactic molecules. 
Box 2.1 
Chemokine receptors are G protein-
coupled receptors. Classically, one of 
the initial events in chemokine-receptor 
signalling is the physical association of 
heterotrimeric Gi proteins to the 
receptor, resulting in the inhibition of 
adenyl cyclase activity and intracellular 
calcium mobilization. Consistent with Gi 
association, the majority of chemokine 
responses are inhibited by treatment 
with the pertussis toxin. 
Nervertheless, in some circumstances, 
the pertussis toxin cannot block 
completely chemokine-induced 
responses, owing to chemokine-receptor 
association to G proteins other than Gi, 
for example, Gq/11 or G16 (Viola et al., 
2006). 
Thus, depending on their coupling to 
different G proteins, chemokine 
receptors can initiate distinct signal-
transduction pathways and exert several 
biological functions. Therefore, one key 
question is what specifies G protein-
coupling to a chemokine receptor or, in 
general, to any GPCR. 
An intriguing possibility is that GPCRs 
can adopt various conformations at 
the cell membrane, exposing distinct 
residues responsible for ligand 
recognition and G protein-coupling. 
According to this model, by binding to 
different receptor sub-states, different 
agonists might direct trafficking of the 
GPCR stimulus to different G proteins. 
Another factor potentially influencing 
chemokine receptor conformations and 
signalling is their homo- and/or hetero-
dimerization an event that changes the 
receptor pharmacology modifying not 
only its coupling and signalling but also 
the GPCR regulation and trafficking. 
G protein-coupling might also be 
influenced by the lipid environment 
surrounding the receptor. Different G 
proteins might be targeted differently to 
distinct membrane microdomains by 
acylation of the α subunit and, thus, 
localization in lipid rafts could 
modulate the specificity of GPCRs and 
Gα coupling. 
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Upon encountering a chemotactic molecule, responding leukocytes begin to migrate 
directionally from regions of low ligand concentration toward the sites of chemoattractant 
production which tipically possess more substantial levels of soluble chemotactic factors. 
Many chemoattractans have been shown to bind to endothelial cells and various adhesive 
substrates within the tissue lesion facilitating the haptotactic migration of leukocytes while 
still maintaining a bound concentration gradient. Many of these chemoattractants not only 
induce leukocyte migration, but also facilitate leukocyte adhesion to endothelial cells and 
purified adhesive ligands. This enhanced adhesiveness occurs within seconds of stimulation 
and, as with migration, is highly concentration-dependent. The subtype of leukocyte that 
appear in inflammatory infiltrates can differ markedly depending on the identity of the 
inflammatory irritant as well as the duration of irritation. The chemotactic factors 
responsible for these differences are likely to be cell type-specific (selective) 
chemoattractants and/or chemoattractant receptor. 
 Chemokines appear also to play important roles in cellular activation and leukocyte 
effector functions. They have been found in the tissues of a variety of disease states 
characterized by distinct leukocytic infiltrates including rheumatoid arthritis, sepsis, 
atherosclerosis, asthma, psoriasis, ischemia/reperfusion injury, and a variety of pulmonary 
disease states (Table 2.2). 
 The role of chemokines in eosinophil migration and adhesion has currently received 
a great deal of attention due to their apparent role in asthma and allergy development. 
RANTES and MCP-3 have been shown to be potent chemoattractants for human 
eosinophils in vitro, as well as MIP-1α although with less efficacy. Interestingly, IL-5-primed 
eosinophils exhibited an even greater responsiveness to RANTES than non-primed cells. 
This RANTES effect on eosinophils was further supported by in vivo studies demonstrating 
the profound infiltration of eosinophils into the RANTES injection site in dog skin. 
Furthermore, within a murine airway inflammation model, MIP-1α and RANTES but not 
MCP-1 have been shown to play a role on eosinophil accumulation in pulmonary tissues 
post antigen challenge. Moreover, eotaxin is a C-C chemokine selective for eosinophils. 
Strangely, eotaxin mRNA also appears to be constitutively expressed in both guinea pig, but 
not human, intestines and lung and is upregulated in pulmonary allergic inflammation. 
Subsequently, the intradermal injection of human eotaxin, as a potent chemoattractant for 
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human eosinophils with no significant effect on human neutrophils or lymphocytes, into 
rhesus monkeys induced the selective accumulation of eosinophils in the skin of these 
animals (Gonzalo et al., 1996). These studies, along with the findings of substantial human 
RANTES and eotaxin in human eosinophil-containing nasal polyp tissue and murine 
eotaxin in the sensitized pulmonary tissue of murine allergic inflammation model, strongly 
support a role for these chemokines in allergic inflammation. Interestingly, there is evidence 
that some mediators as SCF, histamine and TNF-α, are able to potentiate the IgE-mediated 
chemokine release. Therefore, it is not surprising that treatment of mice with eotaxin 
(CCL11) produced a time-dependent accumulation of eosinophils that was significantly 
reduced if the animals were pre-treated with histamine H1 antagonists (Jose et al., 1994). 
Thus, the effect of mediators from mast cells on other cell populations has not been fully 
appreciated. One aspect of chemokine biology is the ability of several of them to cause mast 
cell activation. In fact, recent studies indicate that activation of mast cells with MCP-1 (via 
CCR2) can induce mediator release, including histamine and leukotriene release, further 
exacerbating airway hyperreactivity (Campbell et al., 1999). It is, therefore, to take in 
account that chemokines not only act as chemoattractants, but they elicit a more profound 
role potentiating the activation of the cells under their influence. Chemokine receptors are, 
in fact, highly versatile players fine-tuning immune responses. 
 
Table 2.2 
Pathological Disease State Chemokines 
Acute Glomerulonephritis IL-8 
Acute Respiratory Distress Syndrome IL-8; MCP-1 
Alcoholic Epatitis IL-8 
Angiogenesis 
IL-8; GROα; GROβ; ENA-78; GCP-
2; NAP-2 
Angiostatic PF-4; IP-10, mig, GROβ 
Asthma IL-8; ENA-78; MCP-1; MIP-α 
Atherosclerosis 
MIP-1α; MIP-1β; MCP-1; RANTES; 
IL-8 
Bacteremia IL-8 
Bladder Inflammation IL-8 
Bronchial Carcinoma IL-8 
Cardiac Allograft MIP-1α; MIP-1β; RANTES 
(continued) 
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Contact Dermatitis IL-8; MCP-1; IP-10 
Cryptococcal Infections MIP-1α; MCP-1; MIP-2 
Cutaneous T Cell Lymphoma IL-8; IP-10 
Cystic Fibrosis Lavage fluids/tissues IL-8; ENA-78; MCP-1 
Endotoxemia and Sepsis IL-8; MIP-1α; RANTES; MIP-2 
Gastritis IL-8 
Gingivitis IL-8 
Gouty Arthritis IL-8 
HIV-infected Monocytes MIP-1α; MIP-1β 
Idiopathyc Pulmonary Fibrosis IL-8; MCP-1 
Inflammatory Bowel Syndrome IL-8 
Kawasaki Disease IL-8 
Lepromatous/Tuberculoid Leprosy 
Lesions 
IP-10 
Meningococcal Infections IL-8 
Mycobacterial Infections IL-8 
Nasal Polyps IL-8; RANTES; eotaxin 
Ocular Inflammation IL-8 
Osteoarthritic Synovial Fluids MIP-1β 
Palmoplantar Pustulosis IL-8 
Pancreatitis IL-8 
Peritonitis Elevated plasma IL-8 
Pertussis IL-8 
Pleural Emphysema IL-8 
Post-major Surgery Elevated plasma IL-8 
Pregnancy, Parturition IL-8 
Psoriatic Scale Extracts IL-8; GROα; MCP-1; IP-10 
Pulmonary Reperfusion Injury IL-8; MCP-1 
Pulmonary Fibrosis IL-8 
Red Cell Incompatibility IL-8 
Relapsing Fever IL-8 
Renal Ischemia GROα; MCP-1 
Rejection of Lung Transplant IL-8; MCP-1 
Rheumatoid Synovial Fluids 
IL-8; ENA-78; MCP-1; MIP-1α; 
RANTES 
Sepsis, Endotoxemia IL-8; MCP-1 
S. Mansoni-induced Granulomas MIP-1α; MCP-1; RANTES 
Sarcoidosis IL-8; MCP-1 
β-thalassemia IL-8 
(continued) 
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Transplantation IL-8; MCP-1 
Ulcerative Colitis IL-8 
Uremia IL-8 
Uveoretinitis 
IL-8; IP-10; MIP-1α; MIP-1β; 
RANTES; MCP-1 
Wound Healing IL-8; GROα; PF-4; MCP-1; MIP-1α 
 
‡ CCRs 
CCL2 (MCP-1) activates CCR2 on monocytes and T cells. CCL2 is a potent 
chemoattractant or monocytes and may therefore be involved in the 
accumulation of macrophages in the inflamed tissue. 
CCR3 is expressed predominantly on eosinophils and mediates the 
chemotactic response to several chemokines, including CCL11, CCL24 (aka 
eotaxin-2), CCL26 (aka eotaxin-3), CCL13 (aka MCP-4), and CCL5 (aka 
RANTES), all of which show increased expression in allergic individuals. 
Small molecule antagonists of CCR3 are effective in inhibiting pulmonary 
eosinophilic inflammation in mice exposed to CCR3 and may also be 
important in the differentiation of eosinophils and their release from bone 
marrow (Ravensberg et al., 2005). Further, CCR3 is also expressed on Th2 
cells and mast cells in humans, although most attention has focused on 
CCL11, CCL24 and CCL26 may play a role in prolonged eosinophilia after 
allergen exposure (Bocchino et al., 2002). 
CCR4 is selectively expressed on Th2 cells and activated by CCL22 and 
CCL17, which are released from airway epithelial cells and dendritic cells in 
allergic tissues and are further increased after antigen challenge in association 
with increased Th2 cytokines. CCL8 is also expressed on Th2 cells but 
neither it nor its ligand CCL1 (aka I-309) are increased in asthmatic airways. 
CCR5 is activated by CCL3 (aka MIP-1α), CCL4 (aka MIP-1β), and CCL5, 
all of which are elevated in the tissues of allergic individuals. CCR5 is 
selectively expressed on Th1 and Tc1 cells and contributes to the 
recruitment of these cells into the tissues of patients with allergy. CCL5 also 
shows increased increased expression in epithelial and smooth muscle cells. 
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‡ CXCRs 
CXCL8 activates CXCR1, which is almost specific for this chemokine, and 
CXCR2, which is also activated by several related CXC chemokines, 
including CXCL1 (aka GRO-α) and CXCL5 (aka ENA-78). CXCL1 and 
CXCL8 levels are markedly increased in allergic patients and correlate with 
the increased proportion of neutrophils. CXCL8 is further increased during 
exacerbations and CXCL5 shows a markedly increased expression during 
this process. Small molecule inhibitors of CXCR2 block the chemotactic 
response of neutrophils and monocytes to CXCL8 and CXCL1 in animals in 
vivo. 
CXCR3 is expressed by T cells and is activated by CXCL9, CXCL10 and 
CXCL11, all of which are induced by IFN-γ. Since Th1 and Tc1 cells 
produce IFN-γ, this provides a potential amplification loop to perpetuate T 
cell accumulation in tissues. CXCR3 may also play a role in the recruitment 
of T cells after antigen challenge. On the other hand, CXCR3 ligands 
antagonize CCR3, suggesting that they might suppress eosinophilic 
inflammation. 
CXCR4 is preferentially expressed on Th2 cells and is activated by CXCL12 
(aka SDF-1α). A small molecule inhibitor of CXCR4 (AMD3100) reduces 
inflammation in sensitized mice, and these effects are associated with a 
reduction in Th2 cytokines. CCL12 may also be involved in mobilization of 
eosinophil progenitor cells from the bone marrow as eosinophils express 
CXCR4. 
‡ CX3CR1 
CX3CL1 (aka fractalkine), the sole member of a third family of CX3C 
chemokines, is produced by epithelial cells after stimulation with TNF-α, 
IL-1β, and IFN-γ. CX3CL1 is chemotactic for monocytes, T cells and mast 
cells and also functions as an adhesion molecule in its membrane-bound 
form (El Shazly et al., 2006). 
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2.5 Antinflammatory cytokines 
 Although most cytokines increase or orchestrate the inflammatory process, some 
cytokines have inhibitory or anti-inflammatory effects. For example, IL-12 through the 
release of IFN-γ from Th1 cells, can suppress Th2 cytokine release and allergic 
inflammation. TGF-β has potentially immunomodulatory effects through inhibition of 
CD4+ T cells, but does not have therapeutic potential in view of its profibrotic actions. IL-
10 is a potent anti-inflammatory cytokine that inhibits the synthesis of many inflammatory 
proteins, including several cytokines (such as TNF-α, GM-CSF, IL-5, and several 
chemokines) that are overexpressed in allergies, and also inhibits antigen presentation. 
There is a reduction in IL10 transcription and secretion from macrophages in individuals 
who suffer from allergy (John et al., 1998). IL-10 is produced by a subset of Tregs and by 
macrophages. Specific allergen immunotherapy results in increased production of IL-10-
producing Tregs. IL-10 might also be beneficial in the chronic obstructive pulmonary 
disease as it not only inhibits the production of TNF-α and chemokines, but also MMP-9, 
which may be involved in the distruction of lung elastin (Takanashi et al., 1999). 
 
2.6 Eosinophilia 
 A marked accumulation of eosinophils occurs in several important disorders, such 
as allergic diseases, parasitic infections, and cancer. The level of eosinophils in the body 
in normally tightly regulated. In normal subjects, eosinophils account for only a small 
minority of peripheral blood leukocytes, and their presence in tissues is primarily limited to 
the gastrointestinal mucosa. In certain disease states, however, eosinophils can selectively 
accumulate in the peripheral blood or any tissue in the body. Any perturbation that results 
in eosinophilia, defined here as abnormal accumulation of eosinophils in blood or tissue, 
can have profound clinical effects. Eosinophilia can be harmful because of the 
proinflammatory effects of eosinophils, or it may be helpful, because of the antiparasitic 
effects of these cells. Eosinophilia occurs in a variety of disorders (Table 2.3) and is 
arbitrarily classified as mild, moderate or severe depending on the numer of eosinophils 
present per blood cubic millimiter. The most common cause of eosinophilia worldwide is 
helminthic infections, and the most common cause in industrialized nations is atopic 
disease. 
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Table 2.3 
Disease associated with eosinophilia 
Type of Disease Eosinophilia Possible Causes 
 Peripheral Blood Tissue  
Infectious Present Present or Absent 
Infections with 
especially invasive 
helminths 
Respiratory Present or Absent Present 
Eosinophilic 
pneumonitis, asthma 
Gastrointestinal Present or Absent Present 
Inflammatory bowel 
disease, eosinophilic 
gastroenteritis, 
allergic colitis 
Allergic Present or Absent Present 
Allergic 
rhinoconjunctivitis, 
asthma, eczema 
Systemic Present Present 
Idiopathic 
hypereosinophilic 
syndrome, vasculitis 
Iatrogenic Present Present or Absent 
Drug reaction, 
cytokine infusion 
Malignant Present or Absent Present or Absent 
Lymphona, colonic 
carcinoma 
  
Eosinophils are produced in the bone marrow from pluripotential stem cells. The 
latter cells differentiate into hybrid precursors with properties of basophils and eosinophils 
and then into a separate eosinophil lineage. Three cytokines – IL-3, IL-5 and GM-CSF – 
are particularly important in regulating the development of eosinophils. Of the three 
cytokines, IL-5 (also known as eosinophil differentiating factor) is the most specific for the 
eosinophil lineage and is responsible for selective differentiation of eosinophils (Sanderson, 
1992). IL-5 also stimulates the release of eosinophils from bone marrow into the peripheral 
circulation. The migration of eosinophils from the circulation into tissues involves a 
stepwise interaction between eosinophils and endothelial cells. The steps are mediated by 
adhesion molecules on endothelial cells and counter-ligands on eosinophils and are 
followed by the passage of eosinophils through endothelial cells. 
 Tissue eosinophilia is a hallmark of atopic diseases and eosinophils are a major 
effector cell in these disorders. After IgE-triggered activation, mast cells may promote 
inflammation with eosinophils by producing pro-inflammatory mediators (TNF-α, IL-1) 
and eosinophil directed cytokines (e.g. IL-4, IL-5). These substance, in turn, induce 
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chemokines that attract eosinophils. Moreover, helper T lymphocytes are essential for the 
late-phase response, because they produce three cytokines that promote allergic responses: 
IL-4 and IL-13, both of which regulate IgE and VCAM-1 production, and IL-5. The 
helper cells that orchestrate this type of response are Th2 cells. Antigen presenting cells not 
only activate Th2 cells, but also secrete pro-inflammatory mediators that induce resident 
cells (e.g. epithelial cells) to produce the chemokines that attract eosinophils. 
 Once eosinophils are localized at the inflammatory site, they produce unique toxic 
inflammatory mediators, which are stored in granules and synthesized after cellular 
activation. The granules contain a crystalloid core composed of a major basic protein and a 
matrix composed of eosinophil cationic protein, eosinophil-derived neurotoxin, and 
eosinophil peroxidise (Fig. 2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 The migration of eosinophils from the circulation into tissues involves a stepwise 
interaction between eosinophils and endothelial cells. The steps are mediated by adhesion 
molecules on endothelial cells and counter-ligands on eosinophils and are followed by the 
passage of eosinophils through endothelial cells (see Chapter 1). Although the different 
types of leukocytes migrate into tissues in a similar way, their migration is mediated by 
different molecules. Eosinophils initially adhere to the endothelium by means of three 
selectins and their corresponding ligands. After cellular activation following exposure to 
chemoattractants, eosinophils adhere firmly to the endothelium through adhesion molecules 
of the integrin family. These include the CD18 family (β2 integrins) and very late antigen 4 
 
Figure 2.3 
Activated eosinophil with evident secretory granules. 
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(VLA-4) molecules (β1 integrins). The β2 integrins interact with the intercellular adhesion 
molecule 1 (ICAM-1) on endothelial cells, whereas the β1 integrins interact with vascular 
cell adhesion molecule 1 (VCAM-1). Although the CD18-ICAM-1 pathway is used by all 
leukocytes, the VLA-4-VCAM-1 pathway is used by eosinophils and mononuclear cells but 
not by neutrophils. ICAM-1 is induced by a variety of proinflammatory mediators, such as 
IL-1 and TNF-α, whereas VCAM-1 is induced primarily by IL-4. Resting eosinophils 
normally express β1 and β2 integrins, but the level of expression of these adhesion 
molecules and their affinity for their appropriate endothelial receptors is increased by 
chemoattractants. 
 Eosinophils, unlike neutrophils, can survive in tissues for prolonged periods 
(perhaps weeks), depending on the cytokines in the microenvironment. Only eosinophils 
and basophils have receptors for IL-3, IL-5, and GM-CSF present on both the precursor 
cells in bone marrow and the circulating cells. The lifespan of tissue eosinophils is not 
known, but IL-3, IL-5 and GM-CSF inhibit eosinophil apoptosis for at least 12 to 14 days in 
vitro and in explants of allergic sinus tissues. In contrast, eosinophils survive for less than 48 
hours in the absence of these cytokines. Tissue eosinophils can also regulate their own 
survival through an autocrine pathway. 
 Moderate to severe eosinophilia occurs as a pathophysiologic response to infections 
with helminthic parasites. Eosinophilia induced by parasitic infection is dependent on IL-5 
produced by Th2 lymphocytes. Eosinophils participate in the immune response against 
helminthic parasites by discharging their cytotoxic granular content onto the parasites, 
which kills them. However, depletion of eosinophils in mice with antibodies to IL-5 does 
not always increase their susceptibility to helminthic infections. 
 Since eosinophilia is a hallmark of atopic diseases and eosinophils are a major 
effector cells in these disorders, allergic diseases serve as a prototype for understanding the 
pathogenesis and consequences of eosinophilia. Patients with eosinophilia of any magnitude 
who have end-organ involvement should be treated with the goal of reducing eosinophil 
counts or blocking the effect of eosinophil products. Glucocorticoids, the most effective 
agents for reducing eosinophilia, suppress the transcription of a series of genes for 
inflammatory mediators, including the genes for IL-3, IL-4, IL-5, GM-CSF, and various 
chemokines. In addition, glucocorticoids inhibit the cytokine-dependent survival of 
eosinophils. In most patients, treatment with systemic or topical glucocorticoids causes a 
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rapid reduction in eosinophils, but a few patients have a resistance to glucocorticoids, with 
persistent eosinophilia despite high doses. The mechanism of resistance to glucocorticoids 
is unclear, but a reduced level of glucocorticoid receptors and alterations in activator protein 
1, a transcription factor, are at least in part responsible in some patients. Patients with 
glucocorticoid resistance sometimes require other therapy such as myelosuppressive drugs 
(hydroxyurea or vincristine) or INF-α. The latest appears to be especially promising 
because it inhibits the degranulation and effector functions of eosinophils. Cyclophyllins 
(e.g. cyclosporine) have also been used because they block the transcription of numerous 
eosinophil-active cytokines (e.g. IL-5 and GM-CSF). Drugs that interfere with eosinophil 
chemotactic signals include recently approved leukotriene antagonists and inhibitors. The 5-
lypoxygenase inhibitors (e.g. zileuton) block the rate-limiting step in leukotriene synthesis 
and inhibit the generation of the chemoattractant leukotriene B4 and the sulfidopeptide 
leukotrienes, leukotrienes C4, D4 and E4. These drugrs therefore decrease airway infiltration 
by eosinophils during the late-phase response. Drugs (e.g. zafirlukast) that block the 
receptor for leukotirene D4, which is also a receptor for leukotriene E4 and C4, prevent the 
muscle contraction and increased vascular permeability mediated by eosinophil-derived 
leukotrienes. These drugs have been found to decrease exercise-induced 
bronchoconstriction and include base-line lung obstruction in patients with asthma. Some 
of the third generation anti-histamines (e.g. cetirizine) inhibit the vacuolization and 
accumulation of eosinophils after an allergen challenge and directly inhibit eosinophils in 
vitro. Cromolyn and nedocromyl inhibit the effector function of eosinophils, such as 
antibody-dependent cellular cytotoxicity. Phosphodiestare inhibitors raise intracellular cyclic 
AMP concentrations in eosinophils, and this in turn inhibits intracellular signalling, leading 
to decreased activation of eosinophils. The identification of molecules that specifically 
regulate the function or production of eosinophils offers new therapeutic strategies. 
Antibodies against IL-5 are especially promising because they have been effective in animal 
with allergic airway disease. Another molecular target interrupts the adhesion of eosinophils 
to the endothelium through the interaction of CD18 with ICAM-1 or VLA-4 with VCAM-
1. In addition, phosphodiesterase inhibitors that are specific for leukocyte isoenzyme type 
IV are being developed. 
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2.7 Ocular allergy 
 In this thesis will be treated, more in depth, the aspects of ocular allergy, because of 
its very wide diffusion among the population and considering it as the model of allergy 
taken as an example. 
 The slow development of ocular and nasal allergic symptoms after exposure to plant 
products was originally noted by Blacklay in 1873 (see reference). Ocular allergy results 
from the exposure of the conjunctiva to an allergen and include a spectrum of clinical 
disorders that involve different levels of immune activity at the conjunctival or corneal 
interface. Each of these clinical entities is caused by an IgE-mediated sensitization to an 
antigen and the activation of mast cells and eosinophils. In the more chronic entities 
there is also an interaction of the allergen with T cells and a T helper 2 patter of cytokine 
release. The spectrum of ocular allergy is variable and notably seasonal allergic conjunctivitis 
(SAC) and perennial allergic conjunctivitis (PAC) are the most basic and least severe of the 
allergic inflammatory disorders. The seasonal incidence of SAC is closely linked with cycle 
of release of airborne plant-derived allergens, and specific IgE against grass and tree pollens 
has been found in the tears of patients with this condition (Allansmith et al., 1970). In SAC 
and PAC a type I hypersensitivity reaction appears to be responsible for the signs and 
symptoms. In SAC there are minimal pathological changes and only the early signs of 
cellular activation at the molecular level occur. In PAC the inflammatory markers become 
more pronounced with the increased duration of allergenic stimulation. In the more chronic 
forms of allergic conjunctivitis, namely vernal keratoconjunctivitis (VKC) in childhood and 
atopic keratoconjunctivitis (AKC) in adulthood, there is a mixed type I and type IV 
hypersensitivity reaction. There is a persistent state of mast cell, eosinophil and lymphocyte 
activation and this may result in the serious corneal complications that can occur with these 
diseases. Giant papillary conjunctivitis (GPC) that manifest in conctact lens wearers also tends 
to be chronic with a mixed hypersensitivity reaction but has no corneal significant 
involvement. 
 Conjunctival allergen challenge has been undertaken since 1932 (Peshkin, 1932). 
Conjunctival provocation tests (CPTs), which consist of instilling an offending pollen into 
the conjunctival sac, also produce the typical symptoms of hay fever conjunctivitis (Stegman 
et al., 1975; Friedlaender, 2003) and was the original method for evaluating allergic 
responses. Ocular challenge is used as a pharmacologic model for the evaluation of new 
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antiallergic medications and immunotherapy (Abelson et al., 1988). The positivity may be 
assessed by a sign and symptom scoring system that include subjective and objective 
signs such as conjunctival erythema, chemosis, tearing and pruritus. CPTs have also been 
shown to have a relatively good reproducibility in both eyes (Aichane et al., 1993). A CPT 
of ocular mast cells by way of opioid receptors has shown that 80% of normal patients 
reflect mast cell activation by detection of the release of histamine (7 versus 18 ng/L) and 
prostaglandin D2 (0 versus 273 ng/L). The release of these mediators can be blocked by 
pretreating patients with cromolyn (Campbell et al., 1993). 
It is estimated that ocular/conjunctival symtomatology is present in 40/60% of 
allergic individuals, and occasionally the ocular component may be the most prominent and 
disabling feature of their allergy. In a large study of 5000 allergic children, 32% had ocular 
disease as the single manifestation of their allergy (Marrache et al., 1978). Allergic 
conjunctivitis is encountered on a daily basis in general practice and its diagnosis and 
management are the responsibility not only of ophtalmologists, but also general 
practitioners, paediatricians, allergists and pharmacists. Conjunctivitis can vary from being 
seasonal, where some individuals are affected for only a few weeks to months, to perennial 
with symptoms that last throughout the year. 
 The eye presents unique immunological features since it is relatively isolated from 
the systemic immune system, and has an efficient local protection system in the structure of 
the external eye. The eye is constantly exposed to foreign substances, and the ocular tissuea 
have an array of immune cells to interact with these offending antigens. This represents an 
ideal site for hypersensitivity reactions because of the large number of mast cells in the 
conjunctiva and the potential for local synthesis of IgE (Bielory et al., 2000). Ocular allergy 
is not confined to the conjunctiva, but affects the entire ocular surface including 
conjunctiva, lids, cornea, lacrimal gland and tear film. 
 Ocular allergic conditions represent a spectrum of diseases that affect the ocular 
surface, from the acute and self-limited mild form of seasonal allergic conjunctivitis to the 
chronic, severe, sight-threatening atopic keratoconjunctivitis. Two acute disorders, SAC and 
PAC, and three chronic diseases, VKC, AKC, and GPC are described (Ono and Abelson, 
2005). 
 Physicians in all specialties frequently encounter various forms of allergic diseases of 
the eye that present as “red eyes” in their general practice. However, allergists or clinical 
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immunologists are trained to uniquely understand and manage atopic disorders, because the 
eye is rarely the only target for an immediate allergic-type response. However, ocular signs 
and symptoms may be the initial and most prominent features of the entire allergic response 
that patients present to their physician. 
 Allergens and other ocular irritants are easily deposited directly on the surface of the 
eye. Many agents that are systemically absorbed also can be concentrated and secreted in 
tears, causing allergic conjunctivitis or an irritant form of conjunctivitis. Allergic diseases 
affecting the eyes constitute a heterogeneous group of clinicopathologic conditions with a 
vast array of clinical manifestations that range from single intermittent symptoms of itching, 
tearing, or redness, to severe sight-threatening corneal impairment. These conditions may 
be considered as part of an immunologic spectrum that affect the anterior surface of the eye 
with a variety of disorders that may overlap and may include seasonal allergic conjunctivitis 
(SAC) and perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC) and 
atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis (GPC) (Hodges et al., 
2007). In addition, tear film dysfunction (otherwise known as dry eye syndrome, DES) 
commonly complicates ocular allergy and its treatments, especially as the age of the patients 
increases and is included to reflect the spectrum of hypersensitivity responses from 
immunoglobulin E (IgE) mast cell hypersensitivity conditions to a mixture of mast cell and 
cell mediated disorders that involve different mechanisms, cytokines and cellular 
populations. For example, mast cell degranulation and histamine release play key roles with 
limited eosinophil involvement in the common forms of SAC and PAC, whereas AKC and 
VKC are characterized by more chronic inflammatory cellular infiltrates primarily 
composed of Th2 lymphocytes with an interplay with activated mast cells and eosinophils, 
and tear film dysfunction, a Th1 mediated disorder, commonly can overlap ocular allergy 
syndromes. Mast cell mediators such as histamine, tryptase, leukotrienes, and prostaglandins 
in the tear fluid have diverse and overlapping biologic effects, all of which contribute to the 
characteristic itching, redness, watering, and mucous discharge associated with both acute 
and chronic allergic eye disease. Histamine alone has been shown to be involved in the 
regulation of vascular permeability, smooth muscle contraction, mucus secretion, 
inflammatory cell migration, cellular activation, and modulation of T cell function. 
Histamine is a principal mediator involved in ocular allergy and inflammation. Large 
amounts of histamine are present in several mammalian ocular structures, including the 
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retina, choroid and optic nerve. Histamine receptors have been found on the conjunctiva, 
cornea, and ophthalmic arteries. Two separate histamine receptors, H1 and H2, have been 
identified in the conjunctiva. Histamine in the conjunctiva of allergic conjunctivitis patients 
can reach values greater than 100 ng/mL as compared with values of 5-15 ng/mL in 
controlled patients. Histamine can induce changes in the eye similar to those seen in other 
parts of the body. These changes include capillary dilation leading to conjunctival redness, 
increased vascular permeability leading to chemosis, and smooth muscle contraction. 
Allergic conjunctivitis is caused by the direct exposure of the ocular mucosal surfaces to 
environmental allergens (such as pollens from trees, grasses and weeds) interacting with the 
pollen-specific IgE found on the mast cells of the eye. Of all the various pollens, ragweed 
has been identified as the most common cause of conjunctivo-rhinitis in the United States, 
approaching 75% of all cases of “hay fever” with variations of prevalence in different age 
groups in various regions of the world. Common conjunctival symptoms include itching, 
tearing, and perhaps burning. Clinical signs include include a milky or pale pink conjunctiva 
with vascular congestion that may progress to conjunctival swelling (chemosis). A white 
exudate may form during the acute state and become stringy in the chronic form. While 
ocular signs are typically mild,  the conjunctiva frequently takes on a pale, boggy appearance 
that often evolves into diffuse areas of papillae (small vascularised nodules). These papillae 
tend to be more prominent on the superior palpebral conjunctiva. Occasionally, dark circles 
beneath the eyes (allergic shiners) are present as a result of localized venous congestion 
(Bielory, 2005). Symptoms usually consist of low-grade ocular and peri-ocular itching 
(pruritus), tearing (epiphora), burning, stinging, photophobia, and watery discharge. 
Redness and itching seem to be the most consistent symptoms (see table 2.4). The 
symptom of itching is strikingly characteristic of allergic conjunctivitis. In allergic patients, it 
is unusual to have conjunctival symptoms without nasal symptoms (Singh et al., 2007). The 
nasal mucosa is expected to react in the same fashion as the conjunctival mucosa. 
In the early-phase reaction, an allergen binds to allergen-specific IgE on the mast 
cell. The mast cell Fc receptors are cross-linked by the allergens, sending signals via the cell 
membrane into the cytoplasm, activating the mast cells and resulting in the release of 
allergic mediators (Trocme et al., 2002). This early-phase reaction is immediate. More severe 
allergic reactions may demonstrate a late-phase reaction. These may be either sustained 
early-phase reactions or more discrete second peaks of response. The second-peak late 
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phase  conjunctival reaction occurs from 2 to 9 hours after antigen exposure (Bonini et al., 
1990). 
 
Table 2.4 
Signs AC VKC AKC GPC DCS 
Predominant 
Cell Types 
Mast Cells, 
Eosinophils 
Lymphocytes, 
Eosinophils 
Lymphocytes, 
Eosinophils 
Lymphocytes, 
Eosinophils 
Lymphocytes 
Chemosis + ± ± ± - 
Discharge Clear mucoid 
Stringy 
mucoid 
Stringy 
mucoid 
Clear white 
mucoid 
± 
Lid 
Involvement 
- + + - ++ 
Itching + ++ ++ ++ + 
Burning - - - - - 
Gritty 
Sensation 
± ± ± + - 
Seasonal 
Variation 
+ + ± ± - 
 
This occurs at a cellular level and does not correlate with a separate clinical late-phase 
response of allergic conjunctivitis. Usually, about 4-6 hours after allergen exposure, an 
influx occurs into conjunctival tissue of non-specific cells of the inflammatory response, 
including neutrophils, basophils, eosinophils and T lymphocytes (Trocme et al., 1988).  It 
has been proposed (Gleich, 1982; Iliopoulos et al., 1990) that the late response explains the 
transition of the of the early acute inflammatory response into days or weeks of disease. 
The most striking piece of evidence in support of the clinical late phase response is the 
presence of two separate peaks of histamine in tears at 20 minutes and 6 hours after 
challenge, which have been found by several authors after ocular and skin challenge (Bacon 
et al., 2000; Abelson et al., 1990; Helleboid et al., 1991; Charlesworth et al., 1989). The late 
phase response represents, with its increase in inflammatory cells and adhesion molecules, 
the transition between a transient type I response and clinical disease, with a marked 
increase in tissue reactivity to challenge, contributing to the symptoms seen in asthma, 
atopic dermatitis, and allergic type disease. A conjunctival late phase response has been 
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described (Bonini et al., 1990; Bonini et al., 1988; Leonardi et al., 1990; Trocme et al., 1988). 
In the guinea pig model used by Leonardi and collegues (1990), the late phase response 
manifested in several forms, including a classic biphasic response (33%), a multiphasic 
response (25%), and a single prolonged response (41%). The histologic evaluation of the 
conjunctiva revealed the typical influx of non-specific cells of the inflammatory response, 
including neutrophils, basophils, and eosinophils. Tears collected from timed periods over 
the course of 6 hours after allergen challenge or CPT reflected the ability of mediators 
released during the late phase response to reproduce the influx of cells commonly seen after 
ocular allergen testing; however, clinical symptoms were not reproduced in this single 
patient. Direct application of leukotriene B4 has been found to increase the number of 
eosinophils and neutrophils in rat conjunctiva (Trocme et al., 1988). Ocular challenge with 
PAF also resulted in an inflammatory response. The substantia propria was the primary site of 
vascular changes that included endothelial cell swelling, capillary dilation, and edema. 
Ocular challenge with histamine revealed vascular permeability, but not an inflammatory 
response, as measured by the epithelial expression of ICAM-1 (Ciprandi et al., 1993). 
The eosinophils and T helper type 2 (Th2) lymphocytes and cytokines are primarily 
responsible for the late-phase reaction. The infiltration of eosinophils is paramount to the 
allergic response. Eosinophils are not ordinarily found in conjunctival scrapings from non-
allergic individuals. The presence of even one eosinophil or esoinophil granule is 
considerable evidence in favour of a diagnosis of allergic conjunctivitis (Friedlaender et al., 
1984). However, the absence of eosinophils should not rule out a diagnosis of allergy. 
Eosinophils are often present in the deeper layers of the conjunctiva and may be absent or 
undetectable in the upper layers. The frequency of eosinophils in the conjunctival scrapings 
from patients who have allergic conjunctivitis may vary from 20 to 80% (Abelson et al., 
1983) depending on the patient population, the chronicity of the allergic condition, and the 
persistence of the examiner. Corneal infiltrates may occasionally be seen in severe allergic 
patients and tend to be nummular, subepithelial, and peripheral. Chemotactic factors, 
released during mast-cell degranulation, aid in eosinophil attraction and activation. The 
eosinophils release toxic proteins such as eosinophil major basic protein (MBP) and 
eosinophil cationic protein (ECP). These proteins have profound cytotoxic effects and 
stimulate further degranulation of mast cells, initiating a cascade of allergic events (Venarske 
et al., 2003). 
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 The Th2 lymphocytes commonly release cytokines (e.g. IL-4, IL-5, IL-6 and IL-13) 
during the late-phase allergic inflammatory response and a recent study now indicates that 
mast cells may also be a source of Th2-type cytokines (Anderson et al., 2001). This study 
also shows that the phenotype of the conjunctival mast cell may further delineate which 
cytokines are released. For example, tryptase-positive mast cells secrete IL-5 and IL-6, 
whereas tryptase- and chymase-positive mast cells preferentially secrete IL-4 and IL-13. The 
tryptase- and chymase-positive mast cells tend to be the more prevalent phenotype in 
conjunctival tissue. The function of mast cells in SAC and PAC is clearly an important one 
and ongoing research continues to demonstrate their multifunctional role. The other factors 
that appear to play a crucial role in the inflammatory process of SAC and PAC include the 
above mentioned Th2-type cytokines, an increase in the ratio of Th1/Th2 cytokines, and an 
increased statement of adhesion molecules (Pesce et al., 2001). 
 The finding that after allergen challenge there is increased expression of E-selectin 
and ICAM-1 is of interest and would explain the recruitment of cells into the conjunctiva 
(Bacon et al., 2000). 6 hours after conjunctival challenge there is an increase in E-selectin 
(Bacon et al., 1998) and ICAM-1 (Ciprandi et al., 1993) expression correlating with 
lymphocyte and granulocyte levels that would explain the increased infiltration of these cell 
types in the conjunctiva. VCAM-1 induction is slower and has been shown to peak at 24 
hours after conjunctival allergen challenge (Bacon et al., 2000). Increased E-selectin and 
ICAM-1 have been found at 6 hours, and increased VCAM-1 has been found at 24 hours 
after antigen challenge (Montefort et al., 1994; Bentley et al., 1993; Leung et al., 1991). 
 As our understanding of the underlying immunological mechanisms in allergic eye 
disease continues to grow future avenues for pharmacological targeting of different 
categories of allergic eye disease will be available. Appropriate treatment may be based on 
the specific immunopathology, and directed at the activated cell types primarily responsible 
for the disease process. 
 
2.8 Treatment of ocular allergy 
 Mast cells are important effector cells in the conjunctiva. Several drugs used 
clinically for treating SAC (azelastine, epinastine, ketotifen, olopatadine, levocabastine) combine anti-
histamine, mast cell stabilization and anti-inflammatory roles, do not penetrate the blood-
brain barrier and exert effects on other cells. Nedocromil is a gold standard mast cell stabilizer 
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that has been used for many years in the therapy of SAC. Mast cells also synthesize and 
release cytokines of the T helper type 2 profile (IL-4, IL-5, IL-6, IL-8, IL-13, and TNF-α). 
These cytokines promote T cell growth and differentiation, class switching of B cells to 
produce IgE, adhesion molecule expression, inflammatory cell infiltration, and mediator 
release from activated cells. Release of histamine by mast cells also causes the 
pathognomonic itching associated with allergic eye disease and can result in chronic eye 
rubbing and further mechanical degranulation of mast cells (Siddique et al., 2007; Greiner et 
al., 1985; Raizman et al., 2000). 
 Some cases of ocular allergy cannot be explained by mast cell degranulation alone, 
especially in late-phase responses. This finding suggests that degranulation and mediator 
release of other cells such as basophils, eosinophils and neutrophils may trigger and 
perpetuate inflammatory responses observed in allergic conjunctivitis. 
 Structural components of the ocular surface also participate in the mechanisms of 
allergic inflammation. Fibroblasts have been shown to promote the formation of giant 
papillae as well as express adhesion molecules, extracellular matrix proteins, cytokines and 
chemokines. Mediators present in tear samples from ocular allergy patients have been 
recently found to upregulate eosinophil adhesion to human conjunctival epithelial cells ex 
vivo, providing further insight into which adhesion factors (e.g. β2 integrins) may be 
responsible for eosinophilic infiltration to the conjunctiva (Cook et al., 2006). 
 
 Antihistamines 
Antihistamines may be systemically to relieve allergic symptoms. These 
drugs may only partially relieve ocular symptoms, and patients often 
complain of side effects such as drowsiness and dryness of the eyes, nose 
and mouth. Antihistamine such as antazoline and pheniramine are available as 
eye drops and are usually combined with a topical vasoconstrictor such as 
naphazoline hydrochloride. These antihistamine-vasoconstrictor eye drops 
are useful in treating mild allergic conjunctivitis. They also relieve itching in 
most patients. Absorption of topical levocabastine is evident within 15 minutes 
after administration and persists for at least 4 hours, indicating high-speed 
and long-duration binding affinity of levocabastine for histamine H1 
receptors. In addition, it has been demonstrated that levocabastine 
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significantly downregulates ICAM-1 expression on blood vessel endothelial 
cells in the conjunctiva, which inhibits a late-phase response including 
recruitment of eosinophils and neutrophils (Bielory et al., 2005; Buscaglia et 
al., 1996). 
 Mast cell stabilizers 
Mast cell stabilizers have been a useful addition to the other drugs available 
for treating allergic conjunctivitis. Often, patients notice improvement 
within 24 to 48 hours. Mast cell stabilizers are most useful for relief of mild 
and moderate symptoms of allergic conjunctivitis. More severe cases may 
require the addition of topical corticosteroids. An extra-benefit of mast cell 
stabilizers is the relief of nasal symtoms caused by the drainage of tear fluid 
into the nasal passage. Nedocromil sodium is an example available in Europe 
and the Us. 
Lodoxamine tromethamine 0.1% (Alomide) is a mast cell stabilizer that prevents 
the release of histamine and leukotrienes (Caldwell et al., 1992). Lodoxamine 
inhibits mediator release from mast cells, presumably by inhibiting calcium 
influx, thereby indirectly inhibiting increased vascular permeability. It is 2500 
times more potent than cromolyn in inhibiting mediator release from mast 
cells; however, it appears to be roughly equivalent to cromolyn in controlling 
the symptoms of allergic conjunctivitis, vernal conjunctivitis, and giant 
papillary conjunctivitis. 
Ketorolac tromethamine (Acular) belongs to the nonsteroidal anti-inflammatory 
drugs (NSAIDs) class and has been shown to relieve itching associated with 
allergic conjunctivitis. It also reduces levels of PGE2 in tears. There may be 
some burning on instillation. It is unexpected that an NSAID would relieve 
itching, but research from Woodward and collegues (1996) suggested that 
some of the prostaglandins, particularly PGE2 and PGI2 , may be 
pruritogenic. 
Olopatadine (Patanol, Pataday) inhibits mast cell degranulation and antagonizes 
histamine receptors to manage the itching, redness, chemosis, tearing, and 
lid swelling of the ocular allergic reaction. Its mast cell stabilizing ability has 
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been demonstrated in vitro (using human conjunctival mast cells) and in vivo 
(human clinical experience). 
Ketotifen (Zaditor) is a benzacylcoheptathiophen derivative, approved for the 
temporary prevention of itching due to allergic conjunctivitis. It is a 
selective, non-competitive blocker of the H1 histamine receptor. It inhibits 
inflammatory mediator release from mast cells, basophils and eosinophils. It 
inhibits chemotaxis and degranulation of eosinophils, type 1 hypersensitivity 
reactions, and leukotriene activity. In animal studies it decreases vascular 
permeability and leukocyte extravasation in rat and guinea pig models of 
anaphylaxis. 
Nedocromil (Alocril) is a disodium salt of pyranoquinolone dicarboxylic acid 
approved for treatment of itching associated with allergic conjunctivitis. It 
inhibits histamine, LTC4, and TNF-α. It decreases chemotaxis of 
neutrophils and eosinophils and renders them unresponsive to mediators. It 
blocks the expression of cell surface adhesion molecules involved in 
eosinophil chemotaxis and decreases vascular permeability induced by 
inflammation. It reduces itching and to a lesser extent redness associated 
with allergic conjunctivitis. It has an onset of action of 2 minutes after 
dosing and a duration of about 8 hours. 
Pemirolast (Alamast) is a mast cell stabilizer with antihistamine properties. It is 
approved for the prevention of itching associated with allergic conjunctivitis. 
In SAC studies it decreased itching and, to a lesser extent, redness 
throughout the allergy season. It also decreased itching after conjunctival 
antigen challenge. 
Azelastine (Optivar) is a phtalazinone derivative approved for the prevention 
or treatment of itching due to allergic conjunctivitis. It inhibits histamine 
release from allergen-stimulated mast cells and suppresses inflammation. It 
decreases expression of ICAM-1, reduces eosinophil chemotaxis, and 
inhibits PAF. It interfere with calcium influx in mast cells and inhibits the H1 
histamine receptor. It reduces itching and, to a lesser extent, redness in SAC, 
PAC, and after conjunctival antigen challenge. 
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Epinastine (Elestat) is a topically active, direct H1 receptor antagonist and has 
affinity for the H2, α1, α2, and 5-HT2 receptors. It also inhibits histamine 
release from mast cells. Epinastine has a duration of action of at least 8 
hours and it is administered twice a day. It is indicated for the prevention of 
itching associated with allergic conjunctivitis. 
For a summary of the effects of these first two classes see Table 2.5. 
 
Table 2.5 
 IgE Epinastine Olopatadine Azelastine Ketotifen Nedocromil 
In vitro       
CBMC       
IL-5 -  -    
IL-8   -  - - 
IL-10    - - - 
TNF-α       
TNF-β  -   - - 
Histamine       
Conjunctival 
Mast Cells 
      
IL-5   ND ND ND ND 
IL-6 -  ND ND ND ND 
IL-8   ND ND ND ND 
TNF-α  - ND ND ND ND 
TNF-β  - ND ND ND ND 
Histamine   ND ND ND ND 
In vivo       
Edema   - ND ND - 
Tearing   - ND ND  
Redness    ND ND  
Neutrophils   - ND ND - 
Eosinophils    ND ND  
Note: CBMC = Human Cord Blood Stem-cell Derived 
 
 Corticosteroids 
Corticosteroids may be extremely effective in relieving symptoms of allergic 
rhinitis, but because the disease is a chronic, recurrent, benign condition, 
these drugs should be used only in extreme situations, commonly as a 
“burst” treatment for no more than 1 or 2 weeks. Topical steroids are 
associated with glaucoma, cataract formation, and infections of the cornea 
and conjunctiva. Any prolonged use (e.g. longer than 2 weeks) should 
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therefore be applied with the greatest caution, and the patient should 
preferably be monitored by an ophthalmologist. Fluorometholone 0.1% eye 
drops are often selected as a useful treatment of external ocular 
inflammation. This steroid is highly effective in allergic conjunctivitis. It 
appears that fluorometholone penetrates the cornea well, but is inactivated 
quickly in the anterior chamber. Thus, the complications of fluoromethone 
are rare. It may be that fluorometholone is inactivated before it has an 
opportunity to combine with trabecular meshwork or lens receptor. Thus, 
the incidence of glaucoma and cataract formation is expected to be lower 
than with prednisolone or dexamthasone. Two “modified” steroids have 
recently investigated for their efficacy in allergic conjunctivitis. Rimexolone 
(Vexol) is a derivative of prednisolone that is quickly inactivated in the 
anterior chamber. During a 4-week treatment period in patients who had 
uveitis, rimexolone caused an increase in intraocular pressure of 10 mmHg 
or more in 5% of patients, whereas prednisolone acetate 1% caused 
elevation in nearly 14% of patients. In a 6-week steroid-responder study, 
prednisolone 1% and dexamethasone 0.1% caused mean pressures to rise to 
30 mmHg after 3 weeks. Rimexolone and fluorometholone caused mean 
pressures to rise to only 22 mmHg at 3 weeks and 24 mmHg at 6 weeks. 
Rimexolone has recently been approved for treatment of postcataract 
inflammation and for irititis. 
Another modified corticosteroid that shows great promises is loteprednol 
etabonate (Lotemax). It also seems to be highly effective in allergic 
conjunctivitis and is only rarely associated with a significant rise in 
intraocular pressure. A low-dose loteprednol etabonate (Alrex) has been 
approved for the relief of allergic conjunctivitis. Alrex is a useful treatment 
when mast cell stabilizers have been inadequate. 
 Other drugs 
Other antiallergic drugs are being investigated and show promising results in 
the treatment of allergic conjunctivitis, including emedastine, a selective 
blocker of the H1 histamine receptor. Cyclosporine, a fungal antimetabolite 
that can be used as an anti-inflammatory drug, inhibits IL-2 activation of 
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lymphocytes. It is used systemically to prevent rejection of various solid-
tissue transplants. It has been used as an eye drop in a variety of conditions 
including dry eye vernal keratoconjunctivitis and in high-risk corneal 
transplant patients. Cyclosporine appears to interfere with antigen 
processing and presentation of antigen to the uncommitted T lymphocytes. 
Immunotherapy has been successful in treating allergic conjunctivitis, and may 
alter the progression of atopic conditions. 
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CHAPTER 3 
THE INTEGRINS 
 
 
 
3.1 Integrins in Immunity 
 A successful immune response depends on the capacity of immune cells to travel 
from one location in the body to another. Their ability to penetrate into tissues and make 
contact with other cells depends on intergin-like interactions with the surrounding 
environment. 
 Immune cells are collectively termed leukocytes and the key players are the B and T 
lymphocytes, the dendritic cells, the neutrophils and monocytes that differentiate into tissue 
macrophages, and the eosinophils. Leukocytes, especially T cells, migrate rapidly and a 
successful immune response depends on their capacity to quickly access lymph nodes and 
sites of injury and infection elsewhere in the body. Lymph nodes collect foreign antigens 
that drain into them from the body’s tissues and thus act as the central immune-response 
centres or information hubs. It is in lymph nodes that T cells can screen antigen-presenting 
cells, such as dendritic cells or B cells, and is this event that initiates a standard immune 
response. 
 As a wound might occur anywhere in the body, lymphocytes migrate continuously 
through the widely distributed lymph nodes where they spend around 24 hours before 
exiting into the lymphatic circulation and back into the blood (Cyster, 2005; von Andrian 
and Mempel, 2003). This timing allows maximal exposure to any foreign antigen that is 
trapped on antigen presenting cells in the lymph nodes. Neutrophils and monocytes 
circulate in the blood until they are directed into wounded tissues by stimulants that are 
generated locally. Here they act as an early warning system for the lymphocytes that have 
been stimulated in the in nearby lymph nodes. These lymphocytes follow later and help to 
generate an immune microenvironment within the wounded tissue that can be very similar 
to that of a lymph node. Although the myeloid cells do not normally circulate through 
lymph nodes, they do so during infections. In fact, in some infections, large numbers of 
neutrophils enter lymph nodes through the lymph and are found in the T cell and dendritic 
cell regions of the node (Abadie et al., 2005; Chtanova et al., 2008). Therefore, the 
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movement of leukocyte from the blood into peripheral tissues is critical for immune 
surveillance and host defense. Further, aberrant leukocyte trafficking contributes to the 
pathogenesis of inflammatory and autoimmune diseases. Leukocyte trafficking is 
orchestrated and controlled by combinatorial inputs of adhesion and chemoattractant 
molecules located on both the leukocyte and the vascular endothelium. Numerous in vitro 
and in vivo studies have established that leukoctyes circulating in the blood are recruited to 
target organs by a series of sequential steps mediated initially by leukocyte and endothelial 
selectins and selectin ligands or subsets of leukocyte integrins and their endothelial ligands 
of the immunoglobulin superfamily (Springer, 1994; Butcher et al., 1995; Luster et al., 
2005). 
 These functions of leukocytes depend greatly, but not exclusively, on the β2 (CD18, 
ITB2) class of integrins. This class of four αβ heterodimers consists of: leukocyte 
function-associated antigen 1 (LFA-1, CD11a/CD18, αLβ2, ITAL antigen), Mac-1 
(CD11b/CD18, αMβ2, ITAM antigen), p150,95 (CD11c/CD18, αXβ2, CR4, ITAX 
antigen), αDβ2 (CD11d/CD18, ITAD antigen). Leukocytes also express β1 integrins 
(CD29) and α4β1 (CD49d/CD29, ITA4 antigen) is particularly important in immune 
responses. 
 Integrins on leukocytes are not constitutively active, but have their activity 
controlled by signalling through other membrane receptors that are active in an immune 
response. This is defined as inside-out signalling that convert integrins from an inactive to an 
active conformation, while the outside-in signalling that describes the signalling directed by 
integrins themselves once they are active. 
 
3.2 Control of integrin activity 
 Integrins are normally in an inactive or non-ligand binding conformation when the 
leukocytes are circulating in the blood. Binding to other receptors on leukocytes, such as the 
chemokine receptors, antigen-specific T cell receptors or B cell receptors, triggers the 
inside-out signalling that activates the integrins. The end result of this signalling is a 
conformational change in the cytoplasmic and transmembrane domains of the integrin, 
which is relayed to the ectodomain, altering its ability to bind ligands (Kinashi, 2005). 
 In recent years, electron microscopic and crystallographic studies have identified 
three predominant β2-integrin conformations that are thought to reflect different stages of 
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activation (Luo et al., 2007; Xiong et al., 2001). These are the bent form, the extended 
form (intermediate affinity) with a closed ligand-binding head that is of intermediate 
affinity for ligand, and the extended form (high affinity) in which the hybrid domain has 
swung out, enabling the ligand-binding I domain of the α-subunit to bind with higher 
affinity (Figure 3.1). These β2 conformations can be distinguished by their interactions with 
specific antibodies, which react with the different epitopes that become exposed. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemokine receptor-signalling leads to extension of the bent low affinity form of 
LFA-1, and this happens in less than 0,4 seconds (Shamri et al., 2005). The interaction of 
intermediate-affinity LFA-1 with its ligand intercellular adhesion molecule 1 (ICAM-1) 
 
Figure 3.1 
The three conformations of a β2 integrin (ITGB2). Integrins are heterodimeric glycoproteins comprising 
non-covalently linked α- and β-subunits. Each subunit consists of a large extracellular region, a single 
hydrophobic transmembrane domain and a short cytoplasmic tail. (A) Bent – inactive. The inactive 
integrin is in a V shape with the ligand binding I domain close to the membrane. There is close 
association between the α- and β-subunits in the membrane-proximal region. (B) Extended – 
intermediate affinity. Inside-out signalling extends the integrin in a “switchblade-like” motion, orientating 
the I domain away from the membrane for optimal ligand binding. This epitope for the monoclonal 
antibody KIM127, which is located on I-EGF2 and obscured in the bent formation, becomes exposed. 
The KIM127 epitope, thus, serves as a marker for the extended β2 integrin. (C) Extended with open 
conformation – high affinity. Local conformational changes within the α and β I domains, potentially 
generated by shear force, result in the hybrid domain swinging out and the subunit separation at the 
genu. This remodelling of the I domain ligand-binding site forms the epitope for monoclonal antibody 24 
and causes increased affinity for ligand. (modified from Evans et al., 2009) 
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leads to the high affinity conformation that stabilizes adhesion. However, there is no clear 
evidence of how this switch happens. The purported mechanism is based on the capacity of 
mechanical forces to drive allosteric alterations in integrin conformation (Katsumi et al., 
2004) and, for leukocytes, the shear of blood flow would be the major supplier of this 
force (Alon and Dustin, 2007). 
The small GTPase Rap1 is a key integrin regulator, and constitutively active mutant 
of Rap1 (such as Rap1V12) increase the affinity and avidity at the lymphocyte membrane 
(Katagiri et al., 2000; Sebzda et al., 2002). Impaired activation of Rap1 has been in some 
patients with the rare disorder leukocyte adhesion deficiency III (LAD-III) (see Chapter 1 and 
Kinashi et al., 2004). The leukocytes of the patients express normal levels of β1, β2, and β3 
integrins, but have faulty inside-out signaling (Alon et al., 2003; Kuijpers et al., 1997; 
McDowall et al., 2003). The LAD-III syndrome demonstrates the importance of integrin 
activation through this route. The patients suffer from severe and often life-threatening 
infections, because their leukocytes cannot migrate into tissues and their myeloid cells 
cannot use integrins to engulf pathogens. As for other GTPases, the GDP-GTP exchange 
cycle of Rap1 is regulated by guanine-exchange factors (GEFs). Certain Rap1 GEFs are 
activated by the second messenger Ca2+ and diacylglycerol (DAG), and one of the key Rap1 
regulators in hematopoietic cells is CalDAG-GEF1 (aka RasGRP2). Rasgrp2-/- mice have 
impaired integrin-mediated adhesion in platelets and neutrophils and are considered to be a 
model of human LAD-III (Bergmeier et al., 2007; Crittenden et al., 2004). This might be so 
because several LAD-III patients have a mutation in CalDAG-GEF1 that has been 
reported to affect splicing (Pasvolsky et al., 2007). These findings implicate this Rap1-GEF 
in the inside-out signaling of leukocyte integrins. Another route to Rap1 activation is 
through protein kinase C (PKC), which – similarly to CalDAG-GEF1 – is also responsive 
to Ca2+ and DAG. In platelets, rapid chemokine induction of Rap1 occurs via CalDAG-
GEF1, whereas more sustained activation is via PKC (Cifuni et al., 2008). There also seems 
to be fast versus slow routes to Rap1 activation in lymphocytes, as chemokines activate 
Rap1 within seconds, which lasts a few minutes, whereas a more sustained level of Rap1 
activation occurs through the T cell receptor (Katagiri et al., 2002; Shimonaka et al., 2003). 
Thus, there may be similarities between lymphocytes and platelets in the choice of pathways 
that lead to Rap1 activation that result in integrin activation. A downstream effector of 
PKC that leads to Rap1 activation is proposed to be protein kinase D1 (KPCD1; aka 
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PKD1, PKCµ), which forms a complex independently of its kinase activity, together with 
Rap1 and the β1-integrin cytoplasmic domain, redistributing Rap1 to the membrane 
(Medeiros et al., 2005). However, PKC signaling does not always lead to Rap1 activation 
and Rap1 might not be involved in the activation of all classes of integrins. Ghandour et al. 
(2007) report that LFA-1 activation is dependent on CalDAG-GEF1 and Rap1, whereas 
VLA-4 integrin appears to be activated via a Rap1-independent PKC-mediated pathway. A 
conflicting report shows that the Rap1 inhibitor GTPase-activating protein (GAP) signal-
induced proliferation-associated protein (SPA1) blocks both LFA-1 and VLA-4 integrin-
dependent adhesion (Shimonaka et al., 2003). 
 A further set of proteins can bring Rap1 to the membrane and cause its activation. 
The Rap1-interacting adaptor molecule (RIAM) is expressed by T cells and activates Rap1 
through TCR signaling (Lafuente et al., 2004). This pathway involves the adaptor adhesion- 
and degranulation- promoting adaptor protein (ADAP) and its binding partner SRC-kinase-
associated protein of 55 kDa (SKAP55), which interact with RIAM (Kliche et al., 2006; 
Menasche et al., 2007). 
 The activation of Rap1 leads to the redistribution of integrins from the rear to the front 
of the cell. Associated with Rap1 are the adaptor protein RAPL (regulator of cell adhesion and 
polarization enriched in lymphoid tissues) and Mst1 (mammalian sterile 20-like kinase 1) that are 
colocalized with LFA-1 in vescicular compartments (Katagiri et al., 2003; Katagiri et al., 
2006). The implication is that the RAPL-Mst1 complex has a regulatory function in the 
intracellular transport of LFA-1. A final step requires the recruitment of talin by Rap1, 
which then binds to integrin causing the conformational shift that leads to an increase in 
affinity (Campbell and Ginsberg, 2004; Legate and Fässler, 2009) (Fig. 3.2). 
The recruitment of talin and the ensuing integrin activation has become more 
complex with the identification of kindlin-3 (URP2, Mig2B) as a haematopoietic-specific 
activator of integrins (Moser et al., 2008). Kindlin-3 belongs to an adhesion plaque protein 
family of three members, each with distinctive tissue distributions: kindlin-1 (FERM1), 
epithelial expression; kindlin-2 (FERM2), widespread expression; kindlin-3 (FERM3), 
haematopoietic cell-specific expression. Both talin and kindlin-3 have similar FERM (protein 
4.1, ezrin, radixin, and moesin) domains that bind the β-subunit of integrins and the two 
NPxY sites (in which x denotes any amino acid) – talin at the membrane-proximal site and 
kindlin-3 at the membrane-distal site (Ma et al., 2008; Moser et al., 2008). Kindlin-3 
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knockout mice (Ferm3-/-) have severe bleeding problems similar to the Rasgrp2-/- mice, 
suggesting that kindlin-3 is also a candidate gene involved in LAD-III. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3 Outside-in integrin signalling 
 A further level of integrin-activity control is the regulation of avidity, and it is the 
outside-in signals from activated LFA-1 itself that appear to control the state of clustering. 
Macroclustering of LFA-1 on T cells follows on from the initial binding of LFA-1 to ICAM-1 
in multivalent form, thus strengthening adhesion (Kim et al., 2004). On macrophages, 
inactive LFA-1 is randomly distributed, but primed LFA-1 forms nanoclusters and then 
macroclusters when it binds to ICAM-1 (Cambi et al., 2006). Whether the nature of the 
interaction with the cytoskeleton also controls clustering is unclear. It has been shown that 
intermediate affinity LFA-1 on T cells is attached to the actin-binding protein α-actinin-1, 
whereas high affinity LFA-1 is attached to the cytoskeletal protein talin (Smith et al., 2005; 
Stanley et al., 2008). On macrophages, the LFA-1 macroclusters colocalize with talin. 
Considered together, the evidence suggests that the high-affinity LFA-1-talin connection 
favours the formation of stable clusters that further enhance adhesion. 
 
Figure 3.2 
A model of inside-out signalling from agonist to integrin. For integrins to become activated, they need to 
be triggered by the inside-out signalling cascade. The key target of this pathway is the GTPase Rap1. 
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 It is well recognized that the successful functioning of T cells and other leukocytes 
depends on cytoskeletal remodelling (Billadeau et al., 2007; Vicente-Manzanares and 
Sanchez-Madrid, 2004). As outside-in signalling through leukocyte integrins causes cell 
spreading and migration, the implication is that cytoskeletal reorganization is downstream 
of the integrin-specific signalling. For T cells, LFA-1-mediated adhesion to ICAM-1 causes 
extensive F-actin remodelling, but little is understood of the integrin-proximal signalling 
that is involved. More detail is known about signalling in neutrophils and macrophages, 
which promotes β2-integrin-mediated adhesion, spreading, chemotaxis, and other myeloid-
specific functions, such as the production of reactive oxygen species and the release of 
cytokines and cytotoxic granules. The involvement of integrins in these activities is 
highlighted by the finding that neurophils from β2-integrin-null mice are unable to carry out 
these functions. 
 The Src and Syk families of protein tyrosine kinases have been implicated in 
outside-in signalling in myeloid cells that express β2 integrins, in platelets that express αIIbβ3, 
and also downstream of TCR and BCR in lymphocytes (Fig. 3.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 
Ouside-in signalling associated with integrins on leukocytes. The inactive β2 and β3 integrins on myeloid 
cells and platelets, respectively, are constitutively associated with inactive Src kinase. 
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Syk is recruited by its tandem SH2 domains to an adaptor molecule containing an 
immunoreceptor tyrosine-based activation motif (ITAM) that is di-phosphorylated by Src 
kinase. By these means, Syk is brought within range of Src, which then phosphorylates it. 
 
3.4 The role of integrins during extravasion 
 Three overlapping adhesion events mediate the migration of leukocytes out of the 
blood and into tissues. These sequential steps are required to enable the leukocytes to 
overcome the shear forces of blood flow. During the first step, circulating leukocytes are 
captured, become loosely attached to the vascular endothelium and begin to roll along using 
their selectine molecules. This rolling is mediated by L-selectin on the leukocyte and E- and 
P-selectins on the endothelium. The selectins bind to sialyl-LewisX moieties that decorate a 
number of glycosilated counter-receptors (Uchimura and Rosen, 2006). Rolling allows the 
leukocyte to examine the endothelial target for its repertoire of endothelial chemoattractants 
and integrin ligands. 
 The arrest of leukocyte rolling on target vascular beds involves rapid formation of 
shear resistant adhesions by specialized leukocyte integrins. The next step is mediated by 
chemokines that are constitutively produced in lymph nodes or induced in injured tissues 
and become tethered to proteoglycans on the vasculature. Most circulating leukocytes 
maintain their integrins in largely low affinity state (Carman and Springer, 2003). Leukocyte 
integrins must undergo in situ modulation to develop high avidity for their endothelial 
ligands to establish shear-resistant adhesion and firm leukocyte arrest on the target 
endothelial site. This dramatic change in integrin affinity is triggered when the rolling 
leukocyte encounters and rapidly responds to a proper chemoattractant signal presented on 
the apical endothelial surface. Lymphocytes and myeloid cells cease rolling and arrest on 
lymph node high endothelial venules as well as on peripheral tissues upon activation of at 
least one of the four major leukocyte integrins: VLA-4, α4β7, LFA-1, and the myeloid-
specific integrin, Mac-1 (Luster et al., 2005). New structural and functional data strongly 
suggest that bidirectional integrin signals involve rearrangements of their α and β subunit 
cytoplasmic tails and changes in the extracellular domain that follow binding of extracellular 
ligands. 
Chemokines activate the integrins VLA-4 and LFA-1 by engaging the specific 
GPCRs (inside-out signalling) on leukocytes which leads to the third step of the cascade 
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of the integrin-mediated arrest of the leukocyte on the vessel wall. The integrin VLA-4 is 
important at this stage and can have a role in both leukocyte rolling and arrest (Tsuzuki et 
al., 1996). A new role of VLA-4 in lymphocyte homing to lymph nodes has been recently 
investigated. In this scheme, the lipase autotaxin, which is expressed by HEVs, binds active 
integrin VLA-4, generating lysophosphatic acid that, in turn, act on GPCRs that then further 
amplifies the process of homing (Kanda et al., 2008). In light of the short time frame 
required for biologically significant integrin activation by chemokines, integrins may exist as 
preformed associations with different cytoskeletal adapter and membrane proteins (Liu et 
al., 2000), such as tetraspanins, CD47, CD98, and CD44 (Feigelson et al., 2003; Ticchioni 
et al., 2001; Suga et al., 2001; Nandi et al., 2004). 
 Chemokines also activate LFA-1, enabling leukocytes to firmly attach to the 
endothelial surface and to subsequently migrate across it. The crawling of leukocytes 
through the vasculature is known as diapedesis, and this can occur by both paracellular 
(through endothelial cell junctions) and transcellular (through the endothelial cell itself) routes 
(Carman and Springer, 2008). 
 Once a leukocyte establishes firm adhesion to the vascular endothelium, it 
undergoes a morphological change known as polarization. Subsequently, the leukocyte 
migrates over the apical endothelial surface toward interendothelial junctions, where it can 
then transmigrate into the subendothelial tissues. Polarization establishes the front (or 
leading edge) and the trailing edge (in leukocyte an extended rear projection, termed 
uropod, forms a specialized trailing edge) of a cell. After polarization is achieved, the cell is 
poised for directional movement. Depending on the adhesive and chemotactic cues, 
integrins on the polarized leukocyte generate highly dynamic adhesions. These integrins 
must constantly integrate both biochemical information from ligands and inside-out 
activation signals as well as mechanical signals in the form of external forces exerted by the 
shear stress experienced by the leukocyte at the endothelial contact site and internal foces 
generated by polymerized actin and actomyosin contractility (Alon and Dustin, 2007; 
Schwartz and Horwitz, 2006; Gupton and Waterman-Storer, 2006). 
 Polarization in leukocytes is primarily triggered by chemokines and involves 
reorganization of the actin cytoskeleton, Golgi, and microtubule-organizing center as well as 
redistribution of cell surface molecules. F-actin goes from being radially symmetric around 
the cell, to being focused in areas such as the leading edge. Chemokine receptors 
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redistribute to the leading edge, while other cell surface molecules, such as the adhesion 
molecule CD44, redistribute to the uropod. Integrin molecules also reorganize, forming 
clusters at the leading edge and the uropod. In addition, the activation state of the integrins 
can change in a spatially distinct manner during polarization, with high and intermediate 
affinity integrins being primarily localized to the leading edge (Shimonaka et al., 2003; 
Green et al., 2006). 
 Once a leukocyte establishes polarity on the endothelial surface, it can start the 
process of migrating across the endothelium to enter the underlying tissues. For the most 
part, the leukocyte relies on cues in the form of chemokines, adhesive integrin ligands, and 
shear flow to maintain later migration along the endothelial surface until it reaches the 
junction of two or more endothelial cells. Transendothelial migration involves 
spatiotemporal bidirectional signalling between the leading edge of the transmigrating 
leukocyte and specific junctional molecules that reversibly remodel the endothelial junction 
through contractility events that allow the leukocyte passage and the sealing of the 
contracted endothelial junction soon after the leukocyte has terminated its passage. The 
general model of cell motility involves repetitive cycles of new projections being sent out at 
the leading edge in the form of lamellipodia and filopodia. At these sites, new adhesions by 
integrins are laid down with the underlying substratum. This allow for traction as the bulk 
of the cell body is propelled forward, while at the same time adhesions are released at the 
rear of the cell. Integrins play key roles in cellular migration acting both as adhesive 
molecules that maintain locomotion over the apical endothelial surface and as signalling 
molecules, which, together with chemokine signals, maintain polarity and motility (Kinashi, 
2005). 
 The signalling needed to coordinate migration is complex. Just as Rap1 activation 
plays a key role in integrin activation and leukocyte polarization, the activation of the small 
GTPase Rac has emerged as a key signalling event controlling cell motility on adhesive 
substrata (Srinivasan et al., 2003; Xu et al., 2003; Fenteany and Glogauer, 2004). Rac 
activation drives actin polymerization and lamellipodia formation (Hall, 2005). However, 
efficient migration requires this Rac activation to be spatially and temporally restricted to 
the leading edge of the cell. A recently defined signalling pathway provides for spatial and 
temporal regulation of Rac activation during VLA-4-integrin-dependent cell migration on 
both the vascular ligand VCAM-1 and on the extracellular matrix protein fibronectin. This 
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VLA-4-dependent modulation of Rac activation is mediated by the reversible binding of 
paxillin to the α4 cytoplasmic domain. The α4 integrin subunits bind directly to the 
signalling adapter molecule paxillin (Liu et al., 1999), and this interaction is regulated by 
selective phosphorylation of the α4 cytoplasmic domain at serine 988 in a protein kinase A-
dependent manner. Phosphorylation at this position leads to release of paxillin from the α4 
subunit, while depshosphorylation promotes the α4 integrin-paxillin interaction (Han et al., 
2001). In a migrating cell, the phosphorylated α4 integrins are localized to the leading edge 
of the cell, while dephosphorylated α4 integrins are localized to the lateral and trailing edge 
of the cell. This spatial regulation of α4 integrin-paxillin binding promotes effective 
leukocyte migration, as either disrupting or enforcing the association of α4 with paxillin 
greatly impairs cell migration (Han et al., 2003). The α4 integrin-paxillin interaction 
contributes to effective cell migration by spatially regulating Rac activity. Paxillin bound to 
α4 integrin provides scaffolding for recruitment of additional signalling molecules to this 
site. One of these recruited signalling molecules is an adenosine diphosphate-ribosylation 
factor (Arf)-GAP, GIT1. GIT1 ultimately leads to inhibition of Rac activation by inhibiting 
the activation of another small GTPase, Arf6. Arf6 modulates Rac function through 
mechanisms involving changing in cellular distribution of Rac1 by endosomal trafficking 
and recruitment or Rac activators such as Rac-guanine nucleotide exchange factor (GEF), 
DOCK180/ELMO (Goldfinger et al., 2003; Han et al., 2003; Brown and Turner, 2004; 
Nishyia et al., 2005; Vitale et al., 2000; Santy et al., 2005). Thus, during α4-dependent 
migration, the α4 integrin-paxillin interaction contributes to the inhibition of Rac activation 
at the later and trailing edges through the recruitment of Arf-GAP. 
 α4 integrins can also regulate Rac activation and cell migration through Src kinases, 
independent of the α4-paxillin interaction. Thus, VLA-4 integrin-dependent activation of Rac at the 
leading edge can proceed through activation of Src kinases. Polarization and motility are also 
maintained by inhibition of Rac at the later and trailing edges mediated by the α4-paxillin 
complexes that recruit an Arf6 inhibitor. These two integrin-mediated signalling pathways 
can be complemented by chemoattractive signals presented to the leukocyte on the apical 
junctional and subluminal compartments of the endothelial barrier. When these 
chemoattractant signals are robust, the VLA-4-Rac activation pathway may be less 
important for migration (Fig. 3.4). One unique feature of the α4 cytoplasmic domain is that 
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it direcly binds to paxillin, and this interaction is negatively regulated by α4 serine-988 
phosphorylation. Therefore, as described by Hsia et al. (2005) the fibronectin binding 
integrins generate signals promoting cell migration through distinct mechanisms: a paxillin-
mediated linkage to α5β1 facilitates FAK activation, the formation of an activated FAK-Src 
complex, and increased cell motility, in part due to the tyrosine phosphorylation of 
p130Cas, generating signals leading to Rac activation and lamellipodium formation at the 
leading edge of migrating cells (Mitra et al., 2005; Schlaepfer and Mitra, 2004); even though 
Src activation is a common signalling component promoting α4β1- and α5β1-cell motility, 
α4β1-induced Src activity does not involve FAK. Notably, phosphorylation of p130Cas 
by c-Src or a FAK-Src complex occurs via a shared pathway associated with enhanced Rac 
activation, lamellipodium formation, and cell motility (Fig. 3.4). Thus, the α4 cytoplasmic 
domain connection to c-Src activation is a FAK-independent linkage to a common motility-
promoting signalling pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 
Model of receptor-proximal differences in α4β1 and α5β1 signalling events promoting p130Cas 
phosphorylation associated with Rac activation in migrating cells. α4β1 binding to VCAM-1 or 
fibronectin (FN) (CS-1) stimulates c-Src-family PTK phosphorylation at Y418 and promotes Src 
catalytic activation in a FAK-independent manner. This linkage between α4 and Src does not require 
paxillin binding to α4, which has been shown to down-regulate Rac activation at posterior regions of 
migrating cells through a signalling linkage involving paxillin binding to the ADP ribosylation factor 
GTPase-activating protein (Arf6-GAP) GIT1. From Hsia et al., 2005 
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 The above described paradigm for α4β1 integrin-dependent regulation of Rac 
activation and migration is just one mechanism that contributes to leukocyte 
transendothelial migration. Certainly other cues that drive migration, such as 
chemoattractants and signals generated by mechanical force on the cell (such as shear flow), 
will come into play to regulate Rac activation and cell migration. The combined input of 
these cues will ultimately determine how and where leukocytes migrate. Furthermore, the 
relative importance of each of these cues may vary widely between different types of 
leukocytes. For example, while a fluid shear plays an important role in lymphocyte 
transendothelial migration, it plays a lesser role in neutrophil migration, especially on 
endothelium expressing high amounts of β2 integrin ligands (Cinamon et al., 2001; Cinamon 
et la., 2004). 
 Not all forms of leukocyte migration are the same with respect to mechanics and 
signalling. In lateral migration, leukocytes migrate to reach the junction of endothelial cells, 
and in migration across the junction, the leukocyte moves between two endothelial cells. 
Junctional migration involves highly specialized adhesive interactions between the leukocyte 
and endothelial cells, which allows for the initial separation and reforming of endothelial 
junction as the leukocyte passes through. These differences in migration are reflected in 
different signalling pathways involved. For example, later migration of lymphocytes, driven 
by chemokines, requires DOCK2-dependent activation of Rac, while junctional migration 
of lymphocytes is DOCK2 independent. 
 Where and when leukocytes leave the blood and enter the peripheral tissues play key 
roles in immunity and inflammatory diseases. These locations are selected by repertoires of 
chemoattractants and adhesion molecules. The precisely regulated expression and 
functional state of these molecules allows for accurate specification of leukocyte 
trafficking throughout the body. Integrins are adhesion and signalling molecules involved in 
the adhesive interactions between leukocytes and the vascular endothelium needed to resist 
the physical forces of blood flow and mediate effective migration across the endothelium. 
To meet the challenge of adhesion under shear flow conditions, leukocyte integrins link to 
the cytoskeleton to resist detachment under shear flow condition and undergo rapid 
reversible modulation of their ligand-binding affinities within subseconds of stimulation by 
chemoattractants. In addition, integrin-mediated signal transduction must be both spatially 
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and temporally regulated in leukocytes to allow for effective migration across the 
endothelial barrier. Unravelling the molecular machineries that regulate adhesion, motility 
and transendothelial migration in different subsets of leukocytes may help to identify 
therapeutic targets to selectively modify leukocyte trafficking. 
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CHAPTER 4 
HIGH-THOUGHPUT SCREENING 
 
 
 
4.1 Drug screening using cell lines 
 The rapid progress in combinatorial chemistry continues to yeald a myriad of 
potentially bioactive compounds everyday. With thousands of pharmaceutically valuable 
drugs at hand, there is an urgent need for engineered tissue equivalents that could serve as 
in vitro model systems during the initial stages of drug discovery, specifically during the 
preclinical stages of cell/tissue-based high-throughput screening (HTS). 
 The major research focus of the pharmaceutical and agrochemical industries is the 
fast and efficient detection of active compounds (“leads”) with a pronounced 
developmental and market potential. During the past decades, remarkable efforts have been 
made to accelerate the lead discovery process (Fig. 4.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enabling technologies (e.g. robotics, high-throughput screening assay technologies as well 
as genomics and proteomics) were put into place throughout the industry to generate the 
necessary high-profile clinical and developmental candidates. 
 
Figure 4.1 
Scheme of the high-throughput procedure to screen compound libraries for the identification of 
suitable candidates for clinical studies. 
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 Another approach that parallels HTS technologies is the virtual screening (VS) 
that is one of the readily available technologies that may contribute to deliver clinical 
candidates more rapidly and economically. This technique can effectively identify 
biologically active compounds, or hits, from a pool of millions of virtual compounds 
(Waszkowycz, 2002; Shoichet, 2004). 
 A modern drug discovery program generally starts with the target selection, 
followed by hit identification, hit-to-lead transition, lead optimization, and clinical 
candidate selection. Hit identification, although it occurs at an early stage of the whole 
process, has a profound influence on the success of a program. HTS is the mainstream 
method widely applied in the pharmaceutical industry to identify hits, yet HTS suffers from 
many limitations – most importantly it is costly and time consuming. The basic costs of 
HTS include collecting and maintaining screening libraries of thousands to million of 
compounds, the reagents for the assay, and maintaining the robot systems. It usually takes 
months to complete an HTS, from designing and optimizing the assay, to cloning, 
expressing and purifying the target protein, to plating compounds, and to finally confirming 
the hits. In addition, experimental HTS inevitably suffers from misidentification or decision 
errors, i.e. “false positives” and “false negatives” (Malo et al., 2006). “False positives” 
and “false negatives” are frequently associated with technical or procedural problems during 
the assay, or result from the properties of the screened compounds themselves, such as low 
solubility or poor stability. 
 Both HTS and VS aim to identify a small subset of biologically active compounds 
from a vast number of compounds. Experimental HTS directly or indirectly detects the 
interactions between small molecules in an existing library and the target protein, while VS 
applies rule-based or property-based pattern recognition and molecular docking to filter 
a library of virtual compounds, which may not be synthesized yet. 
 Cell-based assays, if appropriately designed, can be used to rapidly identify 
molecular mechanisms of human disease and develop novel therapeutics. In the last 20 
years, many gene that cause or contribute to diverse disorders, including cancer and 
neurodegenerative disease, have been identified. With such genes in hand, scientists have 
created numerous model systems to dissect the molecular mechanisms of basic cellular and 
developmental biology. Meanwhile, techniques for high-throughput screening that use large 
chemical libraries have been developed, as have cDNA and RNA interference libraries that 
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cover the entire human genome. By combining cell-based assays with chemical and genetic 
screens, we now have vastly improved our ability to dissect molecular mechanisms of 
disease and to identify therapeutic targets and therapeutic lead compounds. 
A selected cell line for HTS must express the desired function in the correct signal 
context with a stable and reproducible signal window. The different cell types from which 
to choose have different advantages: primary cells best resemble the physiological 
situation, but cultivation and available cell numbers are critical issues, even when using 
techniques such as conditional immortalization or stem cell differentiation. A large panel of 
easy-to-cultivate immortalized cell lines is available with cell history, growth behaviour 
and functional information. These cells are ideal for functional screens as proliferation 
assays. Recombinant cell lines overexpressing the target are often used for screening, 
because cell lines with an optimal growth behaviour and signal window can be selected. 
 In order to obtain reproducible cell material for HTS, the favourite procedure is to 
generate a stable target-expressing cell line. This allows adjustment of the expression level 
by using different promoter elements and/or amplification with the methotrexate or 
glutamine synthase system combined with clone selection. In addition to stable cell lines, 
identical cell material can be produced by transient transfection of one large cell batch, 
followed by freezing the transfected cells in portions. Directly before HTS, the frozen cells 
are seeded into assay plates. For an optimal large-scale transient transfection, special 
standards must be fulfilled for the cell line, the expression plasmid, the medium, and the 
transfection reagent. 
 The ideal cell for HTS is fast growing, had good adherence, a stable cellular phenotype, a broad 
tolerance against solvents, and is insensitive against culture modifications. All of these parameters must 
be tested for each cell line and each assay, using HTS equipment and conditions early 
during cell development. 
# Adherence: most HTS are plate-based assays involving one washing or 
separation step, as well as the uncontrolled loss of cells is a frequent reason 
for low assay reproducibility. The degree of negative charges on the cell at 
physiological pH seems to be one important factor for good adherence. In 
addition, the present of bivalent cations (Mg2+, Ca2+) and the presence of 
extracelluar proteins determine the adherence of cells. Poor adherence can 
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be improved by coating the wells with charged substrates such as poly-L- or 
–D-lysine, or with components of the extracellular matrix. 
# pH and temperature: most cells grow best at a pH between 6.8 to 7.6, and the 
pH of most commercial media is 7.2 to 7.4. Media based on Earl’s salt 
composition are buffered by bicarbonate/carbonic acid, and the pH is 
regulated by constant CO2 delivery in an incubator. After 30 minutes at 
atmospheric pressure, the pH rises by about 0.1 to 0.2 pH units; after 4 
hours the pH is raised by about 0.3 to 0.5 pH units. Media with Hank’s salt 
composition are buffered by phosphoric acid and should be used at normal 
atmosphere. The addition of 10-20 mM HEPES to the media with a good 
buffering capacity between pH 7.2 and 7.4 helps to keep the pH constant. 
Depending upon the available instruments, screen conditions minimizing 
pH variations must be selected. 
# Media and additives: the medium is not only a food source but also represents 
the environment in which the cells live. Medium selection for the screen is 
dependent on the cell type and on the assay. The medium composition must 
support the desired cell function needed, and provide an optimal energy 
source as well as all important nutrients such as vitamins, growth factors, 
minerals, and essential lipids that the cells need. A media for cell production 
can differ from one used for plate generation, as the latter often contains 
antibiotics and HEPES. The optimal amount of foetal calf or bovine serum 
and ingredients such as glucose and glutamine can be different for the 
production phase compared to the plating medium. For fluorescence read-
outs, as well as some reporter assays, the presence of phenol red in the 
medium enhances the background. All medium components such as 
FCS/FBS, growth factors, hormones, vitamins, ions, and nucleotides should 
be evaluated for possible interference with the assay signal. FCS contains 
different amounts of stress-protecting factors such as vitamin E and ATP, 
as well as calcium, which modulates cell function and influences cell 
adhesion, proliferation, and differentiation. Charges of media and additives 
must be checked for functionality for each assay, and should not be charged 
during HTS and development. 
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# Solvent tolerance: Most compound libraries are dissolved in dimethyl sulfoxide 
(DMSO), the tolerance of which is dependent on the cell line and the 
duration of exposure. The solubility of a compound can also determine its 
useable concentration in the screen. Often-used cell lines such as CHO, 
BHK, NIH-3T3, and HEK293 show no growth inhibition and functional 
difference in the presence of up to 1% DMSO or ethanol, but primary cells 
are more sensitive in general. 
# Cell density: The optimal cell density must be determined. For transport and 
receptor function assays, a good confluent cell layer enhancing the target 
density is often advantageous, and cell numbers in the range of 8000 to 
12000 per 384 wells should be considered. The influence of cell number and 
variations on the signal must also be monitored. Functions such as 
sensitivity to drugs, transcriptional activity, permeability, cells in mitosis or 
the differentiation state often change with cell density. For these assays, 
semi-confluent cultures are often preferable. Surface proteins (e.g. receptors) 
can be sensitive to proteases such as trypsin. Receptor function must be 
carefully checked if cells are to be used at different time-points after seeding. 
It is recommended that cells are harvested using nonenzymatic solutions. 
For image analysis, and for localization assays, a good separation of the 
single cells is needed, and aggregates must be avoided. Larger cells with a 
clearly separated, round nucleus and minimal morphological variation are 
ideal. 
 
Unlike ordinary assay reagents, living cells are prone to change during their time in culture, 
in response to environmental changes, and they require between 4 and 24 hours after 
plating to adhere properly. Differences in cell density, metabolism and function on has to 
take into a consideration if using cells as reagents. Cells often function optimally at defined 
time points after plating or confluence. In particular, the signals of reporter assays are 
known to be sensitive to changes in cell number. 
 The use of growth-arrested cells for screening provides another possibility of 
enhancing flexibility and reproducibility. CHO cells which had been frozen after mitomycin 
C-induced division arrest in a calcium flux assay, and reported a stable signal-to-noise ratio for 
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four days after plating. Similarly, by using mitomycin C treatment it is possible to improve 
the robustness of a reporter assay to a Z’-value of 0.79, compared to 0.35 for normal 
cultured cells. 
 Differentiated cells reflect naturally growth-arrested cells by keeping their functional 
phenotype stable for several days in culture. Differentiated cells are more difficult to prepare, 
but this is acceptable if they provide reliable cell material for screening. 
 Maintaining plated cells under hypothermic conditions (4-8 °C) offers another 
possibility of enhancing flexibility in cell delivery. By using special solutions, normal 
coronary artery smooth cells, hepatic cells and skeletal muscle cells can be kept for between 
2 and 7 days at 4-8 °C. This effect is due to the solutions balancing the altered cellular ion 
concentrations and counteracting cell swelling at low temperature. 
 
4.2 General HTS assay prerequisites and set up 
 A certain level of automation is a prerequisite for an efficient HTS laboratory. In 
general the microplate has established itself as the major assay platform, starting with the 
96-well plate which has been the first major step towards parallelization. The pressure to 
reduce the cost of screening, combined with technical improvements in pipetting 
equipment and plate manufacture, has led to increased use of higher-density plates with 
384-1536 wells. Despite the clear advantage in reagent savings, the use of smaller volumes is 
more demanding on the equipment used for liquid handling and detection. Thus, the 
reduction of assay volumes can lead to compromised assay parameters, especially due to 
stronger evaporation effects and changed surface-to-volume ratios. Although the number 
of screened wells per unit time is an easily measurable and objective performance 
parameter, this does not directly define the desired output, which is the efficient 
identification of novel lead structures. As a consequence, further emphasis must be given to 
novel screening strategies and physiologically relevant screening approaches. Advanced 
screening approaches using cellular read-outs are one of the means by which this goal may 
be achieved. 
 Certain quality parameters must be met during the development of the assay. One 
of the basic parameters is to outline the controls used to define assay performance, and to 
calculate activities. Whereas uninhibited samples typically are used to serve as the positive 
control, the negative or blank control is often more difficult to define. In the best case, a 
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pharmacologically relevant standard can be used to define the level of maximal effect or the 
level of nonspecific signal blank (NSB). During assay development, it must be determined 
if there is sufficient faith that these control values are not too artificial to be reached by a 
pharmacologically active compound. In some cases the positive controls might require the 
addition of an agonistic compound to stimulate the system. Assays searching for agonistic 
activities might have accordingly reversed controls: for example, the blank value might 
represent the unperturbed control. 
 Assay performance and its suitability for HTS is usually calculated using the mean 
(M) and standard deviation (SD) of such control wells. The screening window coefficient 
(z’) is the most commonly used statistical parameter to describe the quality of an assay: 
 
 
 
 
z’ is a statistical tool that reflects the assay’s dynamic range and the variability associated 
with the measurements. In recent years, the z’-value has been accepted as the most relevant 
parameter describing the assay robustness, and z’-values above 0.5 are considered as 
sufficient for screening campaigns. However, all of these parameters describe to a certain 
level only the robustness of the assay, and not whether the assay can detect the correct 
pharmacology and/or is capable of detecting hits with the desired sensitivity.  In addition to 
the difficult quest for the correct pharmacology of novel targets, target-unrelated effects have 
been recognized as a major challenge for HTS operation. Such undesired assay interference 
leads to so-called false positive or negative results, and these can create a significant 
burden on resources during the hit validation phase. Phenomena such as the inner filter effect, 
which is caused by coloured compounds, the quenching of fluorescence by various 
mechanisms, autofluorescence of compounds, light scattering resulting from particles, and 
photo bleaching are common mechanisms of assay interference. Many compound-related 
assay interferences are concentration-dependent and this creates a barrier for the selection 
of high compound concentrations for screening. Another major disturbing effect is caused 
by compound precipitation; hence, exceeding a compound’s solubility limits in HTS is not 
recommended but, due to the variety within the compound collection, this cannot always be 
avoided (McGovern et al., 2002). However, the most important parameter – the relevance 
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of the screening approach for the pathophysiological in vivo situation is the most difficult to 
appreciate a priori. One strategy to improve the level of confidence in the physiological 
nature of the screening is to present the target of choice within its cellular environment. 
 High-throughput and virtual screening are widely used to discover new lead 
compounds for drug design. These screening methods have discovered novel molecules, 
dissimilar to known ligands, that nevertheless bind to the target receptor at micromolar or 
submicromolar concentrations. Often screening hits are subsequently found to have 
peculiar inhibition properties: they act noncompetitively, show little relationship between 
structure and activity, and have poor specificity. These traits are non-drug-like and are 
undesirable in lead compounds. Accordingly, many attempts have been made to identify 
and remove molecules with these properties from screening databases. Such efforts have 
not been entirely successful because the underlying causes of these unusual behaviours are 
not completely understood. Consequently, screening hit lists continue to be populated, even 
dominated, by compounds that act with atypical properties that cannot be described by 
any existing model; such compounds are unlikely to be pharmaceutically useful. These 
properties are due to the biophysical characteristics of the compounds. 
 In creating a disease model, a researcher must balance the ease of working with the 
system against the relevance of the disease process. Typically, “relevance” is determined 
empirically when predictions made by a simple system (e.g. a cellular assay) are tested in a 
more complex system (e.g. a transgenic mouse model). The balance between tractability and 
relevance becomes even more challenging when attempting to create a cellular model that is 
amenable to HTS. It is reasonable that using a discrete and quantifiable molecular event 
that closely correlates with pathogenesis as the readout for cell-based HTS increases the 
likelihood of discovering compounds with activity in more stringent in vivo models. The 
value of a cell-based assay is greatly enhanced if the end point is specific to the disease 
mechanism. Most basic cellular phenotypes that can be readily measured (e.g. proliferation, 
death, and process extension) are under the control of multiple regulatory pathways. When 
such readout are used in screening assays to identify genetic or chemical modifiers, there is 
consequently a great chance that a nonspecific effect will account for the result. Conversely, 
when a highly specific molecular event (e.g. protein folding) is monitored within a cell, the 
odds are much lower that nonspecific processes could account for the result. 
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 The choice of a library is critical to the success of a screening project. It is important 
to consider the size and the cost of the library, how to determine the mechanism of action 
of hits, and how to translate them in viable drugs. Because the cost of a library is high and 
the success rate is low, it is suggested that academic laboratories by screening small 
collections of biologically active molecules in cell-based assays. Ideally, compounds should 
be cell-permeant, nontoxic, and nonmutagenic and have good bioavailability. These 
characteristics will make them more effective in live cells and improve their likelihood of 
activity in vivo. Screening an established molecular space offers many advantages. These 
compounds are generally known to be biologically active, which increases their chance of 
modifying the molecular event of interest. 
 
4.3 Shifting to high-content screening 
 The term “high-content screening” (HCS) describes the analysis of drug activities 
in cell-based assays. It is a technology platform designed to define temporal and spatial 
activities of genes, proteins,  and other cellular constituents in living cells. The measured 
events can include general effects (e.g. cellular morphology, apoptosis, migration), 
metabolic stimulation or inhibition, and specific effects on discrete target proteins. 
From a biology-orientated perspective, the term “phenotypic screening” is also often used to 
describe complex cell-based compound screening. HCS is not a novel technique, but 
combines cellular manipulation, data acquisition and data processing within an integrated 
process. 
 In contrast to target-based approaches, assays which recapture generic cellular 
parameters deliver in-depth results with regard to the mode of action of screening 
compounds. Cellular assays with multiparametric readouts are desired when a 
multifaceted cellular phenomenon such as apoptosis is studied: 
 They can provide access to targets not amenable to screening in 
conventional assays 
 Multiplexed assays enable the direct identification of pharmacologically 
active compounds which can modulate the physiology or morphology of a 
cell. 
These advantages must be reflected knowing that most successful drugs descend from 
natural products selected in intact biological systems, and many drugs show several 
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biological activities as nonsteroidal anti-inflammatory agents, cyclosporine, and 
antihistamines (Kubiniy, 2003). Even for the most popular drugs, not all of the targets and 
signalling pathways influenced in one cell are realized, much less the effect on the whole 
organism. 
 The minimization of biological complexity by screening isolated targets or individual 
pathways causes most emergent properties and all network responses of a cell to be missed. 
Hence, the future use of complex cell systems in combination with testing of several targets 
will allow the collection of information covering several disease parameters and pathways by 
selecting for cell-permeable, nontoxic drug candidates. Today, a series of new, more 
physiologically relevant cell culture methods have become available: tumour cells have been 
grown to three-dimensional spheroids and tested for their response against cytotoxic agents 
(Bartholoma et al., 2005), while embryonic stem cells allow the effects of compounds to be 
monitored in complex cell systems. 
 In future, the main challenges for complex cellular screens are: 
Ж the identification of drug targets; 
Ж the determination of target-based structure-activity relationships of the 
compounds; 
Ж the regulatory issues. 
The management and presentation of the growing amount of data as well as the integration 
of analyzed cellular parameters into a physiological context, represent a major challenge for 
cellular bioinformatics. 
 
4.4 Scintillation proximity assay (SPA) 
 The recent advances in generating small molecules by a wide variety of 
combinatorial chemistry approaches has increased the pressure on screening methodology 
to rapidly evaluate the compound library data base and accordingly identify lead chemical 
structures. In order to screen such large numbers effectively the high throughput screening 
must be robust, automatable and precise. 
 Scintillation proximity assay is a radioisotopic homogeneous assay technology which 
allows the design of high-flux assays for a wide variety of biochemical and cellular targets. 
The method requires no separation steps and relies entirely on pipetting on a “mix and 
measure” format. The SPA technology is therefore easily automatable and precise and when 
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utilized with microtitre plate scintillation counters and robotics provides a highly versatile 
high throughput assay technology. The technique has been utilized effectively for 
radioimmunoassays, receptor binding assays, and a wide variety of enzyme assays. More 
recently, SPA has been applied to cellular adhesion molecule binding, protein-protein 
interactions, protein-DNA interactions, and cellular biochemistry assays. 
 The technique relies on upon the observation that a γ particle emitted from a 
radioisotope will only travel a limited distance in an aqueous environment. This path length 
is determined by the energy of the β particle. The β electron from [3H] is emitted as a 
spectrum with an average path length of approximately 1.5 µm and the two monoenergetic 
Auger electrons emitted by [125I] have path lengths of 1 µm and 17.5 µm respectively. In 
general these two isotopes are ideally suited for SPA. 
 In SPA the target of interest is immobilized to a small microsphere approximately 5 
microns in diameter. The microsphere consists of a solid scintillant core which has been 
coated with a polyhydroxy film, which in turn contains coupling molecules such as 
antibodies, which allow generic links for assay design. 
 When a radioisotopically labelled molecule binds to the microsphere the 
radioisotope is brought into close proximity to the scintillant and effective energy transfer 
from the β particle will take place resulting in the emission of light. While the radioisotope 
remains in free solution it is too distant from the scintillant and the β particle will dissipate 
the energy into the aqueous medium and therefore remain undetected. 
 The technique has been successfully applied to radioimmunoassay by capturing 
specific antibodies onto SPA beads either through a secondary species specific antibody or 
protein A beads. Radiolabelled antigen binding may then be detected easily without the 
requirement for separating bound and free antigen. The SPA technique therefore replaces 
the requirement for charcoal or PEG precipitations. 
 For the assay of receptor-mediated binding events, an SPA bead has been designed 
which is coated with the lectin wheat germ agglutinin (WGA). This bead captures 
glycosilated cellular membranes and glycoproteins and has been used for a wide variety of 
receptor sources and cultured cell membranes. The receptor is immobilized onto the WGA 
SPA bead and a signal is generated on binding of an [125I] or [3H] labelled ligand. While the 
ligand is in free solution no signal is detected. As SPA is a homogeneous assay technology, 
it is possible to monitor in “real time” the binding event of interest without a need to 
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disturb the interaction with a separation step. SPA can therefore be used to monitor the 
time course of a binding event in “real time” by continuously monitoring a single assay. 
 All of these features of SPA make it an ideal rapid screening technology for all 
forms of combinatorial, chemical and natural product library screening programs. 
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CHAPTER 5 
AIM OF THE RESEARCH 
 
 
 
 
 
5.1 To develop a prototype of high-throughput screening (HTS) based on SPA 
technology 
 One of the primary aims of this thesis was to develop a homogeneous high-
throughput screening (HTS) assay for indentification of novel integrin antagonists for the 
treatment of ocular allergy, and to better understand the mechanisms of action of drugs that 
are already available. 
 Integrins are adhesion molecules ubiquitously expressed throughout the organism. 
Some of them are specifically expressed by immune cells and play pivotal roles in immune 
responses, directing leukocytes to the sites of a lesion or infection and helping their 
migration from the circulation to the injured tissues. Specifically, this thesis is focused on 
the actions of the α4β1 integrin (VLA-4) in allergic inflammation. This integrin is expressed 
in activated leukocytes and interacts with its counter-receptor vascular cell adhesion 
molecule 1 (VCAM-1), enabling them to overcome the shear flow forces and localize at the 
level of inflammation. There is a series of undesired  immune responses that, if non-treated, 
can result in harmful and permanent consequences; an example is the allergic inflammation. 
The study of compounds able to block cell adhesion mediated by VLA-4 could lead to the 
development of novel anti-inflammatory strategies. Therefore, an accurate and robust 
receptor-binding assay is highly desirable to screen a large collection of chemical entities. 
Scintillation proximity assay (SPA), because of its simplicity and high-throughput nature, 
has broad applications in measuring receptor-ligand interactions. Conventional filter-
binding assays involve one or more separation steps and, thus, are laborious, non-
homogeneous and not suitable for automation. SPA technology, on the other hand, 
provides a homogeneous screening approach that does not require post-reaction liquid 
handling steps and is well suited to automation. 
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 In this study we propose a novel SPA method to assess specific binding properties 
of known selective VLA-4 ligands and of some anti-allergic drugs (such as levocabastine) 
indicated for the treatment of ocular allergy. 
 
5.2 To better understand the role of integrins in ocular allergy 
 Once the ability of levocabastine – a second generation anti-histaminic agent – to 
bind to the integrins typically expressed in allergic eye disease was assessed, our research 
was aimed to demonstrate the contribution of this mechanism in the anti-allergic profile of 
this drug. 
 The ocular allergic response results from the exposure of the conjunctiva to an 
allergen. This event causes the mast cells to degranulate and release mediators such as 
histamine, prostaglandins and leukotrienes that induce itching, vasodilation and increased 
vascular permeability, that finally lead to tissue invasion of immune cells, particularly of 
eosinophils. Current guidelines for the treatment of ocular allergies advocate anti-histamines 
for occasional or intermittent symptoms, whereas in patients with moderate seasonal 
disease, and in patients with perennial disease, topical corticosteroids (with or without 
additional rescue anti-histamines) represents first-line treatment. 
 The movement of leukocytes from the blood into peripheral tissues plays a key role 
in immunity as well as in chronic inflammatory and allergic diseases. Therefore, 
pharmacological antagonism of VLA-4 is an attractive prospect for the treatment of 
predominantly eosinophil-mediated diseases such as allergic conjunctivitis. 
 In this study I investigated the ability of levocabastine to block the adhesion to 
immobilized VCAM-1 or to TNF-α activated HUVEC monolayers of human eosinophils 
or EoL-1 (human eosinophilic leukemia) cells. 
 Immune-modulation is coordinated by cytokines, which are chemical mediators with 
autocrine and paracrine effects that play a fundamental role in immune-modulation and in 
the perpetration of allergic inflammation. This thesis intends to ascertain whether 
levocabastine can modify the release of some eosinophilic cytokines that support allergic 
inflammation. 
 Finally, by means of an in vivo model of allergic conjunctivitis in guinea pig, the 
clinical symptoms of ocular allergy (redness, itching, swelling, lid reversion) was measured in 
animals treated and non-treated with levocabastine, in a time-dependent manner in order to 
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distinguish between the events involved in the early and the late phase responses. Excised 
conjunctivas were probed to weigh up the ability of levocastine to block eosinophil 
infiltration and/or activation. 
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CHAPTER 6 
MATERIALS AND METHODS 
 
 
 
6.1 Materials 
 
Reagents 
 Levocabastine 0.05% solution eye drops containing cyclodextrins, without 
benzalkonium chloride; placebo containing cyclodextrins, without benzalkonium chloride; 
levocabastine 0.05% suspension eye drops containing benzalkonium chloride; levocabastine 
powder in a solution of sodium edetate, propylenglycol, disodium phosphate anhydrous, 
sodium dihydrogen phosphate monohydrate, hypermellose, polysorbate 80, purified water; 
BOL-303242 powder; BOL-303242-X emulsion; BOL-303242-X vehicle; were all provided 
by Bausch & Lomb (Rochester, NY, USA). Trimeton® (chlorpheniramine acetate) was 
obtained from Schering-Plough (Segrate, Italy). Decadron® (dexamethasone, 21 disodium 
phosphate) was obtained from Visufarma (Rome, Italy). Opatanol® (olopatadine 
hydrochloride) was from Alcon (Hemel Hempstead, UK). RPMI-1640 with L-glutamine, 
penicillin-streptomycin solution, AlexaFluor® 488 and 568 conjugated secondary antibodies, 
Hank’s balanced salt solution, chloromethylfluoresceine diacetate (CellTracker Green 
CMFDA), G418, MagicMark™ XP western standard were purchased from Invitrogen 
(Carlsbad, CA, USA). PBS and FBS were purchased from Lonza Group Ltd (Basel, 
Switzerland). Recombinant human GM-CSF, soluble human vascular cell adhesion 
molecule 1 (VCAM-1) and soluble human tumour necrosis factor α (TNF-α) were 
purchased from R&D Systems (Minneapolis, MN, USA). IL-5, anti-CXCR4 antibody, 
ionomycin from streptomyces conglobatus, anti-β-actin antibody, lectin from triticus vulgaris 
(wheat germ agglutinin, WGA), calcimycin A-23187, fibronectin from human plasma, 
ovalbumin (OVA) grade V crystallized and lyophilized fraction, aluminium hydroxide 
[Al(OH)3] gel, o-phenylendiamine, hydrogen peroxide (30%), triton-X-100, phorbol 12-
myristate 13-acetate (PMA) and peroxidase acidic isoenzyme from horseradish, 
polyachrylamide/bispolyachrilamide, TEMED, ammonium persulphate, and sodium 
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dodecylsuphate (SDS) were obtained from Sigma-Aldrich (Steinheim, Germany). NE-PER™ 
extraction reagent, BCA protein assay, T-PER™ tissue protein extraction reagent were 
purchased from Pierce (Rockford, IL, USA). BIO1211 [(4-((2-
methylphenyl)aminocarbonyl)acetyl-fibronectin CS-1 fragment (1980-1983))] was purchased 
from Bachem (Weil am Rhein, Germany). Monoclonal antibody mouse anti-human and 
rabbit anti-human α4 subunit of human VLA-4 integrin were purchased from Calbiochem 
(Nottingham, UK) and Santa Cruz Biotechnologies Inc (Santa Cruz, CA, USA). Secondary 
antibody horseradish peroxidase-conjugated (goat anti-mouse and goat anti-rabbit), 
CruzMarker (sc-2035) and anti-annexin-1 antibody were purchased from Santa Cruz 
Biotechnologies Inc (Santa Cruz, CA, USA). Scintillation proximity assay (SPA) beads and 
Na[125I] were obtained from Amersham Biosciences (GE Healthcare Europe) (Milan, Italy). 
Annexin-V-Fluos was obtained from Roche Applied Science (Monza, Italy). Protran™ 
nitrocellulose membrane was bought from Whatman® (Kent, UK). Anti-caspase-3 antibody 
was purchased from CellSignalling (Danvers, MA, USA). All plastic disposables were from 
Sarstedt (Verona, Italy) except form 96-well black clear bottom plates that were purchased 
from Corning Costar (Celbio, Euroclone) (Pero, Italy). 
 
Cell lines 
 EoL-1, Jurkat clone E6.1, HEK293 cell lines and human umbilical vein endothelial 
cells (HUVEC)  were obtained from Health Protection Agency Culture Collections 
(HPACC) (Salisbury, UK). HMC-1 cell line was a kind gift of Dr Pio Conti of the 
University of Chieti (Chieti, Italy). Human eosinophils, isolated from whole blood by 
density centrifugation followed by negative selection using immunomagnetic anti-CD16 
beads (purity and viability were greater than 95%), were purchased from 3H Biomedical AB 
(Uppsala, Sweden) and cultured in complete cell culture medium (3H Biomedical AB) 
supplemented with IL-5 (1 ng/mL; R&D Systems) and granulocyte macrophages colony 
stimulating factor (GM-CSF) (10 ng/mL; R&D Systems) for 24 hours before being used in 
adhesion assays. The human T cell line Jurkat clone E6.1 was cultured in RPMI-1640 
medium supplemented with L-glutamine, 10% heat-inactivated foetal bovine serum, 
antibiotic-antimycotic solution in a humidified incubator at 37 °C with 5% CO2. EoL-1 
(human eosinophilic leukemia) (Saito et al., 1985; Mayumi, 1992) and HMC-1 cell lines were 
maintained in RPMI-1640 medium with L-glutamine supplemented with 10% (v/v) FBS at 
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37 °C in a humidified atmosphere with 5% CO2. All the lines were routinely grown in 75 
cm2  tissue culture flasks. Where indicated, 24 hours before the experiment 25 ng/mL PMA 
was added to the medium to induce eosinophil granulation and differentiation (Ohtsu et al., 
1993; Zimmermann et al., 2000). Before steroidal treatment, EoL-1 cells were stabilized in 
serum-depleted medium (0.1% FBS) for 24 hours and then treated with dexamethasone (1 
µM), levocabastine (1 mM), olopatadine (100 µM), BOL-303242-X (100 nM, 1 µM, or 10 
µM), BOL-303242 (100 nM, 1 µM, or 10 µM) in a time-lapse between 24 and 96 hours to 
evaluate apoptosis or glucocorticoid-induced transactivation. Recombinant human GM-
CSF (1 ng/mL) or IL-5 (1 ng/mL) were added at the beginning of incubation, where 
indicated for cytokine-mediated eosinophil survival assay. HEK293 cells stably transfected 
with the plasmid (pcDNA3.1, Invitrogen) containing the coding sequence for the α4 
integrin subunit gene (Fig. 6.1) were cultured in minimum essential medium (MEM) with L-
glutamine, supplemented with 10% (v/v) FBS and non-essential amino acids, and kept at 37 
°C in a humidified atmosphere (5% CO2). Cells were transfected using a modified calcium 
phosphate procedure (Invitrogen) and selected with 400 µg/mL of G418 for at least three 
weeks. HUVEC were grown in endothelial cell growth medium (HPACC) and used within 
six passages in all experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 
Descriptive image of the subcloning of the α4 integrin subunit gene in naïve HEK293 cells. After 
transfection, cells were selected and expanded in the presence of G418 (400 µg/mL). 
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Animals 
 Male Dunkin-Hartley guinea pigs (250-300 g) were purchased from Charles-River 
Laboratories (Calco, Italy). Animals were handled in accordance with the Guiding Principles 
in the Care and Use of Animals Committee of the University of Bologna. Further, all 
experiments conformed to the ARVO (Association for Research in Vision and 
Ophthalmology) resolution on the use of animals in research. 
 
6.2 Methods 
 
Cell dhesion assay 
 Adhesion of cultured cells was performed as described by Marcinkiewicz et al. 
(1996) (Fig.6.2). Briefly, 96-well plates were coated by passive adsorption overnight at 4 °C 
with 5 µg/mL of VCAM-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 6.2 
Schematic picture of a typical cell-adhesion assay. HUVEC cells (or human recombinant VCAM-1 or 
ICAM-1 can be adsorbed to the bottom of the well) are seeded and then treated for 12-24 hours with the 
pro-inflammatory cytokine TNF-α in order to make them express the adhesion molecules commonly 
expressed by the vascular endothelium during the inflammatory response. The day of the experiment, 
CMFDA-labelled leukocytes and test compounds are pre-incubated in microtubes to equilibrium, and 
then aliquoted in the wells with the activated-HUVEC monolayer. After washings with PBS to remove 
the non-specifically bound and unbound cells, the adherent leukocytes can be lysed to free the 
fluorescence that can be finally read. 
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A saturation curve for the ligand was achieved to establish the best signal-to-noise ratio (fig. 
6.3). The non-specific hydrophobic binding sites were blocked by incubation with a 1% 
BSA/HBSS (w/v) solution for 30 minutes at 37 °C. On the day of the assay, the cells were 
counted and stained with 12.5 µM CMFDA for 30 minutes at 37 °C. After three rinses with 
HBSS/BSA in order to remove the excess of the dye, aliquots of 50000 cells were divided 
in a number of microcentrifuge tubes correspondent to the number of treatments. 
 
 
 
 
 
 
 
 
 
 
 
For inhibition experiments, cells were mixed with the drug and pre-incubated at 37 °C for 
30 minutes to reach the equilibrium before being plated. After 30 minutes incubation at 37 
°C in the coated wells, the non-specifically bound cells were washed away with the same 
HBSS/BSA solution. Bound cells were lysed by addition of a solution of PBS and Triton-
X-100 0.5% (v/v) solution for 30 minutes at 4 °C. Fluorescence was measured by Victor2 
Wallac-1420 Multilabel Counter (Perkin Elmer) (Waltham, MA, USA) at excitation 485 
nm/emission 535 nm, and the number of adherent cells was determined by interpolation 
with the standard curve. The efficacy of putative antagonists is determined by the 
decrement of adherent cells as compared to the control. Each experiment was performed in 
quadruplicate and the presented data represent the mean ± SEM of at least three 
independent assays. 
 Another version of the assay was performed with HUVEC cells, placed at the 
bottom of the wells, instead of the immobilized VCAM-1 ligand. 20000 HUVEC cells/well 
were grown to confluence in a 96-well plate and exposed for 12 hours with TNF-α which is 
a pro-inflammatory cytokine that induces the expression adhesion molecules typical of the 
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Figure 6.3 
Saturation curve of EoL-1 adhesion to a 96-well plate coated with increasing concentration of VCAM-1, 
ranging from 0.5 µg/mL to 10 µg/mL. On the left the bar chart is shown, whereas the saturating 
hyperbola obtained by non-linear regression is displayed on the right. Each experiment was performed 
with eight replicates per point. The mean of three experiments was charted. 
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inflammatory process such as VCAM-1 and ICAM-1. Then, CMFDA-labelled EoL-1 cells 
(100000 cells/well) for 30 minutes at 37 °C in 5% CO2 atmosphere. Integrin antagonists or 
anti-α4 integrin subunit antibodies were administered to EoL-1 cells before their addition to 
HUVEC. After two hours incubation non-adhering EoL-1 cells were removed by gentle 
aspiration and wash with PBS. Cells were then lysed, and the signal was read as described 
above. 
 
Flow cytometry analysis 
FACS analysis were performed to characterize the specificity of action of the drugs 
to the integrin receptors. Jurkat clone E6.1 or EoL-1 cells (106 cells/sample) were incubated 
with a range of concentrations of the purported antagonist at 37 °C for 30 min in 1% 
BSA/HBSS. The excess of unbound drug was washed away and, then, all samples (except 
the negative controls) were incubated with a saturating concentration of the primary 
antibody anti-α4 integrin subunit at 4 °C for 30 min. After two washes, cells were incubated 
with FITC-conjugated secondary antibody for 45 minutes in the dark. Finally, the excess of 
the unbound antibody was removed and the cells were resuspended in HBSS/BSA buffer, 
ready to be analysed in a EPICS® ELITE (Beckman Coulter®) flow cytometer 
(Marcinkiewicz C. et al.; 1996). 
 Moreover, FACS analysis were performed to measure the induction of surface 
expression of annexin I and the CXCR4 as a measure for transactivation. Eol-1 cells were 
double-stained with a red dye-conjugated secondary antibody to trace the variations in the 
expression of CXCR4 and annexin I, and a green dye-conjugated annexin V to exclude 
apoptotic cells from the analysis. The cells were counted and transferred to a 24-well plate 
(106 cells/well) where they were serum-starved (0.1% FBS) for 24 h. The cells were then 
exposed to dexamethasone, BOL-303242, levocabastine, olopatadine, and their vehicles, 
alone or in combination, for 24 or 72 h at 37 °C and 5% CO2 atmosphere. At the end of the 
incubation time, the cells where harvested and each sample was divided into two tubes to 
perform a parallel test for annexin I and CXCR4 surface expression analysed by flow 
cytometry. After rinsing all samples with a HBSS solution with 1% BSA, the cells were 
incubated for 45 min on a shaker with anti-annexin I or anti-CXCR4 antibodies (1:200) on 
ice, with the exception of the negative control. The cells were, then, spun down and washed 
twice with the HBSS/BSA buffer before being exposed to the AlexaFluor® 568-conjugated 
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secondary antibody. The excess of unbound antibody was washed away, and all samples 
were incubated for 15 min in the presence of annexin-V-Fluos in a buffer and a dilution 
suggested by the manufacturer, as previously described. The cells were then rinsed and 
resuspended in HBSS/BSA buffer, ready to be analysed in a Biorad Bryte HS flow 
cytometry system (Biorad, UK). Electronic gates were set on annexin V negative cells and 
CXCR4 or annexin I positive cells. 
 
Determination of eosinophil apoptosis 
In order to assess glucocorticoid induced apoptosis and cytokine-induced eosinophil 
survival, EoL-1 cells were double-stained with annexin V-Fluos and propidium iodide. 
Annexin V-FLUOS was used according to manufacturer’s instructions. Briefly, the cells 
were washed in PBS and suspended in Annexin V-Fluos labeling solution (10 mM 
Hepes/NaOH, pH 7.4, 140 mM NaCl, 5 mM CaCl2) added of propidium iodide (PI) (1 
µg/mL). The cell suspension was incubated at room temperature for 10 min and analysed in 
a Biorad Bryte HS flow cytometry system (Biorad, UK). EoL-1 cells were gated on the basis 
of their forward and side light scatter with any cell debris excluded from analysis. Apoptotic 
cells were defined as Annexin+/PI- cells. A two-way dot plot was obtained to assess the 
percentage of apoptotic cells. Annexin-/PI- cells were used as control, whereas 
annexin+/PI+ were considered necrotic. 
 
Western blotting analysis 
Eol-1 cells were pelleted and resuspended in 100 µL of CER I buffer (NE-PERTM 
Extraction reagent; Pierce). After 10 min incubation on ice, 5.5 µL of CER II buffer was 
added and the suspension was resuspended by vortex, incubated on ice for 1 min and then 
resuspended. The cytoplasmic fraction was separated by centrifugation at 16000 g for 5 
min. The protein content was quantified using a BCA protein assay (Pierce). Proteins of the 
cytoplasmic extract (50 µg) were denatured at 95 °C for 3 min before being loaded and 
separated by 15 % sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
We used a MagicMarkTM XP Western Standard as molecular weight standard. Proteins were 
then transferred to ProtranTM nitrocellulose membranes which were blocked with 5% non-
fat milk in TBS (10 mM Tris-HCl, pH 8, containing 150 mM NaCl) plus 0.1% Tween 20 for 
1 h at room temperature (25°C). The blots were then probed overnight at 4°C in TBS 
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containing 0.1% Tween 20, 5% non-fat milk and antibodies with a dilution of 1 : 1000 for 
caspase-3 monoclonal antibody, 1 : 5000 for β-actin antibody (used as loading control for 
cytoplasmic lysates). The membranes were incubated with peroxidase-conjugated secondary 
antibodies at a dilution of 1 : 2000. Blots were finally developed with SuperSignal West Pico 
chemiluminescent substrate according to the manufacturer’s protocol (Pierce). 
Chemiluminescence was acquired using a luminescent image analyzer LAS-3000 (Fuji-Film). 
Excised conjunctivas of immunized and non-immunized animals were homogenized 
in T-PER® reagent (Pierce) and protein were extracted following the manufacturer’s 
protocol.  The protein content was quantified using a BCA protein assay (Pierce). Proteins 
of the cytoplasmic extract (150 µg) were denatured at 99 °C for 4 min before being loaded 
and separated by 7.5 % sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). We used a Cruz marker (sc-2035; Santa Cruz Biotechnology, Inc.) as molecular 
weight standard. Proteins were then transferred to ProtranTM nitrocellulose membranes 
(Schleicher & Schuell Italia, Legnano, Italy) which were blocked with 5% non-fat milk in 
TBS (10 mM Tris-HCl, pH 8, containing 150 mM NaCl) plus 0.1% Tween 20 for 1.5 h at 
room temperature (25°C). The blots were then probed for 1.5 h at room temperature in 
TBS containing 0.1% Tween 20, 5% non-fat milk and antibodies with a dilution of 1 : 800 
for anti-VLA-4 integrin monoclonal antibody, 1 : 5000 for anti-β-actin antibody (used as 
loading control for cytoplasmic lysates). The membranes were incubated with peroxidase-
conjugated secondary antibodies at a dilution of 1 : 10000. Blots were, finally, developed 
with SuperSignal West Pico chemiluminescent substrate according to the manufacturer’s 
protocol (Pierce). Chemiluminescence was acquired using a luminescent image analyzer 
LAS-3000 (Fujifilm). 
 
Scintillation Proximity-Binding Assay (SPA) 
Fibronectin from human plasma (FN) was labeled with Na[125I] as described by the 
manufacturer. The experiments were carried out with a ratio of 1 mg/50 µL anti-rabbit 
coated beads, 200 µg rabbit anti-VLA-4 antibody and 100 µg of VLA-4 receptor, extracted 
from HEK-293 cells stably expressing VLA-4, and purified by affinity chromatography 
following the procedure outlined by  Solorzano et al. (2006) (fig. 6.4). The binding buffer 
was composed of Tris HCl 25 mM pH 7,5; CaCl2 1 mM; MgCl2 1 mM; MnCl2 1 mM; BSA 
2% (w/v); PMSF 1 mM; aprotinin 1 µg/mL; leupeptin 50 µM. Firstly, we allowed the slow 
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interaction between the VLA-4 proteins and the anti-VLA-4 antibodies, incubating them 
together for 1 h at 4 °C; then the anti-rabbit antibody binding beads were added and the 
solution with the three components were incubated for 2 h at 4 °C in the dark. Beyond this 
point all incubations were conducted at room temperature. [125I]FN was added to the vials 
(at least 105 cpm/tube) that were then incubated overnight on a shaker in the dark. Non-
specific binding was determined in the presence of 100 µM Bio1211. The samples were 
read with a LS 6500 multipurpose scintillation counter (Beckham Coulter, Fullerton, CA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cytokine Assay 
Half-million cells were aliquoted per point in a 24 well plate; each experiment was 
performed in triplicate and carried out in parallel with eosinophils differentiated and non 
differentiated with PMA (25 ng/mL, 24 h). Cells were suspended in low serum medium 
(RPMI-1640, 0,1% (v/v) FBS). TNF-α was used to induce cytokine secretion as previously 
described by Steube et al. (2000), and the net release was obtained by comparison to the 
basal (non-TNF-α treated). In the first experiment we evaluated the concentration and time 
 
Figure 6.4 
Scheme of the scintillation proximit assay (SPA) employed. α4 transfected HEK293 cells represented our 
source of α4β1 integrin which was possible to purify by affinity chromatography on a WGA column (see 
materials and methods) 
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relation between TNF-α stimulation and cytokine release. Therefore, 5, 10, and 25 ng/mL 
of TNF-α was administered to the cells at 0, ½, 1, 2, 3, 6, 12 and 24 h (data not shown). An 
aliquot of 150 µL of supernate was collected for cytokines’ analysis. Then, we considered 
whether levocabastine, an anti-allergic drug that demonstrated to be active not only as an H1 
receptor antagonist, could affect the release of these cell mediators. Differentiated and non-
differentiated EoL-1 cells were exposed from 0,1 to 2,3 mM levocabastine, and aliquots of 
the supernates were collected after 12 and 24 h. The content of cytokines at time zero was 
estimated by treating the cells with 400 nM calcimycin (A-23187), which is a cytolytic agent 
that frees all the mediators from the cytoplasmic compartment. In addition, for each 
experiment we tested the effect of the vehicle, that was added to the wells in a 
concentration equal to the maximum amount used for drug dilution. Samples (supernates 
12 and 24 h) in triplicate were shipped to Bausch & Lomb Optical Centre (Rochester, NY, 
USA) and cytokine levels measured using Luminex technology. Half-million cells were 
aliquoted per point in a 24 well plate; each experiment was performed in triplicate. 
 
Animal experiments 
The methods described by Khosravi E. et al. (1995) and 
Ebihara N. et al (1999) were applied. 20 male Dunkin-Hartley 
guinea pigs were divided into 3 groups of five animals: a 
control group (no immunization), a group immunized with 
ovalbumin i.p. (positive control) and a group pre-treated with 
levocabastine eyedrops. At day zero, 2 mL of a saline solution with 100 g/mL ovalbumin 
(OVA) and 20 mg/mL Al(OH)3 as adjuvant, were injected intra-peritoneally to each animal 
except for the negative control. Three weeks later all animals were challenged with 30 L 
per eye of saline solution containing 100 mg/mL ovalbumin.  Levocabastine was 
administered to the animals 60 and 30 minutes prior to the ovalbumin challenge. Pictures of 
both eyes were taken for the clinical score at 1, 2, 4, 6, and 24 hours after topical ovalbumin 
administration. The animals were sacrificed and the conjunctivas collected for the 
subsequent experiments. 
32 male Dunkin-Hartley guinea pigs were divided into 8 groups of 4 animals: 
control group (no immunization), group immunized with ovalbumin i.p. (positive control), 
dexamethasone treated animals, BOL-303242-X group, BOL-303242-X/levocabastine 
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group, BOL-303242-X/olopatadine group, dexamethasone/levocabastine group, 
dexamethasone/olopatadine group. At day zero, 2 mL of a saline solution containing 100 
µg/mL ovalbumin (OVA) and 20 mg/mL Al(OH)3 as adjuvant, were injected intra-
peritoneally (i.p.) to each of the animals, except for the negative control. Three weeks later 
all of the animals were challenged with 30 µL per eye of saline solution, containing 100 
mg/mL ovalbumin. All the drugs were administered to the animals 60 and 30 minutes prior 
to the ovalbumin challenge. Pictures of both eyes were taken for the clinical score at 1, 2, 4, 
and 6 hours after topical ovalbumin administration. The animals were sacrificed and the 
conjunctivas collected for the subsequent experiments. 
 
Eosinophil peroxidase assay 
Eosinophil peroxidase assay was performed as previously described by Izushi K. et 
al.; 2002. Briefly, 24 h after conjunctivitis induction by antigen application, the guinea pigs 
were sacrificed by i.p. injection of Tanax and the upper and lower parts of the conjunctiva 
were excised, cleaned, weighed and washed twice with ice-cold PBS. The tissues were 
homogenized with 50 mM Tris-HCl buffer (pH 8.0) using a Potter-Elvehjem glass/Teflon 
homogeniser (Wheaton, Millville, NJ, USA) on ice. The homogenates were placed in ice 
bath for 1 hour after addition of 350 µl of 50 mM Tris-HCl buffer and 150 µl of 0.1 % 
Triton X-100. Then, the substrate solution (400 µl of 50 mM Tris-HCl buffer containing 
0.1 % Triton X-100, 1 mM o-phenylenediamine, and 0.5 mM hydrogen peroxide) was 
added to 200 µl of the sample and incubated at 37 °C for 10 minutes. The reaction was 
stopped with 200 µl of 4 M H2SO4. Absorbance at 490 nm was measured using a 
spectrophotometer (JASCO V-530, Jasco, UK). A standard curve was prepared using 
different concentrations of peroxidase diluted in 50 mM Tris-HCl buffer (pH 6.0) 
containing 1 mM o-phenylenediamine, and 0.5 mM hydrogen peroxide. Eosinophil 
peroxidase (EPO) activity was measured according to the method of Strath et al. (1985) 
which is based on the oxidation of o-phenylenediamine by EPO in the presence of 
hydrogen peroxide. One unit corresponds to one mmol of hydrogen peroxide decomposed 
in 10 minutes. Data are report as eosinophil peroxidase level (mU of enzyme/mg tissue). 
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Histological examination of eosinophil infiltration in conjunctival tissues 
Twenty-four hours after antigen challenge, guinea pigs were sacrificed and  the 
upper and lower parts of the eye conjunctiva were carefully excised and fixed in 10 % 
buffered paraformaldehyde solution. Samples were manipulated as follows: paraffin-
embedded sections, 6 µm thick, carried out perpendicularly to the conjunctiva palpebral. 
Serial sections were stained with Hansel method modified to show the number of 
infiltrating eosinophils, which appear red. (Sheldon, Lovell and Mathews "A Manual of 
Clinical Allergy" published by W B Saunders Company, 1967). 
Eosinophil peroxidase assay was performed as previously described by Izushi K. et 
al.; 2002: 24 h after conjunctivitis induction by application of the antigen, the guinea pigs 
were sacrificed by i.p. injection of Tanax, and the upper and lower parts of the conjunctiva 
were excised, cleaned, weighed and washed twice with ice-cold PBS. The tissues were 
homogenized with 50 mM Tris-HCl buffer (pH 8.0) using a Potter-Elvehjem glass/Teflon 
homogeniser (Wheaton, Millville, NJ, USA) on ice. The homogenates were placed in ice 
bath for 1 hour, after addition of 350 µL of 50 mM Tris-HCl buffer and 150 µL of 0.1 % 
Triton X-100. Then, the substrate solution (400 µL of 50 mM Tris-HCl buffer containing 
0.1 % Triton X-100, 1 mM o-phenylenediamine, and 0.5 mM hydrogen peroxide) was added 
to 200 µL of the sample and incubated at 37 °C for 10 minutes. The reaction was stopped 
with 200 µL of 4 M H2SO4. Absorbance was measured, using a spectrophotometer (JASCO 
V-530, Jasco, UK), at 490 nm. 
 
Data analysis 
To quantify the intensity of the bands image AIDA (Advanced Image Data 
Analyzer) software (Raytest) was used. All data are presented as mean ± SEM for the 
indicated number of experiments. Statistical significance was determined by Newman-Keuls 
test after ANOVA using GraphPad Prism (version 3.0; GraphPad Software Inc., San Diego, 
CA, USA). P-values < 0.05 were considered to be significant. 
For the clinical score, each group was formed of five animals and the score was performed 
on changes at two hours after ovalbumin challenge for the main eye symptom sum score of 
itching, swelling, redness, and lid eversion. An analysis of variance (ANOVA) was 
performed using treatment as factor. The Newman-Keuls post hoc test was used to 
compare all pairs of groups. 
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 To quantify the intensity of the bands an image AIDA (Advanced Image Data 
Analyzer) software (Raytest) was used. All data are presented as mean ± SEM, for the 
indicated number of experiments. Statistical significance was determined by Friedman test, 
after ANOVA, using GraphPad Prism (version 3.0; GraphPad Software, Inc., San Diego, 
CA, USA). P-values < 0.05 were considered to be significant. 
For the clinical score, each group was formed of 4 animals and the score was performed on 
the changes that occurred at 1, 2, 4 and 6 hours after receipt of ovalbumin challenge. For 
the main eye symptom, a sum score of itching, swelling, redness, and lid eversion was used. 
An analysis of variance (ANOVA) was performed using treatment as factor, and the 
Dunnet’s post hoc test was used to compare all pairs of groups. 
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CHAPTER 7 
RESULTS 
 
 
 
7.1 Scintillation proximity assay optimization 
 For the setting up of the scintillation proximity assay (SPA) was initially performed a 
saturation curve for the [125I]FN, labelled in our laboratory as described in detail in 
Appendix III. 
 Fibronectin from human plasma (FN) was labeled with Na[125I] as described by the 
manufacturer (Pierce; Rockwell, IL, USA). The experiments were carried out with a ratio of 
1 mg/50 µL anti-rabbit coated beads, 200 µg rabbit anti-VLA-4 antibody and 100 µg of 
VLA-4 receptor, extracted from HEK-293 cells stably expressing the VLA-4 integrin (see 
Appendix III for details), and purified by affinity chromatography (WGA column) 
following the procedure outlined by  Solorzano et al. (2006). To ascertain the presence of 
α4β1 integrin dimer, the fractions obtained were probed with both an anti- α4 and anti-β1 
antibodies in a western blot analysis (fig. 7.1). 
  
 
 
 
 
 
 
 
 
 
 
 Of the six collected fractions the presence of the α4 subunit was confirmed in all 
except the first (void elution volume) and the last. The fraction from II to V were then 
assayed for the presence of the β1 integrin subunit. Approximate molecular masses of the 
α4
β1
I II III IV V VI
≈ 150 kDa
≈ 110 kDa
II III IV V
 
Figure 7.1 
Western blot analysis on the fractions obtained by affinity chromatography purification of the α4β1 integrin 
extracted from HEK293 cells stably expressing this protein. The fraction I clearly represents the empty 
volume of the column, in which no protein is detected. The fractions from II to V demonstrate the 
presence of both of the subunits of the dimmer, whereas the lane number VI is empty again because the 
protein had been already completely eluted. 
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α4 and β1 integrin subunits were compared to molecular mass standard, demonstrating 
similarities to the ones described by Takada et al. (1989). 
 After assessing the presence of the whole dimer, the fractions II-V were employed 
in a saturation binding by scintillation proximity assay (fig. 7.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The specific binding of 125I-fibronectin to an SPA bead-associated VLA-4 integrin 
was time-dependent; the signal increased during the first 10 h then reached a plateau that 
remained constant for the remainder of the 24-h incubation time (data not shown). [125I]FN 
was capable to bind to the anti-rabbit bead – anti-VLA-4 Ab – VLA-4 integrin complex in 
concentration dependent and saturable manner. The non-specific binding was evaluated in 
the presence of 100 µM BIO1211; it was non-saturable and directly proportional to [125I]FN 
concentration. This technique had been extremely valuable for the possibility to set up the 
entire binding system in the reaction tube without the necessity to wash away the unbound. 
In fact, SPA is based on the principle of proximity: only if the radioligand is sufficiently 
close and for long enough to the microbead, its energy activate the scintillant leading to 
light emission. Because the emitted β particles or electrons can only travel short distances in 
the bulk solution, the microbead preferentially captures electrons from the bound 
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Figure 7.2 
Saturation SPA binding of [125I]FN to the purified α4β1 integrin extracted and purified from HEK293 
stably ex pressing this protein. The non-specific binding was determined in the presence of 100 µM 
BIO1211. (■) Non-specific binding; (▲) specific binding. Mean and ± SEM of three experiments are 
shown. As displayed the binding was concentration dependent and saturable. At the bottom right there is 
the Scatchard plot that allowed the calculation of the Kd ( and Bmax. 
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radiolabelled ligands. Finally, the amount of emitted light from the scintillant in the bead is 
directly proportional to the amount of radiolabelled ligand. Therefore, we might consider 
this novel method as “one pot” with no need of filtering passages and whose signal can be 
recorded either with a scintillation counter used as a luminometer or as a luminometer itself. 
Also the format can be reduced to multi-well plates and because of its predisposition to 
automatization SPA is extremely suitable for high-throughput screening. These assays give 
both qualitative and quantitative information. An adequate amount of beads is required to 
saturate the protein in order to achieve a maximal binding signal. However, excessive beads 
will lead to undesired exposure of bead surface to non-specific ligand binding. Therefore, 
the amount of bead applied should be kept to a minimum where protein saturation is still 
achievable. On the other hand, stable signal is highly dependent on protein stability and its 
coating ability on the beads. In comparison with conventional filter binding techniques, the 
SPA method omits steps such as pre-coating, pre-incubation, separation and washing, thus 
simplifying the assay protocol, mitigating labour intensity and reducing systemic errors.  
 
7.2 SPA evaluation of levocabastine affinity to α4β1 integrin 
 After SPA optimization and understanding of the binding characteristics through a 
saturation binding assay, the next step has been to try the functionality of this technique by 
the means of a competition binding with levocabastine. Levocabastine is a known 
antagonists of the H1 histamine receptor, indicated for the treatment of allergic 
conjunctivitis. Buscaglia et al. (1996) demonstrated that this compound is able to interfere 
with inflammatory adhesion molecules such as ICAM-1, widening the pharmacological 
profile of what was considered a simpli anti-histaminic. Therefore, we tried to appreciate 
direct competition of levocabastine to the binding to VLA-4 (fig. 7.3). It was learned from 
Gobel et al. (1999) that assay sensitivity can be improved by choosing a radiolabeled ligand 
concentration at or below its Kd to permit effective competition by an unlabelled ligand. In 
this study we selected a relatively higher concentration of [125I]FN (able to produce 100000 
cpm) in order to keep a high level assay sensitivity. Levocabastine caused concentration 
dependent inhibition of [125I]FN binding to the SPA bead-associated α4β1 integrin with an 
IC50 of 406.2 µM. 
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7.3 Levocabastine inhibition of EoL-1 and Jurkat E6.1 cell adhesion in vitro 
 Levocabastine is a potent anti-histaminic commonly used in ophthalmology for the 
treatment of allergic conjunctivitis. After the promising results obtained by SPA that 
confirmed the interaction of levocabastine with α4β1 integrin, by the use of adhesion assays 
both on TNF-α-activated HUVEC cells and the adsorbed ligand VCAM-1, it was possible 
to perform a functional assay on EoL-1 cells. The results obtained were compared to the 
actions of chlorpheniramine, another anti-histaminic (fig. 7.4). 
 EoL-1 cells express the VLA-4 integrin (Higashimoto et al., 1996), and their 
exposure to increasing concentrations of levocabastine proved a dose-dependent decrease 
of adhesion to the immobilized ligand VCAM-1 (5 µg/mL). From the sigmoidal curve 
drew, it was possible to calculate an IC50 of 456.9 µM (fig. 7.4, panel A). Chlorpheniramine 
(fig. 7.4, panel B), instead, did not demonstrate a similar behaviour: the curve obtained is 
not convergent and it is, thus, not possible to calculate an IC50. 
 Another line of leukocytes, Jurkat E6.1 cells, was assayed in the same way revealing 
an analogous behaviour (fig. 7.5, panel A and B). 
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Figure 7.3 
Competition binding of [125I]FN and levocabastine to the VLA-4 integrin. Binding of [125I]-FN to HEK-
293 cell lysates was measured in the presence of increasing concentrations of levocabastine (0.003 – 10 
mM). Non-specific binding was determined in the presence of 100 µM unlabeled Bio1211. Levocabastine 
displaced [125I]FN binding to VLA-4 in a concentration dependent way (IC50). The graph shows the 
mean obtained by three independent experiments. ± SEM is represented. 
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 Moreover, Kwon et al. (2007) reported that HUVEC do not express VCAM-1 in 
the resting state, but the expression of this adhesion molecule is increased after exposure to 
TNF-α. Therefore, we investigated whether levocabastine influenced EoL-1 adhesion to 
TNF-α-stimulated HUVEC. As shown in figure 7.5, the number of EoL-1 cells adherent to 
HUVEC significantly increased after 12 hours exposure to TNF-α (25 ng/mL). 
Levocabastine (100 and 400 µM) reduced this increment in a concentration-dependent 
manner, as did the anti-α4 integrin subunit antibody. 
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Figure 7.4 
Dose-response curves of levocabastine and chlorpheniramine on EoL-1 and Jurkat E6.1 cell adhesion 
to VCAM-1 (5 µg/mL). Panel A: Levocabastine shows a concentration-dependent inhibition of EoL-1 
cell adhesion to the immobilized ligand VCAM-1. The measured IC50 is 456.9 µM. Panel B: The anti-
histaminic chlorpheniramine shows no activity on the adhesion of EoL-1 to VCAM-1. Panel C: Non-
linear regression of the data of Jurkat E6.1 cell inhibition of adhesion mediated by increasing 
concentrations of levocabastine. (IC50 = 395.6 µM). Panel D: Chlorpheniramine shows not to be able 
to block Jurkat E6.1 cells to VCAM-1. Also in this case, the curve drew is not convergent. The 
fluorescence intensity of untreated cells adherent to VCAM-1 (positive control) was considered as 
100%; non-specific adhesion was measured in control wells non-VCAM-1-coated and subsequently 
subtracted. The curve obtained is not convergent and it is impossible to calculate an IC50. The data 
shown are the mean ± SEM of three independent experiments. 
C 
-3 -2 -1 0 1 2
80
90
100
Log[Chlorpheniramine] (mM)
%
 
Ad
he
re
n
t C
el
ls
v
s
CT
R
L
 
D 
 148 
We therefore conclude that levocabastine, but not chlorpheniramine, includes the 
blockade of VCAM-1-mediated leukocyte adhesion to endothelial cells among its 
mechanisms of action. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Furthermore, we ascertained that the adhesion of human eosinophils (2 x 104 cells 
were added to each well) to VCAM-1 ranged from 0.9 to 2.2 x 104 cells. The adhesion of 
EoL-1, Jurkat E6.1  and human eosinophil cells to VCAM-1 (10 µg/mL) was inhibited by 
more than 92% after pre-treatment with 5 µg/mL anti-α4 integrin subunit antibody and 
adhesion of Jurkat E6.1 and EoL-1 cells to fibronectin (10 µg/mL) was inhibited by 92%  
in the presence of this antibody. Neither drug up to 2 mM influenced cell viability, 
evaluated by trypan blue exclusion (data not shown). As shown in Table 7.0, levocabastine 
inhibited α4β1 integrin-dependent adhesion of Jurkat E6.1 cells to VCAM-1 with an IC50 of 
395.6 µM, and the adhesion of EoL-1 cells with an IC50 of 403.6 µM. Moreover, 
levocabastine inhibited adhesion of human eosinophils to VCAM-1 coated wells (IC50 = 
443.7 µM). Levocabastine displayed a similar activity to inhibit α4β1 integrin-dependent 
adhesion of Jurkat E6.1 and EoL-1 cells to fibronectin and also prevented αLβ2 integrin-
 
Figure 7.5 
Levocastine and an anti-α4 integrin subunit antibody reduce TNF-α-induced EoL-1 binding to HUVEC. 
HUVEC were treated for 12 hours with TNF-α (25 ng/mL) or with the vehicle alone (CTRL). EoL-1 cells 
pre-treated for 1 hour to the vehicle, levocabastine (100 or 400 µM) or an anti-α4 integrin subunit antibody 
(5 µg/mL) and incorporated with CMFDA were co-cultured with HUVEC for 30 minutes. In control cells, 
levocabastine or anti-α4 antibody did not influence EoL-1 cell adhesion. On the contrary, HUVEC pre-
treatment with TNF-α caused EoL-1 firm adhesion. The data shown represent the mean ±SEM of three 
independent experiments performed in quadruplicate each. #p<0.001 vs CTRL; **p<0.01 vs vehicle/TNF-
α-stimulated HUVEC; *p<0.001 vs vehicle/TNF-α-stimulated HUVEC. 
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dependent adhesion of Jurkat E6.1 cells to ICAM-1 (IC50 = 33.3 µM). In contrast, 
chlorpheniramine, a potent blocker of H1 histamine receptors (Sharif et al., 1996), did not 
affect Jurkat E6.1 cell adhesion to VCAM-1, fibronectin and ICAM-1 (Table 7.0). 
 Finally, we demonstrated that in these experimental conditions, the small peptide 
BIO-1211 behaves as a potent α4β1 and αLβ2 integrin antagonist that inhibited Jurkat E6.1 
cell adhesion to VCAM-1, fibronectin and ICAM-1 coated wells (Table 7.0). 
 
Table 7.0 
Integrin-mediated Cell Adhesion IC50 (mM) 
Levocabastine      
  α4β1-mediated Cell Adhesion  
    Jurkat/VCAM-1 395,6 
    EoL-1/VCAM-1 403,9 
    Human Eosinophils/VCAM-1 443,7 
    Jurkat/FN 350,7 
    EoL-1/FN 360,6 
         
  αΛβ2-mediated Cell Adhesion  
    Jurkat/ICAM-1 33,3 
         
BIO-1211      
  α4β1-mediated Cell Adhesion  
    Jurkat/VCAM-1 8,6 x 10-3 
    EoL-1/VCAM-1 7,2 x 10-3 
    Jurkat/FN 7,5 x 10-3 
    EoL-1/FN 6,6 x 10-3 
         
  αLβ2-mediated Cell Adhesion  
    Jurkat/ICAM-1 8,4 x 10-5 
         
Clorpheniramine      
  α4β1-mediated Cell Adhesion  
    Jurkat/VCAM-1 not active 
    Jurkat/FN not active 
         
  αLβ2-mediated Cell Adhesion  
    Jurkat/ICAM-1 not active 
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7.4 Flow cytometric analysis of levocabastine-VLA-4 interaction 
 To prove the specificity of action of levocabastine on the VLA-4 integrin receptor, 
flow cytometry experiments were carried out on Jurkat E6.1 cells. Cells were pre-incubated 
with several concentrations of levocabastine and, then, exposed to an anti-VLA-4 primary 
antibody to verify the ability of the drug to compete with it to the binding to VLA-4.  After 
a series of washings to eliminate the excess of unbound primary antibody, a fluorescein 
isothyocyanate-conjugated secondary antibody was added. As shown in fig. 7.6, 
levocabastine is able to shift the fluorescence peak to lower values depending on the 
increase of levocabastine concentration. In each image is reported the negative control, 
determined in the presence of the only secondary antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.5 Effect of levocabastine on EoL-1 cytokine release 
 Cytokines are autocrine and paracrine mediators that support inflammation acting 
on the vascular epithelium and modulating the activity of resident and circulating white 
blood cells. We evaluated the ability of levocabastine to reduce cytokine release from 
differentiated and non-differentiated (immature phenotype) EoL-1 cells using TNF-α as a 
 
Figure 7.6 
Levocabastine competes with a specific anti-α4 integrin subunit in Jurkat E6.1 cells. Cells were incubated 
with an anti-human α4 integrin subunit antibody (5 µg/mL) in the absence (CTRL; panel A) or presence 
of 100 µM (panel C) or 400 µM (panel D) levocabastine; or in the presence of the vehicle alone (panel 
B). The negative control is shown as the white filled curve. 
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proinflammatory stimulus. Table 7.1 and Table 7.2 summarize the effects of levocabastine 
on 13 different cytokines at 12 and 24 h after TNF-α challenge; cells were or were not 
exposed to PMA, as indicated. 
 We received raw data from Bausch & Lomb Rochester, and we analyzed the data 
with statistical tools. EoL-1 cells were exposed to the vehicle in the same amount used to 
obtain the highest concentration of the drug.  
 
Table 7.1 
12h 
TNF−α  
(positive ctrl) 
vs  
Basal 
Vehicle  
vs  
Basal 
TNF-α  
vs  
Lev 0.1 mM 
TNF-α  
vs  
Lev 0.5 mM 
TNF-α  
vs  
Lev 1.0 mM 
TNF-α  
vs  
Lev 2.3 mM 
Fractalkine (PMA) ns p<0.05 ns ns ns ns 
Fractalkine (NO PMA) ns p<0.01 ns ns ns ns 
IL-1α (PMA) p<0.05 p<0.01 ns ns ns ns 
IL-1α (NO PMA) p<0.05 p<0.001 ns ns ns ns 
IL-1β (PMA) ns p<0.001 ns ns ns ns 
IL-1β (NO PMA) ns ns ns ns ns ns 
IL-1ra (PMA) p<0.001 p<0.001 p<0.01 p<0.001 p<0.001 ns 
IL-1ra (NO PMA) p<0.001 p<0.001 ns ns ns ns 
IL-5 (PMA) ns p<0,05 ns ns ns ns 
IL-5 (NO PMA) ns ns ns ns ns ns 
IL-7 (PMA) p<0.05 p<0.01 ns ns ns ns 
IL-7 (NO PMA) p<0.001 p<0.001 ns ns ns ns 
IL-8 (PMA) p<0.01 p<0.01 ns ns ns ns 
IL-8 (NO PMA) ns p<0.001 ns ns ns ns 
IP-10 (PMA) p<0.01 p<0.001 ns p<0.01 p<0.05 ns 
IP-10 (NO PMA) p<0.01 p<0.001 ns ns ns ns 
MCP-1 (PMA) p<0.01 p<0.01 ns ns ns ns 
MCP-1 (NO PMA) p<0.001 p<0.001 ns ns ns ns 
MIP-1α (PMA) ns p<0.01 concentration dependent increase of cytokine secretion p<0.001 
MIP-1α (NO PMA) p<0.05 p<0.001 concentration dependent increase of cytokine secretion p<0.01 
MIP-1β (PMA) p<0.001 p<0.001 ns ns ns ns 
MIP-1β (NO PMA) p<0.001 p<0.001 ns ns ns ns 
RANTES (PMA) p<0.001 p<0.001 ns ns ns ns 
RANTES (NO PMA) p<0.05 p<0.001 increase of cytokine secretion p<0.001 
VEGF (PMA) ns ns ns ns p<0.05 p<0.01 
VEGF (NO PMA) ns ns ns ns ns ns 
 
      
One-way analysis of variance (ANOVA) with Newman-Keuls post hoc test was used to compare all the pairs of treatments. Ns = 
non significant. All the values shown are intended as decrements, except where otherwise stated. 
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Table 7.2 
24h 
TNF-α 
(positive ctrl)  
vs  
Basal 
Vehicle  
vs  
Basal 
TNF-α  
vs  
Lev 0.1 mM 
TNF-α  
vs  
Lev 0.5 mM 
TNF-α  
vs  
Lev 1.0 mM 
TNF-α  
vs  
Lev 2.3 mM 
Fractalkine (PMA) ns ns ns ns ns p<0.01 
Fractalkine (NO PMA) ns p<0.001 ns ns ns ns 
IL-1α (PMA) ns p<0.01 ns ns ns ns 
IL-1α (NO PMA) p<0.01 p<0.001 ns ns ns ns 
IL-1β (PMA) p<0.01 p<0.05 p<0.05 ns p<0.05 ns 
IL-1β (NO PMA) ns ns ns ns ns ns 
IL-1ra (PMA) p<0.01 p<0.05 ns ns ns ns 
IL-1ra (NO PMA) p<0.001 p<0.01 ns ns ns ns 
IL-5 (PMA) ns ns ns ns ns ns 
IL-5 (NO PMA) ns ns ns ns ns ns 
IL-7 (PMA) ns ns ns ns ns ns 
IL-7 (NO PMA) p<0.05 p<0.01 ns ns ns ns 
IL-8 (PMA) ns ns ns ns ns ns 
IL-8 (NO PMA) p<0.01 p<0.01 ns ns ns ns 
IP-10 (PMA) p<0.01 p<0.001 ns ns ns ns 
IP-10 (NO PMA) p<0.001 p<0.001 p<0.05 p<0.05 ns ns 
MCP-1 (PMA) p<0.001 p<0.001 ns ns ns ns 
MCP-1 (NO PMA) p<0.001 p<0.001 ns ns ns ns 
MIP-1α (PMA) p<0.01 p<0.01 ns ns ns ns 
MIP-1α (NO PMA) p<0.01 p<0.001 Increase in cytokine release in a concentration dependent way p<0.001 
MIP-1β (PMA) p<0.001 ns ns ns ns ns 
MIP-1β (NO PMA) p<0.001 p<0.001 ns ns ns ns 
RANTES (PMA) ns ns ns ns ns ns 
RANTES (NO PMA) ns p<0.05 Increase in cytokine release in a concentration dependent way p<0.001 
VEGF (PMA) ns ns ns ns p<0.05 p<0.01 
VEGF (NO PMA) p<0.01 ns ns ns ns p<0.01 
       
One-way analysis of variance (ANOVA) with Newman-Keuls post hoc test was used to compare all the pairs of treatments. Ns = 
non significant. All the values shown are intended as decrements, except where otherwise stated. 
 
Interestingly, levocabastine was able to significantly reduce the release of the 
proinflammatory cytokine IL-1β, and of IP-10, that is known to promote rapid 
transendothelial migration of effector cells of the immune system (Manes et al., 2006). 
Furthermore, we report a very important perturbation from the vehicle, that seems to 
stimulate cytokine release by itself. The placebo group, in fact, produced levels of cytokines 
similar to the one measured using calcimycin, which induces the release of all the vescicular 
content of the cells by lysis. 
The placebo group, in fact, produced levels of cytokines similar to the one measured using 
calcimycin, which induces the release of all the vescicular content of the cells by lysis. Since 
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vehicle did not show toxicity, we speculate that this effect could be due to cyclodextrins 
which interfere with the plasma membrane and, specifically, with integrin functionality 
(Green, 1999; Pande, 2000; Berg, 2007). On this basis, we conclude that the effect of 
levocabastine 0.05% solution eye drops containing cyclodextrins without benzalkonium 
chloride on cytokine release should be further investigated in the absence of an interfering 
vehicle. An analysis of the data summarized in Table 7.1 and Table 7.2 indicates that 
levocabastine – at three different concentrations: 0.1, 0.5 and 1.0 mM – is capable to 
prevent the release of the following cytokines induced by TNF-α.: 
• IP-10 in cells exposed for 12 h without PMA or differentiated with it. This cytokine 
is involved in inflammatory processes (Inukai Y et al, 2007). 
• IL-1ra  in cells exposed for 12 and differentiated with PMA. This cytokine seems to 
act as an antagonist of the inflammatory cytokine IL-1 and this may be a 
controversial result. Although, it should be pointed out that the effect of 
levocabstine was observed only after 12 h  of exposure in cells treated with PMA. 
• IL-1β in cells exposed for 12 h in cells differentiated with PMA. This cytokine is 
involved in the inflammatory response (Hallsworth et al 1998; Wong et al 2007). 
Levocabastine was effective in the PMA-treated group of cells exposed for 12 h. 
• VEGF in cells exposed for 24 h in cells without PMA or differentiated with it. This 
cytokine is relevant for the inflammatory response in eosinophils (Solomon et al. 
2003; Puxeddu et al., 2005). Interestingly, the release of this cytokine induced by 
TNF-α was blocked by levocabastine; however, the vehicle alone (contrary to what 
observed for the other cytokines) did not influence the release of VEGF. 
 
An analysis of the data summarized in Table 7.3 and Table 7.4 indicates that levocabastine 
at the fixed concentration of  2 mM is capable to reduced the release of the following 
cytokines induced by three different concentrations of TNF-α (5, 10 and 20 ng): 
 
• IL-12 P40 in cells exposed for 12 h without PMA or differentiated with it. This 
cytokine is involved in the inflammatory response in eosinophils (Wen et al. 2006). 
• VEGF in cells exposed for 24 h without PMA or differentiated with it. 
• IL-12-P40 in cells exposed for 24 h without PMA. 
• VEGF in cells exposed for 24 h without PMA or differentiated with it. 
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• IL-8 in cells exposed for 24 h in cells differentiated with PMA. This cytokine is 
crucial for the inflammatory response in allergic diseases (Silvestri et al., 2006). 
 
An analysis of the data summarized in Table 6 indicates that levocabastine (2 mM) is 
effective in reducing the release of the following cytokines induced by TNF-α (10 ng) for 24 
h. This effect is not influenced by VCAM-1 or fibronectine: 
• IL-P-40 in cells without PMA or differentiated with it. 
• IL-1-ra in cells did not exposed to PMA. 
• IL-6 in cells did not exposed to PMA Another cytokine relevant for the allergic 
response (Ghazizadeh, 2007; Fritz et al. 2006). 
• IL-8 incells did not exposed to PMA. 
• VEGF in cells cultured without PMA or differentiated with it. 
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Table 7.3 
12 h 
TNF-
α 5ng 
vs 
Basal 
TNF-
α 10ng 
vs 
Basal 
TNF-
α 20ng 
vs 
Basal 
TNF-α 5ng + 
Levocabastine 
2mM 
vs 
TNF-α 
TNF-α 10ng + 
Levocabastine 
2mM 
vs 
TNF-α 
TNF-α 20ng 
+ 
Levocabastin
e 2mM 
vs 
TNF-α 
Fractalkine (PMA) ns ns ns ns ns ns 
Fractalkine (NO PMA) ns ns ns increase of cytokine secretion 
G-CSF (PMA) ns ns ns ns ns ns 
G-CSF (NO PMA) ns ns ns increase of cytokine secretion 
GM-CSF (PMA) P < 0.01 P < 0.01 P < 0.01 ns ns ns 
GM-CSF (NO PMA) ns ns ns ns ns ns 
IL-10 (PMA) ns ns ns ns ns ns 
IL-10 (NO PMA) ns ns ns ns ns ns 
IL-12p40 (PMA) P < 0.001 P < 0.001 ns P < 0.001 P < 0.001 P < 0.001 
IL-12p40 (NO PMA) P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 
IL-1α (PMA) P < 0.001 P < 0.001 P < 0.001 increase of cytokine secretion 
IL-1α (NO PMA) P < 0.001 P < 0.001 P < 0.001 increase of cytokine secretion 
IL-1β (PMA) ns ns ns ns ns ns 
IL-1β (NO PMA) ns ns ns ns ns ns 
IL-1ra (PMA) P < 0.001 P < 0.001 P < 0.001 increase of cytokine secretion 
IL-1ra (NO PMA) P < 0.001 P < 0.001 P < 0.001 increase of cytokine secretion 
IL-5 (PMA) ns ns ns ns ns ns 
IL-5 (NO PMA) ns ns ns ns ns ns 
IL-6 (PMA) ns ns ns ns ns ns 
IL-6 (NO PMA) ns ns ns ns ns ns 
IL-7 (PMA) P < 0.001 P < 0.001 P < 0.001 ns ns ns 
IL-7 (NO PMA) P < 0.001 P < 0.001 P < 0.001 ns ns ns 
IL-8 (PMA) P < 0.001 P < 0.001 P < 0.001 ns ns ns 
IL-8 (NO PMA) P < 0.001 P < 0.001 P < 0.001 ns ns ns 
IP-10 (PMA) P < 0.001 P < 0.001 P < 0.001 ns ns ns 
IP-10 (NO PMA) P < 0.001 P < 0.001 P < 0.001 increase of cytokine secretion 
MCP-1 (PMA) ns ns ns ns ns ns 
MCP-1 (NO PMA) P < 0.01 P < 0.001 P < 0.001 ns ns ns 
MIP-1α (PMA) ns ns ns ns ns ns 
MIP-1 (NO PMA) P < 0.001 P < 0.001 P < 0.001 increase of cytokine secretion 
MIP-1β (PMA) P < 0.001 P < 0.001 P < 0.001 increase of cytokine secretion 
MIP-1β (NO PMA) P < 0.001 P < 0.001 P < 0.001 increase of cytokine secretion 
RANTES (PMA) P < 0.01 P < 0.01 P < 0.01 increase of cytokine secretion 
RANTES (NO PMA) P < 0.001 P < 0.001 P < 0.001 increase of cytokine secretion 
TGF-α (PMA) ns ns ns ns ns ns 
TGF-α (NO PMA) ns ns ns ns ns ns 
VEGF (PMA) ns ns ns P < 0.01 ns ns 
VEGF (NO PMA) P < 0.05 P < 0.05 P < 0.05 P < 0.01 P < 0.01 P < 0.05 
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Table 7.4 
24 h 
TNF-
α 5ng 
vs 
Basal 
TNF-
α 10ng 
vs 
Basal 
TNF-
α 20ng 
vs 
Basal 
TNF-α 5ng + 
Levocabastine 
2mM 
vs 
TNF-α 
TNF-α 10ng + 
Levocabastine 
2mM 
vs 
TNF-α 
TNF-α 20ng + 
Levocabastine 
2mM 
vs 
TNF−α 
Fractalkine (PMA) ns ns ns ns ns ns 
Fractalkine (NO PMA) ns ns ns increase of cytokine secretion 
G-CSF (PMA) ns ns ns ns ns ns 
G-CSF (NO PMA) ns ns ns increase of cytokine secretion 
GM-CSF (PMA) ns ns ns ns ns ns 
GM-CSF (NO PMA) ns ns ns ns ns ns 
IL-10 (PMA) ns ns ns ns ns ns 
IL-10 (NO PMA) ns ns ns ns ns ns 
IL-12p40 (PMA) ns ns ns ns ns ns 
IL-12p40 (NO PMA) P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 
IL-1α (PMA) ns ns P < 0.01 increase of cytokine secretion 
IL-1α (NO PMA) P < 0.05 P < 0.05 P < 0.05 increase of cytokine secretion 
IL-1β (PMA) ns ns ns ns ns ns 
IL-1β (NO PMA) ns ns ns ns ns ns 
IL-1ra (PMA) P < 0.001 P < 0.001 P < 0.001 increase of cytokine secretion 
IL-1ra (NO PMA) P < 0.001 P < 0.001 P < 0.001 P < 0.01 P < 0.05 P < 0.01 
IL-5 (PMA) ns ns ns ns ns ns 
IL-5 (NO PMA) ns ns ns ns ns ns 
IL-6 (PMA) ns ns ns ns ns ns 
IL-6 (NO PMA) ns ns ns ns ns ns 
IL-7 (PMA) ns ns P < 0.05 ns ns ns 
IL-7 (NO PMA) P < 0.01 P < 0.01 P < 0.01 ns ns ns 
IL-8 (PMA) P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 
IL-8 (NO PMA) P < 0.001 P < 0.001 P < 0.001 ns ns ns 
IP-10 (PMA) P < 0.001 P < 0.001 P < 0.001 ns ns ns 
IP-10 (NO PMA) P < 0.001 P < 0.01 P < 0.001 increase of cytokine secretion 
MCP-1 (PMA) ns ns ns ns ns ns 
MCP-1 (NO PMA) P < 0.01 P < 0.01 P < 0.001 ns ns ns 
MIP-1α (PMA) ns P < 0.05 P < 0.01 ns ns ns 
MIP-1α (NO PMA) ns ns ns increase of cytokine secretion 
MIP-1β (PMA) P < 0.001 P < 0.001 P < 0.001 ns ns ns 
MIP-1β (NO PMA) P < 0.001 P < 0.001 P < 0.001 increase of cytokine secretion 
RANTES (PMA) P < 0.001 P < 0.001 P < 0.001 increase of cytokine secretion 
RANTES (NO PMA) P < 0.01 P < 0.01 P < 0.01 increase of cytokine secretion 
TGF-α (PMA) ns ns ns ns ns ns 
TGF-α (NO PMA) P < 0.05 ns P < 0.05 P < 0.05 ns P < 0.05 
VEGF (PMA) ns ns ns P < 0.05 ns P < 0.05 
VEGF (NO PMA) P < 0.05 P < 0.05 P < 0.05 P < 0.001 P < 0.001 P < 0.001 
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Table 7.5 
  
TNF-
α 10ng 
vs 
Basal 
VCAM-1 
vs 
Basal 
VCAM-1 + 
Levocabastine 
2mM 
vs 
VCAM-1 
FN 
vs 
Basal 
FN + 
Levocabastine 
2mM 
vs 
FN 
Levocabastine 
2mM 
vs 
TNF-α 
Vehicle 
vs 
Basal 
Bio1211 
vs 
TNF−α 
CS-1 
vs 
TNF-α 
Fractalkine (PMA) ns ns ns ns Increase ns Increase ns ns 
Fractalkine (NO 
PMA) 
ns ns ns ns ns ns ns P < 0.05 P < 0.001 
G-CSF (PMA) ns ns Increase ns Increase ns Increase ns ns 
G-CSF (NO PMA) ns ns ns ns ns ns ns ns ns 
GM-CSF (PMA) ns ns ns ns ns ns ns ns ns 
GM-CSF (NO 
PMA) 
P < 0.001 P < 0.001 ns P < 0.001 ns ns Increase P < 0.05 P < 0.001 
IL-10 (PMA) ns ns ns ns ns ns ns ns ns 
IL-10 (NO PMA) ns ns ns ns ns ns ns ns P < 0.001 
IL-12p40 (PMA) P < 0.001 P < 0.001 P < 0.01 P < 0.001 P < 0.01 P < 0.001 Increase P < 0.05 P < 0.001 
IL-12p40 (NO 
PMA) 
P < 0.01 P < 0.05 ns P < 0.05 P < 0.05 P < 0.01 ns P < 0.05 ns 
IL-1α (PMA) P < 0.001 P < 0.001 Increase P < 0.001 Increase Increase Increase P < 0.05 ns 
IL-1α (NO PMA) ns ns ns ns ns ns ns ns ns 
IL-1β (PMA) ns ns ns ns ns ns ns ns ns 
IL-1β (NO PMA) P < 0.001 P < 0.05 ns P < 0.001 ns ns Increase ns ns 
IL-1ra (PMA) P < 0.001 P < 0.001 Increase P < 0.001 Increase Increase Increase ns P < 0.01 
IL-1ra (NO PMA) P < 0.001 P < 0.001 P < 0.01 P < 0.001 P < 0.001 P < 0.001 Increase P < 0.001 P < 0.001 
IL-5 (PMA) ns ns ns ns ns ns ns ns ns 
IL-5 (NO PMA) ns ns ns ns ns ns ns ns ns 
IL-6 (PMA) ns ns ns ns ns ns ns ns Increase 
IL-6 (NO PMA) P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 Increase P < 0.05 P < 0.001 
IL-7 (PMA) P < 0.001 P < 0.001 Increase P < 0.001 Increase ns Increase ns ns 
IL-7 (NO PMA) P < 0.001 P < 0.001 ns P < 0.001 ns ns Increase ns P < 0.01 
IL-8 (PMA) ns ns Increase P < 0.05 Increase Increase Increase ns Increase 
IL-8 (NO PMA) P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 ns Increase P < 0.001 P < 0.001 
IP-10 (PMA) P < 0.001 P < 0.001 ns P < 0.001 ns ns Increase P < 0.001 ns 
IP-10 (NO PMA) P < 0.001 P < 0.001 ns P < 0.001 ns ns Increase P < 0.001 ns 
MCP-1 (PMA) P < 0.001 P < 0.001 Increase P < 0.001 Increase ns Increase P < 0.001 P < 0.001 
MCP-1 (NO PMA) P < 0.001 P < 0.001 ns P < 0.001 Increase Increase Increase ns P < 0.001 
MIP-1α (PMA) ns ns Increase ns Increase Increase ns ns ns 
MIP-1α (NO PMA) P < 0.001 P < 0.001 Increase P < 0.001 Increase Increase Increase ns Increase 
MIP-1β (PMA) P < 0.001 P < 0.001 Increase P < 0.001 Increase Increase Increase ns P < 0.001 
MIP-1β (NO PMA) P < 0.001 P < 0.001 ns P < 0.001 ns ns Increase ns Increase 
RANTES (PMA) ns ns Increase ns Increase Increase ns ns ns 
RANTES (NO 
PMA) 
ns ns Increase ns Increase Increase Increase ns ns 
TGF-α (PMA) P < 0.05 P < 0.05 ns P < 0.05 ns ns ns ns P < 0.05 
TGF-α (NO PMA) P < 0.01 P < 0.05 ns P < 0.05 ns ns P < 0.001 ns P < 0.001 
VEGF (PMA) P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 ns P < 0.05 P < 0.001 
VEGF (NO PMA) ns ns P < 0.001 ns P < 0.001 P < 0.001 P < 0.001 ns P < 0.001 
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Figure 7.7 
 Effect of levocabastine with cyclodextrins on interferon-inducible protein-10 (IP-10) release after 12h of TNF-α 
challenge. In panel A EoL-1 cells have been differentiated with PMA 24h before the experiment, whereas 
panel B shows the effects on undifferentiated EoL-1 cells. ** p < 0,01 vs Basal;  *** p < 0,001 vs Basal;  § p 
< 0,05 vs TNF-α;  §§ p < 0,01 vs TNF-α 
A 
B 
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Figure 7.8 
Effect of levocabastine with cyclodextrins on IL-1ra release after 12h of TNF-α challenge. EoL-1 cells have 
been differentiated with PMA 24h before the experiment. *** p < 0,001 vs Basal;  §§ p < 0,01 vs TNF-
α; §§§ p < 0,001 vs TNF-α 
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Figure 7.9 
Effect of levocabastine with cyclodextrins on IL-1β released 12h after TNF-α challenge. EoL-1 cells have been 
differentiated with PMA 24h before the experiment. * p < 0.05 vs basal; ** p < 0.001 vs Basal;  § p < 0.05 
vs TNF-α;  
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Figure 7.10 
Panel A: Levocabastine with cyclodextrins is able to reduce the release of VEGF of EoL-1 cells differentiated with 
PMA 24h before the experiment. Panel B: Naïve EoL-1 cells challenged with TNF-α show a reduced release of 
VEGF after levocabastine with cyclodextrin pre-treatment. ** p < 0.01 vs Basal; § p < 0.05 vs TNF-α;  §§ p < 
0.01 vs TNF-α 
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Figure 7.11 
Panel A and B show the effect of levocabastine with cyclodextrins to reduce the release of IL-12p40 
from, respectively, differentiated and undifferentiated EoL-1 cells 12h after TNF-α challenge. *** p 
< 0.001 vs TNF-α 
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Figure 7.12 
Panel A and B show the effect of levocabastine with cyclodextrins to reduce the release of VEGF from, 
respectively, differentiated and undifferentiated EoL-1 cells 12h after TNF-α challenge. * p < 0.05 vs 
TNF-α; ** p < 0.01 vs TNF-α 
 
 164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IL-12p40 (NO PMA) 24h
Ba
sa
l
TN
F-a
 
5 n
g
TN
F-a
 
10
 
ng
TN
F-a
 
20
 
ng
TN
F-a
 
5 n
g +
 
Le
vo
c
TN
F-a
 
10
 
ng
 
+ 
Le
vo
c
TN
F-a
 
20
 
ng
 
+ 
Le
vo
c
Ca
lcim
yci
n
0
250
500
750
[IL
-
12
p4
0] 
(p
g/
m
L)
*** *** ***
 
Figure 7.13 
Effect of levocabastine with cyclodextrins on IL-12p40 release by undifferentiated EoL-1 cells. 
Supernatants were analysed 24h after TNF-α challenge. *** p < 0.001 vs TNF-α  
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Figure 7.14 
In panel A is shown the effect of levocabastine with cyclodextrins on VEGF release by PMA 
differentiated EoL-1 cells, whereas panel B represents the same experiment performed on naïve cells. 
Supernates were analysed 24h after TNF-α challenge. * p < 0.05 vs TNF-α; ** p < 0.001 vs TNF-α 
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Figure 7.15 
Levocabastine with cyclodextrins demonstrates to be able to reduce IL-8 release by PMA 
differentiated EoL-1 cells after TNF-α challenge. *** p < 0.001 vs TNF-α 
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Figure 7.16 
Effects of levocabastine with cyclodextrins on cytokine release of EoL-1 cells exposed to various 
ligands, after TNF-α exposure. Panel A: IL-12p40 analysis in PMA differentiated EoL-1 cells 
supernatants. Panel B: IL-12p40 presence in the supernatants of naïve EoL-1 cells. * p < 0.05 vs TNF-
α; ** p < 0.01 vs TNF-α; *** p < 0.001 vs TNF-α 
B 
A 
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Figure 7.17 
Panel A: IL-1ra analysis in PMA differentiated EoL-1 cells supernatants. Panel B: IL-1ra presence in 
the supernatants of naïve EoL-1 cells. ** p < 0.01 vs TNF-α; *** p < 0.001 vs TNF-α 
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Figure 7.18 
IL-6 release by non-differentiated EoL-1 cells is inhibited by levocabastine with cyclodextrins even 
in the presence of pro-inflammatory ligands such as VCAM-1 or fibronectin. *** p < 0.001 vs TNF-
α 
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Figure 7.19 
IL-6 release by non-differentiated EoL-1 cells is inhibited by levocabastine with cyclodextrins even in 
the presence of pro-inflammatory ligands such as VCAM-1 or fibronectin. *** p < 0.001 vs TNF-α 
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Figure 7.20 
Measurement of VEGF levels in PMA differentiated and indifferentiated EoL-1 cells supernatants. 
Levocabastine with cyclodextrins is able to reduce VEGF release after TNF-α challenge. *** p < 0.001 vs 
TNF-α 
A 
B 
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7.6 Levocabastine treatment in a guinea pig model of allergic conjunctivitis 
 Giunea pigs were actively immunized by intraperitoneal injection of ovalbumin and, 
two weeks later, challenged with 30 µL of ovalbumin solution (100 µg/mL) in saline 
instilled into the conjunctival sac. Twenty minutes after the antigen challenge we registered 
swelling of the eyes, and chemosis was significantly enhanced in positive controls (p<0.05) 
as compared to negative controls. Levocabastine 0,05% eye drops pre-treatment (30 µL/eye 
60 and 30 min before the challenge) significantly reduced the clinical symptoms of the 
induced allergic response up to four hours and six hours (figs below). Chlorpheniramine 
reduced the clinical symptoms induced by ovalbumin only up to 2 h after antigen challenge. 
One hour after challenge, during the ocular early phase reaction to ovalbumin, swelling of 
the eyelids and chemosis were more evident in treated animals than controls, but was 
significantly reduced by 0.05% levocabastine and 0.1% chlorpheniramine eye drops before 
treatment. However, only levocabastine pre-treated guinea pigs showed a significant 
reduction in the severity of conjunctival symptoms during the late phase reaction of allergic 
conjunctivitis 6h after ovalbumin challenge (Fig. 7.21). 
24 h later, guinea pigs were sacrificed and the conjunctivas excised. Protein were 
extracted for western blot analysis and to test the level of eosinophil infiltration, performed 
as described in the material and methods section. The histological examination of stained 
conjunctivas shows a clear reduction in eosinophil infiltration in the tissues when the 
animals are pre-treated with either of the three formulations of levocabastine, data 
confirmed by the count of eosinophil, whereas chlorpheniramine was ineffective (Fig. 7.22 
and 7.23). Protein electrophoresis analysis clearly shows a reduced expression of VLA-4 in 
the tissues caused by the three levocabastine formulations  but not by chlorpheniramine. 
Similarly, eosinophil peroxidase activity, taken as an index of eosinophil infiltration, was 
increased 24 h after antigen challenge in positive control giunea pigs, whereas a noteworthy 
reduction was observed in eosinophil peroxidase activity of levocabastine-treated guinea 
pigs but not in chlorpheniramine treated animals. 
 Exposure of actively immunized guinea pigs to the topical challenge of ovalbumin 
instilled into the conjunctival sac induced a significant increase, 24 h later, in α4 integrin 
levels evaluated in conjunctival homogenates by western blot analysis (Fig. 7.24).  
 
 
 173 
Placebo 
0h 
 
1h 
 
2h 
 
4h 
 
6h 
 
24h 
 
 174 
Ovalbumin 
0h 
 
1h 
 
2h 
 
4h 
 
6h 
 
24h 
 
 175 
 
Levocabastine 
0h 
 
1h 
 
2h 
 
4h 
 
6h 
 
24h 
 
 
 
 
 176 
Chlorpheniramine 
0h 
 
1h 
 
2h 
 
4h 
 
6h 
 
24h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.21 
Effects of levocabastine and chlorpheniramine on conjunctival symptoms induced by ovalbumin in 
guinea pigs actively immunized by intraperitoneal injection of ovalbumin and, 2 weeks later, challenged 
with ovalbumin (30 µL of 2.5% solution) instilled into both eyes. Levocabastine 0.05% and 
chlorpheniramine 0.1% were instilled into both eyes (30 µL per eye) 60 and 30 minutes before ovalbumin 
challenge; controls received the vehicle alone and were not treated with ovalbumin. Each group 
comprised from three to five guinea pigs and the score was based on changes up to 24h after challenge 
for the eye symptoms of itching, swelling, redness, and lid eversion. The data show the mean ± SEM; 
*p<0.01 vs vehicle (Friedman test followed by Dunn’s post hoc comparison. 
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Figure 7.22 
Photomicrographs of the conjunctiva 24h after topical challenge with ovalbumin. Substantial eosinophil 
infiltration is observed in ovalbumin-treated guinea pigs (OVA) in comparison to negative controls 
(animal non-immunized with ovalbumin) who received saline alone and were not challenged with 
ovalbumin (CTRL). In levocabastine treated guinea pigs there was much less eosinophil infiltration than 
in the ovalbumin treated group and in chlorpeniramine-treated animals. 
 
Figure 7.22 
Effect of levocabastine and chlorpheniramine on eosinophil infiltration in the guinea pig conjunctiva 24 
h after topical challenge with ovalbumin. The eosinophil in each field (500x) magnification were counted 
24 h after antigen exposure. Controls received saline alone and were not challenged with ovalbumin 
(CTRL). 
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Figure 7.23 
Effects of levocabastine and chlorpheniramine on conjunctival eosinophil peroxidase levels in the 
conjunctiva 24 h after topical challenge with ovalbumin. 
 
 Figure 7.24 
Effects of levocabastine and chlorpheniramine on conjunctival levels of α4 integrin subunit 24 h after 
topical challenge with ovalbumin. Guinea pigs were euthanized, the conjunctiva was collected and protein 
extracted and used for western blot analysis. A respresentative western blot of three replicates and the 
densitometric analysis of the bands are shown. The approximate molecular mass of α4 was determined by 
comparison to a molecular mass standard. OD refers to the relative optical density of each band, defined by 
normalization of the α4 integrin subunit band to the β-actin bands (arbitrary units). Mean ±SEM (n=5). 
*p<0.01 vs CTRL (Newman Keuls test after ANOVA). 
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This increase was related to eosinophils and possibly other leukocytes infiltrating the 
conjunctiva and was significantly reduced by pre-treatment with levocabastine eye-drops 
but not by chlorpheniramine. 
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CHAPTER 8 
DISCUSSION 
 
 
 
 In this thesis a prototype of high-throughput screening for the identification of 
novel integrin antagonists was set up. This can be used to screen lead compounds in the 
development of drugs for the treatment of allergic inflammation. Moreover, these new 
technologies have been demonstrated to be extremely useful for the assay of drugs already 
used in therapy in order to better understand their mechanism of action and better specify 
their clinical use. 
A scintillation proximity assay (SPA) allowed to determine the IC50 of levocabastine, 
a know H1 receptor antagonist, toward the α4β1 integrin. The effectiveness of this 
approach was, then, tested in in vitro cell adhesion assays by measuring the ability of 
levocabastine to block the adhesion of EoL-1 and Jurkat E6.1 cell lines to multi-well plates 
coated with VCAM-1 or to monolayers of TNF-α activated HUVEC. Moreover, the 
levocabastine-mediated interference with leukocyte trafficking was corroborated by in vivo 
experiments on a guinea pig model of allergic conjunctivitis, that showed how pre-treating 
the animals with levocabastine eye drops before antigen challenge, significantly limits 
eosinophil tissue infiltration. 
 Tissue-specific recruitment of leukocytes is a requirement for immune surveillance 
in the body and plays a key role in the pathogenesis of various diseases. As a consequence, 
inhibition of immune cell trafficking between their source organ, blood and tissues have 
become a very attractive therapeutic approach. Given that leukocytes would not be 
depleted, impaired in their general function nor compromised to their capacity for 
circulation into the organs thus maintaining the physiological immune surveillance, such a 
strategy should be efficacious and, at the same time, should have little side effects. 
Therefore, targeting leukocyte recruitment is predicted to contrast systemic 
immunosuppressive therapies, which modify immune cell function or viability, resulting in 
the risk of severe side effects such as promotion of tumour development or infections. 
 184 
 Leukocyte tissue homing is generally regarded as a multistep process involving 
several adhesion molecules such as selectins, integrins and cytokine receptors. The very late 
antigen 4 (VLA-4, α4β1 integrin) via its interaction with vascular cell adhesion molecule 1 
(VCAM-1) appears to be of additional importance for leukocyte localization, whereas LFA-
1 (CD11a/CD18, αLβ2) and Mac-1 (CD11b/CD18, αMβ2) bind to the intercellular adhesion 
molecule 1 (ICAM-1) contributing to leukocyte activation. Several lines of evidence have 
indicated that blocking leukocyte migration is efficacious in various animal models of 
inflammatory disorders. This has been demonstrated for all adhesive steps such as tethering 
and rolling, integrin activation by chemokines, firm adhesion, and finally transmigration of 
leukocytes through the endothelium. Indeed, natalizumab (Tysabri; Elan, Dublin, 
Ireland/Biogen Idec, Cambridge, MA, USA), a humanized monoclonal antibody targeting 
VLA-4, showed significant beneficial effects in controlled clinical trials of multiple sclerosis 
and Crohn’s disease (Miller et al., 2003; Ghosh et al., 2003; Polman et al., 2006, Stüve and 
Bennett, 2007). Remission rates in Crohn’s disease were up to 44% and response rates up to 
71%, clearly indicating that therapeutic regimens targeting recirculation can be very 
effective. Unfortunately, soon after approval of natalizumab by the Food and Drug 
Administration (FDA), fatalities due to progressive multifocal leukoencephalopathy caused 
by reactivation of JC virus occurred, and Elan/Biogen Idec stopped sales of Tysabri. Given 
the multiple mechanisms through which VLA-4 may modulate immune function, it is 
incumbent upon future translational research to elucidate the pathways of natalizumab 
action that are relevant to the potential benefits and the risks observed during clinical 
development. 
 Another interesting approach is the one of combinatorial therapies in which a 
blocker of leukocyte trafficking can be associated with a cytokine receptor blocker. The 
pattern of the inflammatory response to an allergen is mediated by a number of different 
cells and a complex release of different inflammatory mediators. Generating small 
molecules against GPCRs is an established technology and, for some of the targets (CCR4, 
CCR10, CCR8, CXCR3), effective antagonists are already in clinical trials. 
 Ocular allergy management strategies are increasing exponentially. A growing list of 
clinically available agents is purposefully aimed at protecting the eye from inflammation. 
Concentrated focus on ocular allergy drug development is a natural derivative of an 
escalating number of allergy sufferers throughout the general population. 
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 The α4β1 integrin/VCAM-1 pathway is crucial for the firm adhesion and 
transmigration of eosinophils into the conjunctiva through vascular endothelial cells. The 
inhibition of conjunctival eosinophil by an integrin α4 monoclonal antibody has been 
reported in a guinea pig model of allergic conjunctivitis (Ebihara et al., 1998). Treatment 
with anti-α4 integrin and anti-VCAM-1 antibodies significantly suppressed the conjunctival 
eosinophil infiltration induced in mice by active immunization with ragweed-primed 
splenocytes (Fukushima et al., 2006). Whitcup et al. (1999) showed that antibodies against 
αLβ2 integrin and its counter-receptor ICAM-1 relieve both the clinical signs of immediate 
hypersensitivity and cellular infiltration into the conjunctiva, 24 h after antigen challenge in 
mice. Several antiallergic drugs, including levocabastine, down-regulate ICAM-1 expression 
(Bielory et al., 2005; Buscaglia et al., 1996; Ciprandi et al., 2003; Schultz, 2006; Ciprandi et 
al., 1996); Pesce et al. (2001) reported that in patients with allergic conjunctivitis, 
conjunctival endothelial cells expressed αLβ2 integrin. Therefore, blocking α4β1 and αLβ2 
integrin-mediated cell adhesion may offer another strategy for the treatment of allergic 
conjunctivitis, as it prevents the development of the early and late phase responses. 
 α4β1 and αLβ2 integrins may act in concert to mediate eosinophil adhesion and 
signalling functions to meet the peculiar challenges these cells fare as they contact the 
vascular epithelium. “Cross-talk” between these integrins was proposed by Chan et al. 
(2000) who suggested that α4β1 integrin, binding to VCAM-1, might also strengthen αLβ2-
mediated adhesion of T lymphocytes to ICAM-1. With regard to eosinophils, Higashimoto 
et al. (1999) reported that adherence of EoL-1 to fibronectin was mediated by α4β1 integrin 
and enhanced ICAM-1 expression, and this might contribute to increasing cell adhesion to 
the extracellular matrix and conjunctival eosinophil accumulation. Our data support this 
latter idea, as the blockade of eosinophil adhesion by levocabastine may prevent further 
eosinophil functional changes, including expression of adhesion molecules, such as ICAM-1 
whereas levocabastine does not influence α4 integrin expression. In fact, we observed that 
in the eosinophilic EoL-1 cell line levocabastine did not affect α4 integrin expression in cells 
maintained  for 12 h in fibronectin- or BSA-coated wells. In agreement with our data, 
Fukuishi et al. (2002) reported that the antiallergic drug olopatadine inhibited antigen-
induced eosinophil infiltration and repressed IL-5-induced expression of αLβ2 integrin but 
not α4β1 integrin. These in vitro data may help explain the reduction of the expression of 
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α4β1 integrin that we observed in the conjunctiva of ovalbumin-sensitized guinea pigs 
treated with levocabastine. In fact, this effect might be a consequence of the reduction in 
recruitment and migration of eosinophils to the site of allergic inflammation by 
levocabastine rather than of levocabastine-induced α4β1 down-regulation. Thus, 
hypothetically, levocabastine might exert its inhibitory effect on eosinophil adhesion 
binding to α4β1 integrin, affecting its avidity as well as affinity for VCAM-1 and fibronectin. 
In fact, integrins increase their affinity or avidity to endothelial ligands upon exposure to 
chemokines and can undergo to conformational changes upon ligand binding apart from 
expression changes on the leukocyte surfaces (Broide and Sriramarao, 2001). 
 We confirmed the positive effect of levocabastine eye drops on early and late phase 
reactions induced by allergen specific-conjunctival challenge. Histamine and eicosanoids are 
responsible for the typical early phase reaction. However, mast cells also contribute to the 
synthesis and release of cytokines, chemokines and growth factors, triggering a cascade of 
inflammatory events on the surface of epithelial and endothelial cells that lead to the late 
phase reaction, with recruitment of eosinophils and neutrophils. Inflammatory cytokines 
may enhance the expression of E-selectin, ICAM-1 and VCAM-1 on the vascular 
endothelial cells and initiate the rolling of immune cells. 
 According to previous studies, levocabastine effect on the early phase response 
seems to be mediated by the blockade of histamine H1 receptors and mast cell stabilization 
(Dechant and Goa, 1991; Awouters et al., 1992). It reduces conjunctival eosinophil 
infiltration in the late phase response and, as proved in this study, affects α4β1 integrin 
functions. However, it cannot be ruled out that levocabastine reduces inflammatory cell 
infiltration in the late phase response by affecting the release of cytokines and chemokines 
(Yanni et al., 1999; Noble and McTavish, 1995) from epithelial and mast cells.  
 Conjunctival epithelial cells do not express α4β1 integrin (Fujihara et al., 1997) and 
its occurrence in the conjunctiva could be a consequence of eosinophil infiltration 
promoted by different mechanisms, independent of histamine binding to H1 receptors. 
This idea is further supported by experiments with the classical H1 antagonist 
chlorpheniramine. In fact, a 0.1% chlorpheniramine eye drops blocked only the early phase 
response of allergic conjunctivitis and did not reduce eosinophil infiltration or expression of 
the adhesion molecule α4β1 in the conjunctiva of guinea pigs treated with ovalbumin. This 
drug did not modify Jurkat E6.1 or EoL-1 cell adhesion to VCAM-1 or fibronectin. First 
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generation anti-histmines like chlorpheniramine are weak inhibitors of histamine-stimulated 
cytokine synthesis (Yanni et al., 1999) while levocabastine is more potent (Dechant and 
Goa, 1991; Awouters et al., 1992). Furthermore, chlorpheniramine in an allergic model of 
allergic cutaneous antigen-induced inflammatory cell infiltration, did not significantly inhibit 
inflammatory cell infiltration in the late phase response (Charlesworth et al., 1992). 
 Up to now, investigations focused on levocabastine have ascertained the action of 
this compound on epithelial cells of the conjunctiva, while little is known on its effect on 
eosinophils. Kaisho and Akira (2006) have recently reported that the functional effects of 
some microbial products on eosinophils enhance their survival, can modulate the 
chemotactic migration and adhesion molecules expression. Focal adhesion kinase (FAK), a 
non-receptor protein tyrosine kinase 2 (PTK-2) involved in signalling downstream of 
integrins (Cary and Guan, 1999; Sieg et al., 2000) has been suggested to mediate 
inflammatory responses through the activation of MAPKs including p38 and ERK 
pathways (Neff et al., 2003; Chen et al., 1998). Cheung et al. (2008) finally speculated that 
FAK might participate in linking TLRs with the activation of MAPK cascade in human 
eosinophils, linking the action of adhesion molecules (integrins included) with degranulation 
and cytokine release of eosinophils (fig. 8.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 
FAK-dependent activation of MAPK in eosinophil stimulation. 
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 Levocabastine caused concentration-related blockad of adhesion of EoL-1 cells to 
VCAM-1 and fibronectin. The drug potency in vitro (IC50 around 400 µM) is important 
when this molar concentration is converted to a percentage weight/volume (400 µM equals 
about 200 µg/mL and is equivalent to a 0.02% solution). Because the conjunctiva is the 
target tissue for this compound, penetration and transport into the eye do not significantly 
affect drug delivery. For these reasons, and in view of the clinical efficacy of 0.05% 
levocabastine in allergic conjunctivitis models, the effect on α4β1 and αLβ2 integrin 
blockade appears acceptable. The analysis of the data related to cytokine release clearly 
shows that levocabastine is capable to cause in EoL-1 cells a statistically significant 
reduction of TNF-α-induced release of the cytokines IL-12p40, IL-8, VEGF. These 
cytokines are all involved, in different measure, in eosinophil survival and eosinophil-
mediated inflammation (Choi et al., 2009; Gorksa et al., 2008; Meyts et al., 2006). Thus, 
levoacabastine seems to limit the autocrine and paracrine effects in support of the 
inflammatory process sustained by eosinophilic cytokine release (fig. 8.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Levocabastine shows potent and sustained antiallergic activity after conjunctival 
administration. In ovalbumin-sensitized guinea pigs, the drug reduced or completely 
 
Figure 8.2 
Levocabastine inhibition of eosinophil activation. The block of integrins  interferes with the activation of 
focal adhesion kinases (FAKs), hampering the FAK-dependent activation of MAPK and Nf-κB an 
important event in eosinophil degranulation and cytokine release. 
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prevented conjunctival symptoms and this effect lasted up to 24 h (Feinberg and Stokes, 
1987). Complete inhibition of histamine-induced conjunctivitis persisted 24 h after topical 
levocabastine. Therefore, topical levocabastine may persist at an adequate conjunctival 
concentration for up to 6-8 h, long enough to interfere with eosinophil migration to the 
ocular surface. 
 Finally, we propose that levocabastine acts through different mechanisms as an 
antiallergic agent and some of the drug cellular targets may play a role in eosinophil 
adhesion. Topical levocabastine, by blocking integrin-mediated cell adhesion, may inhibit 
the development of the late phase response of allergic conjunctivitis. This compound easily 
reaches conjunctival cells and vessels when administered topically, and can prevent the 
recruitment and activation of eosinophils as well as other immune cells (e.g. neutrophils and 
other leukocytes). 
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APPENDIX I 
ARTERIES AND VEINS 
 
 
 
Most of our knowledge about the vasculature is restricted to conduit vessels, namely 
the large arteries and veins. Arteries deliver well oxygenated (red-coloured) blood from the 
heart to the various tissues of the body, whereas veins collect and return deoxygenated 
blood (blue in color) back to the heart. Arteries have a thick muscular wall; veins have a 
thin, distensible wall. Arteries pulsate, whereas veins do not; large arteries are located deep 
within tissues, and are thus protected from traumatic injuries. Veins lie both deep and 
superficial. Capillaries are the macroscopically invisible blood vessels that connect arterioles 
to venules, thus creating a closed circulation, and at this level happens the exchange of gases, 
nutrients and catabolic substances. Their wide presence all over the organs and tissues of 
the body make them the vast majority of the surface area of the circulation. Capillaries have 
an extremely thin wall consisting of a single layer of endothelial cells surrounded to a 
variable degree by occasional perycites and extracellular matrix. The endothelium 
represents the cellular interface between circulating blood and underlying tissues: an healthy 
endothelium is highly active and adaptive. In fact, each endothelial cell is analogous to a 
miniature adaptive input-output device. Input arises from the extracellular environment and 
may include biomechanical and biochemical stimuli; the nature of output depends on the 
level of organization and scale of investigation (Fig a.1). Single endothelial cells may 
undergo a change in cell shape or alteration in protein or mRNA expression, or they may 
proliferate, migrate or undergo apoptosis. Monolayers of endothelial cells express barrier properties 
and may be assayed for adhesion and transmigration of white blood cells. Other properties of the 
endothelium emerge only in the context of the blood vessel, whole organ or organism, such 
as endothelial-dependent regulation of vasomotor tone, angiogenesis, and redistribution of blood flow. 
The input-output device is not a black box, but rather contains a  highly elaborate, non-
linear array of dynamic signal transduction pathways that couple signals at the surface 
membrane to cellular response or phenotype. 
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The input from the microenvironment change in space and time. For example, the blood-
brain barrier endothelium is exposed to astroglial derived factors, whereas capillary 
endothelium in the heart is subject to paracrine signals from neighbouring cardiomyocytes. 
As input is coupled to output, variation in the extracellular environment across space and 
time leads to phenotypic heterogeneity, characteristic of an healthy endothelium (Fig. a.2). 
 Endothelial cells respond selectively to well defined stimuli, becoming activated. 
According to this view, quiescent endothelial cells express an anticoagulant, antiadhesive 
and vasodilatory phenotype, whereas activated endothelial cells express procoagulant, 
proadhesive and vasoconstrictory properties. This events are not simply occurring as an all-
or-none phenomenon. In fact, endothelial cells’ responses are graded on the basis of the 
strength of the stimulus, in a dose-dependent manner. Moreover, this pictures is further 
complicated by a site-specific expression of proteins that cannot be considered as markers 
of activation. For example, while P-selectin is considered a marker of endothelial cell 
activation, it is constitutively expressed in dermal microvessels of uninflamed skin. Another 
example is provided by thrombomodulin, whose expression is usually downregulated in 
endothelial cells during inflammation. However, the brain expresses little or no 
thrombomodulin and the toggle hypothesis would suggest that the blood-brain barrier is a 
chronic state of activation, which is not the case. The brain relies on other anticoagulants to 
 
Figure a.1 
Endothelial cells as input-output devices: as input changes in time and space, these cells adapt leading to 
phenotypic heterogeneity. (illustrated by Steve Moskovitz) 
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balance local hemostasis. Therefore, endothelial cell activation must be adjudicated in an appropriate 
temporal and spatial context.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Endothelial cells are strategically located at the interface between blood and tissues. 
In addition to responding rapidly (seconds to minutes) to agonists such as histamine and 
thrombin, vascular cells, upon exposure to cytokines, undergo profound alteration of 
function that involve gene expression and protein synthesis, requires hours to develop, and 
are relatively long-lasting. Vascular cells are both a target for and a source of cytokines. 
These soluble polypeptide mediators serve as communication signals with leukocytes as well 
as with diverse tissues and organs. The spectrum of responses elicited in endothelial cells by 
different cytokines is extremely vast and varied. Different cytokines activate distinct, largely 
non-overlapping, sets of functions that can be grouped into programs of 
activation/differentiation. 
 
 
 
 
 
 
 
Figure a.2 
In this hypothetical scheme, endothelial cell phenotype is represented by a color shade. On the 
right, according to a model of decomplexification (Golberger et al., 2002), a representation of a 
dysfunctional endothelium. (illustration by Steve Moskowitz) 
 196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 197 
APPENDIX II 
THE IMMUNE SYSTEM ELEMENTS 
 
 
 
 
 
 
 
 
 
 The cells of the immune system originate in the bone marrow, where many of them 
also mature. They then migrate to guard the peripheral tissues, circulating in the blood and 
in a specialized system of vessels called the lymphatic system. During this recirculation, they 
receive so-called tonic signals via their receptors that contribute to their survival. 
 All the cellular elements of blood, including the red blood cells, the platelets and the 
white blood cells derive ultimately from the hematopoietic stem cells in the bone 
marrow. As these stem cells can give rise to all the different types of blood cells, they are 
often known as pluripotent hematopoietic stem cells. 
 The myeloid progenitor is the precursor of the granulocytes, macrophages, 
dendritic cells, and mast cells of the innate immune system. Macrophages are one of the 
three types of phagocyte in the immune system and are distributed widely in the body 
tissues, where they play a critical part in innate immunity. They are the mature form of 
monocytes, which circulate in the blood and differentiate continuously into macrophages 
upon migration into tissues. Dendritic cells are specialized to take up antigen, process it, 
and display it for recognition by T lymphocytes. 
Mast cells, whose blood-borne precursors are not well defined, also differentiate in 
the tissues. They mainly reside near small blood vessels and, when activated, release 
substances that affect vascular permeability. Although best known for their role in 
orchestrating allergic responses they are believed to play a part in protecting mucosal 
surfaces against pathogens. 
The granuolocytes are so called because they have densely staining granules in their 
cytoplasm; they are also sometimes called polymorphonuclear leukocytes because of their 
oddly shaped nuclei. There are three types of granulocytes, all of which are relatively short 
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lived, and they are produced in increased numbers during immune responses, when they are 
produced in increased numbers during immune responses, when they leave the blood to 
migrate to sites of infection or inflammation. Neutrophils which are the third phagocytic 
cell of the immune system, are the most numerous and most important cellular component 
of the innate immune response: hereditary deficiencies in neutrophil function lead to 
overwhelming bacterial infection, which is fatal if untreated. Eosinophils are thought to be 
important chiefly in defense against parasitic infections, because their numbers increase 
when the body has a parasitic infection. The function of basophils is probably similar and 
complementary to that of mast cells. 
The common lymphoid progenitor gives rise to the lymphocytes, and to the 
natural killer cells (NK) of innate immunity. In addition, it is also able to give rise to 
dendritic cells that appear indistinguishable form those derived from the common myeloid 
progenitor. However, as there are more common myeloid progenitors than there are 
common lymphoid progenitors, the majority of the dendritic cells in the body develop from 
common myeloid progenitors (fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
Immune cell differentiation from pluripotent hematopoietic stem cells. 
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Innate immunity is an essential prerequisite for the adaptive immune response, 
because the antigen-specific lymphocytes of the adaptive immune response are activated by 
co-stimulatory molecules that are induced on cells of the innate immune system during their 
interaction with microorganisms. The cytokines produced during these early phases also have 
an important role in stimulating the subsequent adaptive immune response and shaping its 
development. The most frequent sites of encounter between the body and microorganisms 
and other antigens are the mucosal surfaces. A mucosal immune system lines the airways, 
grastrointestinal tract, and urogenital system, and is the most extensive compartment of the 
immune system. 
The adaptive immune response is required for effective protection of the host 
against pathogenic microorganisms. The response of innate immune system to pathogens 
helps to initiate the adaptive immune response, as interactions with these pathogens lead to 
the production of cytokines and the activation of dendritic cells to activated antigen-
presenting cell status (fig. 2). 
 
 
 
 
 
 
 
 
Allergic reactions occur when an individual who has produced IgE antibody in 
response to an allergen, subsequently encounters the same allergen. The allergen triggers 
the activation of IgE-binding cells, including mast cells and basophils, in the exposed tissue, 
leading to a series of responses that are characteristic to allergy. IgE is involved in 
protective immunity, especially in response to parasitic worms, which are prevalent in less 
economically developed countries. Allergy is one of a class of immune system responses 
that are termed hypersensitivity reactions. These are harmful immune responses that 
produce tissue injury and can cause serious disease. 
IgE is produced by plasma cells located in lymph nodes draining the site of 
antigen entry and also locally, at the sites of allergic reactions, by plasma cells derived from 
 
Figure 2 
Innate and adaptive immune responses. 
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germinal centers developing within the inflamed tissue. IgE differs from other antibody 
isotypes in being predominantly localized in tissues, where it is tightly bound to mast-cell 
surfaces through the high-affinity IgE receptor known as FcεRI. Binding of antigen to IgE 
cross-links these receptors and this causes the release of chemical mediators from the mast 
cells, which can lead to the development of a type I hypersensitivity reaction. Basophils 
also express FcεRI; they can therefore display surface-bound IgE and also take part in the 
production of type I hypersensitivity reactions. The factors that lead to an antibody 
response dominated by IgE are still being worked out (fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As many as 40% of people in Western populations show an exaggerated tendency to 
mount IgE responses to a wide variety of common environmental allergens. This state is 
called atopy, has a strong familial basis, and is influenced by several genetic loci. Atopic 
individuals have higher total levels of IgE in the circulation and higher levels of eosinophils 
than their normal counterparts. They are more susceptible to allergic diseases such as hay 
fever and asthma. Genetic variations of the IL-4 gene has been associated with raised IgE 
levels in atopic individuals; the variant promoter directs increased expression of a reporter 
gene in experimental systems. 
 
Figure 3 
Types of hypersensitivity reactions. 
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Eosinophils are granulocytic leukocytes that originate in the bone marrow. They 
are so called because their granules, which contain arginine-rich basic proteins, are colored 
bright orange by the acidic stain eosin. Only very small numbers of these cells are normally 
present in the circulation; most eosinophils are found in tissues, especially in the connective 
tissue immediately underneath respiratory, gut, and urogenital epithelium, implying a likely 
role for these cells in defense against invading oranisms. Eosinophils have to kind of 
effector function. First, on activation they release highly toxic granule proteins and free 
radicals, which can kill microorganisms and parasites but also cause significant tissue 
damage in allergic reactions. Second, activation induces the synthesis of chemical mediators 
such as prostaglandins, leukotrienes, and cytokines. These amplify the inflammatory 
response by activating epithelial cells and recruiting and activating more eosinophils and 
leukocytes. 
The activation and degranulation of eosinophils is strictly regulated, as their 
inappropriate activation would be harmful to the host (fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The first level of control acts on the production of eosinophils by the bone marrow. Few 
eosinophils are produced in the absence of infection or other immune stimulation. But 
when TH2 cells are activated, cytokines such as IL-5, are released that increase the 
 
Figure 4 
Chemical mediators and substances present in eosinophilic granules. 
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production of eosinophils in the bone marrow and their release into the circulation. 
However, transgenic animals overexpressing IL-5 have increased numbers of eosinophils in 
the circulation but not in their tissues, indicating that the migration of eosinophils from the 
circulation into tissues is regulated separately, by a second set of controls. The key 
molecules in this case are CC chemokines, most which cause chemotaxis of several types of 
leukocytes, but three are particularly important for eosinophil chemotaxis and have been 
named eotaxin 1 (CCL11), eotaxin 2 (CCL24), and eotaxin 3 (CCL26). 
The eotaxin receptor on eosinophils, CCR3, is a member of the chemokine family 
of receptors. The eotaxins and these other CC chemokines also activate eosinophils. 
Identical or similar chemokines stimulate mast cells and basophils. For example, eotaxins 
attract basophils and cause their degranulation, and CCL2, which binds to CCR2, similarly 
activates mast cells in both the presence and the absence of antigen. CCL2 can also 
promote the differentiation of naïve TH0 cells to TH2 cells; TH2 cells also carry the receptor 
CCR3 and migrate toward eotaxins. 
A third set of controls regulates the state of eosinophil activation. In their 
nonactivated state, eosinophils do not express high-affinity IgE receptors and have a high 
threshold for release of their granule contents. After activation by cytokines this threshold 
drops, FcεRI is expressed, and the number of Fcγ receptors and complement receptors on 
the cell surface also increases. The eosinophil is now primed to carry out its effector activity 
– for example degranulation in response to antigen that cross-links specific IgE bound to 
FcεRI on the eosinophil surface. 
In a local allergic reaction, mast-cell degranulation and TH2 activation cause 
eosinophils to accumulate in large numbers and to become activated. Their continued 
presence is characteristic of chronic allergic inflammation and they are thought to be major 
contributors to tissue damage. Eosinophils, mast cells, and basophils can interact with 
each other. Eosinophil degranulation releases major basic protein, which in turn causes 
degranulation of mast cells and basophils. This effect is augmented by any or the cytokines 
that affect eosinophil and basophil growth, differentiation, and activation, such as IL-3, IL-
5, and GM-CSF. 
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APPENDIX III 
DETAILED EXPERIMENTAL PROCEDURES 
 
 
 
 
Fibronection labelling with Na[125I] 
 Fibronectin labelling was performed by the use of the IODO-GEN iodination 
reagent (1,3,4,6-tetrachloro-3α-6α-diphenylglycouril) by Pierce (Rockford, IL, USA). 
During oxidative reactions in the pre-coated tubes the iodination reagent remains adherent 
to the vessel because it is insoluble in typical aqueous media. This feature enables the 
sample to be decanted from the coated vessel to terminate the oxidative reaction. 
 1 mL of Tris Iodination Buffer (25 mM TrisHCl, pH 7.5; 0.4 M NaCl) was used to 
rinse the pre-coated tube, in which where then added 100 µL of Tris Buffer (25 mM 
TrisHCl, pH 7.5; 0.4 M NaCl; 5 mM EDTA). At this point 1.0 mCi of Na[125I] (in a volume 
of around 10 µL) are put into the tube and gently mixed. After 6 minutes incubation 
(swirling the tube every 30 seconds) the iodide is activated and can be transferred to the 
fibronectin solution (1.0 nmol in 100 µL of Tris Iodination Buffer) where it is incubated for 
6-9 minutes at room temperature, flicking the tube every 30 seconds. At the end of the 
incubation 50 µL of Scavenging Buffer (10 mg tyrosine/mL in Tris Iodination Buffer or 
PBS, pH 7.4) were added, mixed and incubated for 5 minutes with additional flicking at 1 
and 4 minutes. Then, 1 mL of Tris/BSA Buffer (0.25% bovine serum albumin; 25 mM 
TrisHCl, pH 7.5; 0.4 M NaCl; 5 mM EDTA; 0.05% sodium azide) was added for blocking 
non-specific binding sites on the desalting column. A 5 µL aliquot was taken to assess the 
total amount of 125I incorporated. The sample was then loaded on a 10 mL bed volume 
desalting column pre-equilibrated with 20 mL of Tris/BSA Buffer. At the end of the 
column the radioactive is recovered and the eluted fractions are scanned for radioactivity. 
 
Determination of protein bound and free 125I by standard trichloricacetic acid (TCA) precipitation procedure 
 5 µL of the eluted fraction were aliquoted in a glass tube to which were added 3 mL 
of 10% TCA/ 1% Na4P2O7 and incubated on ice for 20 minutes. Then, class C/glass fiber 
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filters, pre-wet in 10% TCA/ 1% Na4P2O7 solution, were placed on a filtering unit and the 
radioactive solution was decanted over them. After two washes with a 5% TCA solution, 
rinsing the tubes to increase the yield, filters were wet with absolute ethanol and kept under 
vacuum until complete dryness, ready to be counted. 
 
Calculating the labelling yield 
 From the aminoacidic sequence of fibronectin (see image) it is possible to count 93 
tyrosine residues, that represent the reactive moieties toward 125I. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The important parameters that can be calculated are the following: 
 
 
MLRGPGPGLLLLAVLCLGTAVPSTGASKSKRQAQQMVQPQSPVAVSQSKPGCYDNGKHYQINQQWERTY
LGNALVCTCYGGSRGFNCESKPEAEETCFDKYTGNTYRVGDTYERPKDSMIWDCTCIGAGRGRISCTIA
NRCHEGGQSYKIGDTWRRPHETGGYMLECVCLGNGKGEWTCKPIAEKCFDHAAGTSYVVGETWEKPYQG
WMMVDCTCLGEGSGRITCTSRNRCNDQDTRTSYRIGDTWSKKDNRGNLLQCICTGNGRGEWKCERHTSV
QTTSSGSGPFTDVRAAVYQPQPHPQPPPYGHCVTDSGVVYSVGMQWLKTQGNKQMLCTCLGNGVSCQET
AVTQTYGGNSNGEPCVLPFTYNGRTFYSCTTEGRQDGHLWCSTTSNYEQDQKYSFCTDHTVLVQTRGGN
SNGALCHFPFLYNNHNYTDCTSEGRRDNMKWCGTTQNYDADQKFGFCPMAAHEEICTTNEGVMYRIGDQ
WDKQHDMGHMMRCTCVGNGRGEWTCIAYSQLRDQCIVDDITYNVNDTFHKRHEEGHMLNCTCFGQGRGR
WKCDPVDQCQDSETGTFYQIGDSWEKYVHGVRYQCYCYGRGIGEWHCQPLQTYPSSSGPVEVFITETPS
QPNSHPIQWNAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNSYTIKGLKPGVVYEGQLISIQQYGHQ
EVTRFDFTTTSTSTPVTSNTVTGETTPFSPLVATSESVTEITASSFVVSWVSASDTVSGFRVEYELSEE
GDEPQYLDLPSTATSVNIPDLLPGRKYIVNVYQISEDGEQSLILSTSQTTAPDAPPDPTVDQVDDTSIV
VRWSRPQAPITGYRIVYSPSVEGSSTELNLPETANSVTLSDLQPGVQYNITIYAVEENQESTPVVIQQE
TTGTPRSDTVPSPRDLQFVEVTDVKVTIMWTPPESAVTGYRVDVIPVNLPGEHGQRLPISRNTFAEVTG
LSPGVTYYFKVFAVSHGRESKPLTAQQTTKLDAPTNLQFVNETDSTVLVRWTPPRAQITGYRLTVGLTR
RGQPRQYNVGPSVSKYPLRNLQPASEYTVSLVAIKGNQESPKATGVFTTLQPGSSIPPYNTEVTETTIV
ITWTPAPRIGFKLGVRPSQGGEAPREVTSDSGSIVVSGLTPGVEYVYTIQVLRDGQERDAPIVNKVVTP
LSPPTNLHLEANPDTGVLTVSWERSTTPDITGYRITTTPTNGQQGNSLEEVVHADQSSCTFDNLSPGLE
YNVSVYTVKDDKESVPISDTIIPAVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVKNEEDV
AELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQKTGLDSPTGIDFSDITANSFTVHWIA
PRATITGYRIRHHPEHFSGRPREDRVPHSRNSITLTNLTPGTEYVVSIVALNGREESPLLIGQQSTVSD
VPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKSTATISGLKPGVDYTITV
YAVTGRGDSPASSKPISINYRTEIDKPSQMQVTDVQDNSISVKWLPSSSPVTGYRVTTTPKNGPGPTKT
KTAGPDQTEMTIEGLQPTVEYVVSVYAQNPSGESQPLVQTAVTTIPAPTDLKFTQVTPTSLSAQWTPPN
VQLTGYRVRVTPKEKTGPMKEINLAPDSSSVVVSGLMVATKYEVSVYALKDTLTSRPAQGVVTTLENVS
PPRRARVTDATETTITISWRTKTETITGFQVDAVPANGQTPIQRTIKPDVRSYTITGLQPGTDYKIYLY
TLNDNARSSPVVIDASTAIDAPSNLRFLATTPNSLLVSWQPPRARITGYIIKYEKPGSPPREVVPRPRP
GVTEATITGLEPGTEYTIYVIALKNNQKSEPLIGRKKTGQEALSQTTISWAPFQDTSEYIISCHPVGTD
EEPLQFRVPGTSTSATLTGLTRGATYNIIVEALKDQQRHKVREEVVTVGNSVNEGLNQPTDDSCFDPYT
VSHYAVGDEWERMSESGFKLLCQCLGFGSGHFRCDSSRWCHDNGVNYKIGEKWDRQGENGQMMSCTCLG
NGKGEFKCDPHEATCYDDGKTYHVGEQWQKEYLGAICSCTCFGGQRGWRCDNCRRPGGEPSPEGTTGQS
YNQYSQRYHQRTNTNVNCPIECFMPLDVQADREDSRE 
Aminoacidic sequence of fibronectin. The 93 tyrosines are highlighted. 
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Purification of α4β1 integrin from HEK293 cells stably transfected with the α4 subunit gene 
 Cells were harvested using a PBS based Cell Dissociation Buffer (GIBCO™) and the 
cell suspension obtained (108 cells/mL) was spun at 1200 rpm for 5 minutes. The pellet was 
washed once with PBS and resuspended in 5 volumes of lysis buffer (1% NP40; 25 mM 
TrisHCl, pH 7.5; 1 mM CaCl2; 1 mM MgCl2; 1 mM MnCl2; 2% BSA; 1 mM PMSF; 1 
µg/mL aprotinin; 50 µM leupeptin) and homogenized on ice. After centrifuging at 10000g 
for 30 minutes at 4 °C. Load the supernatant sequentially on the affinity chromatography 
column (wheat germ agglutinin, WGA, lectin from Triticum Vulgaris) (Sigma-Aldrich) 
previously equilibrated with the Running Buffer (1% NP40; 25 mM TrisHCl, pH 7.5; 1 mM 
CaCl2; 1 mM MgCl2; 1 mM MnCl2; 2% BSA; 1 mM PMSF; 1 µg/mL aprotinin; 50 µM 
leupeptin). After 10 column volume washes, the proteins are eluted with by addition of 5% 
N-acetylglucosamine to the Running Buffer. 
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GLOSSARY 
 
 
 
 
β-thalassemia Form of thalassemia due to mutations in the HBB gene on 
chromosome 11 inherited in an autosomal recessive fashion 
Acute Respiratory 
Distress Syndrome 
Inflammation of the lung and parenchyma leading to impaired gas 
exchange with concomitant systemic release of inflammatory 
mediators 
Affinity The strength of binding between an individual integrin and its 
ligand. This can be altered by conformational changes in the integrin 
structure 
Antigen-presenting 
Cells 
A general term for all cells that display antigenic peptides in 
complex with major histocompatibility complex (MHC) molecules. 
The professional antigen-presenting cells are the dendritic cells, B 
cells and, occasionally, macrophages. They present antigen to 
lymphocytes 
Avidity A measure of the overall strength of binding of clustered integrins 
Cachexia General physical wasting and malnutrition associated with chronic 
disease 
Chemosis Swelling of the conjunctival tissue around the cornea 
Chymases Family of serine proteases found primarily in mast cells 
Cryptococcus 
Neoformans 
Causes a severe form of meningitis and meningo-encephalitis 
Edema Excess of fluid in interstitial or serous cavities; it can be either be 
exudate or transudate. 
Eicosanoid Class 
Switching 
Changes in production within the arachidonate-derived family – for 
example, prostaglandin and leukotriene to lipoxin – which initiate 
and/or are coincident with termination 
Exudate Inflammatory extravascular fluid that has a high protein 
concentration, cellular debris, and a specific gravity above 1.020 
Exudation Escape of fluid, proteins, and blood cells from the vascular system 
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into the interstitial tissue or body cavities 
Glomerulonephritis Nephritis marked by the inflammation of the glomeruli of the 
kidney 
Haptotaxis Directional motility or outgrowth of cells, usually up a gradient of 
cellular adhesion sites or substrate-bound chemoattractants. 
High Endothelial 
Venule 
Specialized vasculature that is found only in lymph nodes 
Immunological 
Synapse 
The zone of contact between a lymphocyte or a natural killer cell 
and a target cell. On the lymphocyte side the immunological synapse 
receptors are organized to resemble a “bull’s eye” with the T cell 
receptor or B cell receptor in the middle surrounded by a ring of 
LFA-1, with an outermost ring where the phosphatase CD45 is 
found 
Immunoreceptor 
Tyrosine-based 
Activation Motif 
(ITAM) 
A double YxxL motif that is separated by a 7-12 amino-acid linker. 
These motives are often found in immune-cell signalling molecules 
such as the CD3 ξ-chain of the T cell receptors, the γ-chain of the 
Fc receptor (and certain other receptors) and DAP12 proteins. 
Once phosphorylated, often by a Src kinase, the tyrosine residues 
act as a docking site for SH2 domains in other signalling kinases 
Immunoreceptor 
Tyrosine-based 
Inhibitory Motif 
(ITIM) 
A conserved IVLxYxxIVL sequence found in the cytoplasmic part 
of many inhibitory receptors. Upon interaction of an inhibitory 
receptor with its ligand, the ITIM motifs become phosphorylated by 
Src family of kinases, allowing them to interact with phosphatases 
such as the phosphotyrosine phosphatases SHP-1 and SHP-2, or 
the inositol-phosphatase SHIP. The phosphatases recruited to ITIM 
motifs prevent activation of molecules involved in the signal 
transduction in the cell 
Infection Pathologic process caused by the invasion of normally sterile tissue 
or fluid or body cavity by pathogenic or potentially pathogenic 
microorganisms 
Kawasaki Disease Inflammation of the middle-sized arteries that affect many organs 
including the skin, mucous membranes, lymph nodes, and blood 
vessel wall 
Killer-cell 
Immunoglobulin-
like Receptors 
(KIR) 
Family of cell surface glycoproteins expressed by all natural killer 
cells and a subset of T cells that interacts with MHC I molecules. 
KIR proteins are classified according to the number of the 
extracellular immunoglobulin domains (2D or 3D) and by the 
presence of either long (L) or short (S) intracellular domain. KIR 
proteins with the long cytoplasmic domain are capable of induction 
of inhibitory signals and early termination of natural killer cell 
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activity upon ligand binding via one or two ITIM motifs located in 
their cytoplasmic domain. Less common KIR proteins with the 
short cytoplasmic tail, lacking the ITIM motifs, are involved in 
signalling activation 
Leukocytes Collective term for all immune cells such as T and B cells, dendritic 
cells, neutrophils, eosinophils, natural killer cells, and 
monocytes/macrophages 
Lymphocytes Refers only to T lymphocytes (T cells) and B lymphocytes (B cells) 
Lytic Granules A unique type of lysosomes present in natural killer cells and 
cytotoxic T cells that is secreted in a contact-dependent manner, in 
response to lymphocyte activation. Following the release of lytic 
granules at the cell-cell contact interface, the pore forming protein 
perforin, serine proteases (granzymes), and Fas ligand contained in 
the granules mediate the death of a target cell 
Major 
Histocompatibility 
Complex (MHC) 
A complex of genes encoding proteins involved in antigen 
presentation and immune responses. MHC proteins are classified as 
class I, class II and class III. Class I molecules (MHC I) are cell 
surface heterodimers consisting of a chain associated with β2-
microglobulin and are present on all nucleated cells. Class II 
proteins are cell surface heteromdimers comprising an a and b chain 
and are present on antigen presenting cells. Class III molecules are 
distinct from class I and class II and include complement 
components as well as tumor necrosis factor α and β 
Margination White cells assume a peripheral position along the endothelial 
surface 
Nummular Circular or oval in shape 
Palmoplantar 
Pustulosis 
Chronic recurrent pustular dermatitosis localized on the palms and 
the soles only, histologically characterized by intraepidermal 
vescicles filled with neutrophils 
PSGL-1 P-selectin glycoprotein ligand 1 
Pus Purulent exudate: inflammatory exudate rich in leukocytes (mostly 
neutrophils), the debris of dead cells and, in many cases, microbes 
Relapsing Fever Infections caused by certain bacteria in the genus Borrelia. 
Resolvins Resolution phase interaction products. Endogenous local mediators 
possessing stereospecific and potent anti-inflammatory in addition 
to immunoregolatory actions 
Sarcoidosis Multisystem disorder characterized by non-caseating granulomas 
 210 
Schistosoma 
Mansoni 
Parasite of humans of the family of the trematodes. It causes 
schistosomiasis 
Stasis Concentration of red cells in small vessels and increased viscosity of 
the blood 
Steel Locus Encodes for a product which is essential for normal development of 
three distinct populations of stem cells: the neural crest-derived 
melanoblasts, germ cells, and blood cell precursors 
T Cell Receptor 
and B Cell 
Receptor 
The antigen-specific receptors, or immunoreceptors, on T cells and 
B cells, which recognise a wide array of different peptides that have 
been processed and displayed by antigen presenting cells 
Toll-like Receptors 
(TLRs) 
Are homologous to a drosophila protein called Toll, function to 
activate leukocytes in response to different types and components 
of microbes. Different TLRs play essential roles in cellular 
responses to bacterial lipopolysaccharide (LPS), other bacterial 
proteoglycans, and unmethylated CpG nucleotide, all of which are 
found only in bacteria, as well as double stranded RNA, which is 
produced only by some viruses. These receptors function by 
receptor-associated kinases to stimulate the production of 
microbicidal substances and cytokines in the leukocytes. 
Transcellular 
Biosynthesis 
Generation of new bioactive compounds that neither cell type can 
produce on its own 
Transudate Fluid with low protein content (most of which is albumin) and a 
specific gravity of less than 1.012 It is essentially an ultrafiltrate of 
blood plasma that results from osmotic or hydrostatic imbalance 
across the vessel wall without an increase in vascular permeability 
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